quinazolines - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	quinazolines	go back to main search page
Accession:	CHEBI:38530	browse the term
Definition:	Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
Synonyms:	alt_id:	MESH:D011799
	xref_mesh:	MESH:D011799

show annotations for term's descendants Sort by:
Rat (571 ) Mouse (575 ) Human (579 ) Chinchilla (0 ) Bonobo (0 ) Dog (0 ) Squirrel (0 ) Pig (5 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (571)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aurora kinase A

affects splicing

ISO

Quinazolines affects the splicing of AURKA mRNA

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771

G

arginine vasopressin receptor 1B

multiple interactions

ISO

Quinazolines analog binds to and results in decreased activity of AVPR1B protein

NCBI chr13:45,598,116...45,611,680
Ensembl chr13:45,598,763...45,611,277

G

BCL2 associated X, apoptosis regulator

multiple interactions

ISO

Quinazolines inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

ISO

Quinazolines inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in decreased expression of BCL2 protein]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

bromodomain containing 2

decreases splicing

ISO

Quinazolines results in decreased splicing of BRD2 mRNA

NCBI chr20:4,728,282...4,737,286
Ensembl chr20:4,728,951...4,737,290

G

cyclin A2

affects splicing

ISO

Quinazolines affects the splicing of CCNA2 mRNA

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin-dependent kinase inhibitor 1B

affects splicing

ISO

Quinazolines affects the splicing of CDKN1B mRNA

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

epidermal growth factor receptor

multiple interactions
decreases phosphorylation

ISO

Quinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK1 protein]; Quinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK3 protein]
Quinazolines analog results in decreased phosphorylation of EGFR protein

PMID:10753475 PMID:21075094

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

erb-b2 receptor tyrosine kinase 2

decreases phosphorylation

ISO

Quinazolines analog results in decreased phosphorylation of ERBB2 protein

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

G protein-coupled estrogen receptor 1

multiple interactions

EXP

Quinazolines inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]

NCBI chr12:20,331,073...20,336,527
Ensembl chr12:20,327,679...20,337,144

G

interleukin 1 beta

multiple interactions

ISO

Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL1B mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL1B protein]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 33

multiple interactions

ISO

Quinazolines inhibits the reaction [IL33 protein results in increased expression of CXCL8 mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of CXCL8 protein]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL1B mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL1B protein]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL6 mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL6 protein]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of TNF mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of TNF protein]; Quinazolines inhibits the reaction [IL33 protein results in increased phosphorylation of and results in increased localization of and results in increased activity of RELA protein]

NCBI chr 1:237,115,478...237,149,897
Ensembl chr 1:237,115,572...237,150,901

G

interleukin 6

multiple interactions

ISO

Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL6 mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

kinase insert domain receptor

multiple interactions

ISO

Quinazolines analog binds to and results in decreased activity of KDR protein

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192

G

mitogen activated protein kinase 1

multiple interactions

ISO

Quinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions

ISO

Quinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

MCL1 apoptosis regulator, BCL2 family member

affects splicing

ISO

Quinazolines affects the splicing of MCL1 mRNA

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

Quinazolines inhibits the reaction [IL33 protein results in increased phosphorylation of and results in increased localization of and results in increased activity of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

RIO kinase 3

decreases splicing

ISO

Quinazolines results in decreased splicing of RIOK3 mRNA

NCBI chr18:3,602,535...3,628,108
Ensembl chr18:3,602,535...3,628,108

G

solute carrier family 1 member 2

multiple interactions

EXP

Quinazolines inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

tumor necrosis factor

multiple interactions

ISO

Quinazolines inhibits the reaction [IL33 protein results in increased expression of TNF mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

thymidylate synthetase

decreases activity

ISO

Quinazolines analog results in decreased activity of TYMS protein

NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

ISO

AKT1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

BCL2 associated X, apoptosis regulator

multiple interactions

ISO

[CALM2 protein affects the susceptibility to Afatinib] which affects the expression of BAX protein; BAX protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

Bcl-2 binding component 3

multiple interactions

ISO

BBC3 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]

NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666

G

calmodulin 2

multiple interactions
affects response to substance

ISO

[CALM2 protein affects the susceptibility to Afatinib] which affects the expression of BAX protein; [CALM2 protein affects the susceptibility to Afatinib] which affects the localization of DIABLO protein; [CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein; AKT1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; BAX protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; BBC3 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]

NCBI chr 6:12,845,170...12,857,830
Ensembl chr15:64,519,554...64,520,657
Ensembl chr 6:64,519,554...64,520,657

G

caspase 3

multiple interactions

ISO

[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein; AKT1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; BAX protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; BBC3 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

diablo, IAP-binding mitochondrial protein

multiple interactions

ISO

[CALM2 protein affects the susceptibility to Afatinib] which affects the localization of DIABLO protein

NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265

G

epidermal growth factor

multiple interactions

ISO

afatinib inhibits the reaction [EGF protein results in increased expression of EHMT2 protein]; afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein]

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

epidermal growth factor receptor

decreases activity
decreases phosphorylation

ISO

afatinib results in decreased activity of EGFR protein; afatinib results in decreased activity of EGFR protein mutant form
afatinib results in decreased phosphorylation of EGFR protein

PMID:21322567 PMID:22242139 PMID:28787001

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

euchromatic histone lysine methyltransferase 2

multiple interactions

ISO

afatinib inhibits the reaction [EGF protein results in increased expression of EHMT2 protein]

NCBI chr20:3,924,263...3,941,238
Ensembl chr20:3,924,263...3,941,384

G

inhibitor of nuclear factor kappa B kinase subunit beta

decreases expression

ISO

afatinib results in decreased expression of IKBKB protein

NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911

G

IQ motif containing GTPase activating protein 1

decreases phosphorylation

ISO

Afatinib results in decreased phosphorylation of IQGAP1 protein

NCBI chr 1:144,088,788...144,178,989
Ensembl chr 1:144,088,793...144,179,043

G

lactate dehydrogenase A

increases secretion

ISO

Afatinib results in increased secretion of LDHA protein

NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions

ISO

MCL1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

ISO

Afatinib inhibits the reaction [[Smoke results in increased abundance of Particulate Matter] which results in increased expression of MUC5AC mRNA]

NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006

G

nuclear factor kappa B subunit 1

multiple interactions

ISO

afatinib results in decreased activity of [RELA protein binds to NFKB1 protein]

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

POU class 5 homeobox 1

decreases expression
multiple interactions

ISO

afatinib results in decreased expression of POU5F1 protein
afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein]

NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

afatinib results in decreased activity of [RELA protein binds to NFKB1 protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

Set nuclear proto-oncogene

affects localization

ISO

Afatinib affects the localization of SET protein alternative form

NCBI chr 3:33,732,319...33,743,433

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor alpha 1A

affects binding
multiple interactions

EXP
ISO

alfuzosin binds to ADRA1A protein
alfuzosin inhibits the reaction [Prazosin binds to ADRA1A protein]

PMID:7536677 PMID:8183249 PMID:8196478 PMID:21544540

NCBI chr15:45,005,648...45,111,416
Ensembl chr15:45,005,799...45,102,534

G

adrenoceptor alpha 1B

affects binding

ISO

alfuzosin binds to ADRA1B protein

NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347

G

adrenoceptor alpha 1D

affects binding

ISO
EXP

alfuzosin binds to ADRA1D protein

PMID:8183249 PMID:9294627

NCBI chr 3:139,246,333...139,262,331
Ensembl chr 3:139,246,323...139,262,331

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

EXP

alfuzosin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

gonadotropin releasing hormone 1

multiple interactions

EXP

alfuzosin inhibits the reaction [Phenylephrine results in decreased secretion of GNRH1 protein]; alfuzosin inhibits the reaction [Phenylephrine results in increased secretion of GNRH1 protein]

NCBI chr15:46,147,878...46,152,086
Ensembl chr15:46,148,301...46,148,977
Ensembl chr15:46,148,301...46,148,977

G

tachykinin, precursor 1

multiple interactions

EXP

alfuzosin inhibits the reaction [Phenylephrine results in increased secretion of TAC1 protein]

NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546

Anhydrotetrodotoxin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

sodium voltage-gated channel alpha subunit 8

decreases activity

ISO

anhydrotetrodotoxin results in decreased activity of SCN8A protein

NCBI chr 7:133,860,901...134,034,809
Ensembl chr 7:133,861,227...134,030,026

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

decreases phosphorylation

ISO

ARS-1620 results in decreased phosphorylation of AKT1 protein

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

KRAS proto-oncogene, GTPase

affects binding

ISO

ARS-1620 binds to KRAS protein mutant form

NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320

G

mitogen activated protein kinase 1

decreases phosphorylation

ISO

ARS-1620 results in decreased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

decreases phosphorylation

ISO

ARS-1620 results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions

ISO

Canertinib inhibits the reaction [Acetaminophen results in increased transport of AIFM1 protein]

NCBI chr X:132,528,107...132,567,237
Ensembl chr X:132,528,107...132,567,237

G

cyclin D1

multiple interactions

ISO

Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased expression of CCND1 protein]

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin-dependent kinase 4

multiple interactions

ISO

Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased expression of CDK4 protein]

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163

G

epidermal growth factor

multiple interactions

ISO

Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

epidermal growth factor receptor

multiple interactions
decreases phosphorylation
decreases activity

ISO

Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
Canertinib inhibits the reaction [Acetaminophen affects the localization of EGFR protein]; Canertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein]
Canertinib results in decreased phosphorylation of EGFR protein
Canertinib results in decreased activity of EGFR protein; Canertinib results in decreased activity of EGFR protein mutant form

PMID:15956251 PMID:18927496 PMID:21322567 PMID:28123000

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

endonuclease G

multiple interactions

ISO

Canertinib inhibits the reaction [Acetaminophen results in increased transport of ENDOG protein]

NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:33,846,885...33,849,573

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

ISO

Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein]

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

mitogen activated protein kinase 1

multiple interactions

ISO

Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions

ISO

Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

RB transcriptional corepressor 1

multiple interactions

ISO

Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of RB1 protein]

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

transforming growth factor, beta 1

decreases activity

ISO

Canertinib results in decreased activity of TGFB1 protein

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

vascular endothelial growth factor A

decreases expression
decreases secretion

ISO

Canertinib results in decreased expression of VEGFA mRNA; Canertinib results in decreased expression of VEGFA protein
Canertinib results in decreased secretion of VEGFA protein

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor alpha 1B

multiple interactions

EXP

cyclazosin binds to and results in decreased activity of ADRA1B protein

NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions
affects metabolic processing

ISO

Quinidine affects the reaction [CYP2D6 protein polymorphism affects the metabolism of dacomitinib]

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

epidermal growth factor receptor

multiple interactions

ISO

dacomitinib inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

ISO

Doxazosin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

adrenoceptor alpha 1A

affects binding

EXP
ISO

Doxazosin binds to ADRA1A protein

PMID:7536677 PMID:8183249 PMID:21544540

NCBI chr15:45,005,648...45,111,416
Ensembl chr15:45,005,799...45,102,534

G

adrenoceptor alpha 1B

affects binding

ISO

Doxazosin binds to ADRA1B protein

NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347

G

adrenoceptor alpha 1D

affects binding

ISO
EXP

Doxazosin binds to ADRA1D protein

PMID:8183249 PMID:9294627

NCBI chr 3:139,246,333...139,262,331
Ensembl chr 3:139,246,323...139,262,331

G

adrenoceptor alpha 2A

multiple interactions
decreases expression
increases activity

ISO

Doxazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]
Doxazosin results in decreased expression of ADRA2A protein
Doxazosin results in increased activity of ADRA2A protein

PMID:10694191 PMID:10742289

NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:263,065,278...263,069,871

G

adrenoceptor beta 1

increases expression

EXP

Doxazosin results in increased expression of ADRB1 protein

NCBI chr 1:265,777,103...265,780,114
Ensembl chr 1:265,766,079...265,849,237

G

adrenoceptor beta 2

increases expression

EXP

Doxazosin results in increased expression of ADRB2 protein

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

AKT serine/threonine kinase 1

affects phosphorylation

EXP

Doxazosin affects the phosphorylation of AKT1 protein

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

ISO

Doxazosin results in increased expression of BAX protein
SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

ISO

BCL2 inhibits the reaction [Doxazosin results in decreased expression of VEGFA]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

caspase 3

increases activity
multiple interactions

ISO

Doxazosin results in increased activity of CASP3 protein
Doxazosin results in increased cleavage of and results in increased activity of CASP3 protein

PMID:12771931 PMID:15221243 PMID:22845314

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

cyclin A2

decreases expression

ISO

Doxazosin results in decreased expression of CCNA2 protein

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin-dependent kinase inhibitor 1A

increases expression

ISO

Doxazosin results in increased expression of CDKN1A mRNA

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

collagen type I alpha 1 chain

multiple interactions

EXP

Doxazosin inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

C-reactive protein

decreases expression

ISO

Doxazosin results in decreased expression of CRP protein

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514

G

DNA-damage inducible transcript 3

increases expression

ISO

Doxazosin results in increased expression of DDIT3 protein

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

Eph receptor A2

multiple interactions

ISO

[Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein] which results in increased phosphorylation of and results in increased activity of PTPN11 protein; Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein; Lithocholic Acid inhibits the reaction [Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein]

NCBI chr 5:158,888,629...158,917,100
Ensembl chr 5:158,888,629...158,917,234

G

Fas ligand

increases expression

ISO

Doxazosin results in increased expression of FASLG mRNA

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

KLF transcription factor 10

increases expression

ISO

Doxazosin results in increased expression of KLF10 mRNA; Doxazosin results in increased expression of KLF10 protein

NCBI chr 7:71,352,612...71,358,680
Ensembl chr 7:71,350,573...71,358,948

G

mitogen activated protein kinase 1

affects phosphorylation

EXP

Doxazosin affects the phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

affects phosphorylation

EXP

Doxazosin affects the phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

myostatin

decreases expression

EXP

Doxazosin results in decreased expression of MSTN mRNA; Doxazosin results in decreased expression of MSTN protein

NCBI chr 9:55,944,513...55,950,913
Ensembl chr 9:55,944,513...55,950,913

G

NFKB inhibitor alpha

increases expression

ISO

Doxazosin results in increased expression of NFKBIA mRNA; Doxazosin results in increased expression of NFKBIA protein

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

natriuretic peptide B

increases expression
multiple interactions

ISO
EXP

Doxazosin results in increased expression of NPPB protein
[Atenolol co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Atenolol co-treated with Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA

PMID:15969258 PMID:18551024

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310

G

protein tyrosine kinase 2

decreases expression
increases cleavage

ISO

Doxazosin results in decreased expression of PTK2 protein
Doxazosin results in increased cleavage of PTK2 protein

PMID:15221243 PMID:22845314

NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:107,015,733...107,172,091

G

protein tyrosine phosphatase, non-receptor type 11

multiple interactions

ISO

[Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein] which results in increased phosphorylation of and results in increased activity of PTPN11 protein

NCBI chr12:41,026,079...41,085,577
Ensembl chr12:41,043,785...41,085,577

G

RB transcriptional corepressor 1

affects phosphorylation
decreases phosphorylation

EXP
ISO

Doxazosin affects the phosphorylation of RB1 protein
Doxazosin results in decreased phosphorylation of RB1 protein

PMID:15371785 PMID:18084315

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

renin

increases expression

ISO

Doxazosin results in increased expression of REN protein

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

serpin family B member 5

multiple interactions
increases response to substance

ISO

SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA mRNA alternative form]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA protein]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of BAX protein]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 mRNA]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 protein]
SERPINB5 protein results in increased susceptibility to Doxazosin

NCBI chr13:23,500,203...23,520,401
Ensembl chr13:23,500,198...23,520,400

G

solute carrier family 22 member 2

multiple interactions

ISO

Doxazosin inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

SMAD family member 4

increases expression
multiple interactions

ISO

Doxazosin results in increased expression of SMAD4 mRNA; Doxazosin results in increased expression of SMAD4 protein
SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 mRNA]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 protein]

PMID:12771931 PMID:16007219

NCBI chr18:69,518,988...69,549,684
Ensembl chr18:69,518,988...69,549,684

G

vascular endothelial growth factor A

multiple interactions
decreases expression

ISO

BCL2 inhibits the reaction [Doxazosin results in decreased expression of VEGFA]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA mRNA alternative form]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA protein]
Doxazosin results in decreased expression of VEGFA mRNA; Doxazosin results in decreased expression of VEGFA mRNA alternative form; Doxazosin results in decreased expression of VEGFA protein

PMID:12576871 PMID:16007219

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acrosin binding protein

increases expression

ISO

erastin results in increased expression of ACRBP mRNA alternative form

NCBI chr 4:159,537,395...159,550,454
Ensembl chr 4:159,537,391...159,550,454

G

acyl-CoA synthetase long-chain family member 4

increases expression
multiple interactions

ISO

erastin results in increased expression of ACSL4 protein
leonurine inhibits the reaction [erastin results in increased expression of ACSL4 protein]

NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261

G

aryl hydrocarbon receptor

multiple interactions
affects response to substance

ISO

AHR protein affects the reaction [[indol-3-yl pyruvic acid co-treated with erastin] results in increased expression of SLC7A11 protein]; AHR protein affects the reaction [erastin results in increased expression of SLC7A11 mRNA]; AHR protein affects the reaction [erastin results in increased expression of SLC7A11 protein]
AHR protein affects the susceptibility to erastin

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

alkaline phosphatase, biomineralization associated

decreases expression
multiple interactions

ISO

erastin results in decreased expression of ALPL mRNA
picein inhibits the reaction [erastin results in decreased expression of ALPL mRNA]

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167

G

androgen receptor

affects response to substance

ISO

AR protein affects the susceptibility to erastin

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

arginase 1

multiple interactions
decreases expression

ISO

picein inhibits the reaction [erastin results in decreased expression of ARG1 mRNA]

NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713

G

AT-rich interaction domain 3A

multiple interactions
increases expression

ISO

Doxycycline promotes the reaction [erastin results in increased expression of ARID3A mRNA]

NCBI chr 7:10,403,161...10,431,551
Ensembl chr 7:10,405,631...10,427,926

G

activating transcription factor 4

multiple interactions
increases expression

ISO

leonurine inhibits the reaction [erastin results in increased expression of ATF4 protein]

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

autophagy related 5

increases expression

EXP

erastin results in increased expression of ATG5 protein

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821

G

biglycan

multiple interactions
decreases expression

ISO

BGN mRNA alternative form inhibits the reaction [erastin results in decreased expression of MKI67 protein]; erastin inhibits the reaction [[Antineoplastic Agents, Immunological results in decreased susceptibility to Antineoplastic Agents, Immunological] which results in increased expression of BGN mRNA alternative form]
erastin results in decreased expression of BGN mRNA alternative form

NCBI chr X:156,348,633...156,360,797
Ensembl chr X:156,348,615...156,360,799

G

bone morphogenetic protein 4

decreases expression
multiple interactions

ISO

erastin results in decreased expression of BMP4 mRNA
picein inhibits the reaction [erastin results in decreased expression of BMP4 mRNA]

NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172

G

caspase 3

multiple interactions
increases cleavage

ISO

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide promotes the reaction [erastin results in increased cleavage of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

CD163 molecule

decreases expression
multiple interactions

ISO

erastin results in decreased expression of CD163 mRNA
picein inhibits the reaction [erastin results in decreased expression of CD163 mRNA]

NCBI chr 4:158,770,751...158,804,146
Ensembl chr 4:158,770,749...158,804,146

G

CCAAT/enhancer binding protein delta

increases expression
multiple interactions

ISO

erastin results in increased expression of CEBPD mRNA
Doxycycline promotes the reaction [erastin results in increased expression of CEBPD mRNA]

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

multiple interactions
increases expression

ISO

GW 506033X inhibits the reaction [erastin results in increased expression of CHAC1 mRNA]
erastin results in increased expression of CHAC1 protein
leonurine inhibits the reaction [erastin results in increased expression of CHAC1 protein]

PMID:30817950 PMID:38670420

NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361

G

carbohydrate sulfotransferase 4

increases expression
multiple interactions

ISO

erastin results in increased expression of CHST4 mRNA
Doxycycline promotes the reaction [erastin results in increased expression of CHST4 mRNA]

NCBI chr19:54,900,914...54,911,735
Ensembl chr19:54,882,719...54,916,648

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

ISO

[Doxycycline co-treated with erastin] results in increased expression of CITED2 mRNA

NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782

G

collagen type I alpha 2 chain

increases expression

ISO

erastin results in increased expression of COL1A2 mRNA alternative form

NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

ISO

erastin affects the reaction [CYP2E1 protein affects the susceptibility to Ethanol]

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

ISO

erastin promotes the reaction [Silicon Dioxide results in increased expression of DDIT3 protein]; GW 506033X inhibits the reaction [erastin results in increased expression of DDIT3 mRNA]
erastin results in increased expression of DDIT3 protein
leonurine inhibits the reaction [erastin results in increased expression of DDIT3 protein]

PMID:30817950 PMID:37075931 PMID:38670420

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

denticleless E3 ubiquitin protein ligase homolog

increases expression

ISO

erastin results in increased expression of DTL mRNA alternative form

NCBI chr13:105,646,908...105,685,921
Ensembl chr13:105,646,908...105,686,174

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

ISO

erastin results in increased expression of and results in increased phosphorylation of EIF2AK3 protein; leonurine inhibits the reaction [erastin results in increased expression of EIF2AK3 protein]

NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions

ISO

erastin results in increased expression of and results in increased phosphorylation of EIF2S1 protein; leonurine inhibits the reaction [erastin results in increased expression of and results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions
increases phosphorylation

ISO

GW 506033X inhibits the reaction [erastin results in increased phosphorylation of ERN1 protein]

NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791

G

FA complementation group D2

decreases expression

EXP

erastin results in decreased expression of FANCD2 protein

NCBI chr 4:148,234,633...148,299,035
Ensembl chr 4:148,234,708...148,299,035

G

fatty acid synthase

affects response to substance
decreases expression

ISO

FASN protein affects the susceptibility to erastin
erastin results in decreased expression of FASN protein

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

fumarate hydratase

decreases response to substance

ISO

FH protein results in decreased susceptibility to erastin

NCBI chr13:90,056,565...90,082,450
Ensembl chr13:90,056,570...90,089,627

G

ferritin heavy chain 1

multiple interactions
increases expression

EXP
ISO

3-methyladenine promotes the reaction [erastin results in increased expression of FTH1 protein]; Chloroquine promotes the reaction [erastin results in increased expression of FTH1 protein]; Deferiprone inhibits the reaction [erastin results in increased expression of FTH1 protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of FTH1 protein]
[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]

PMID:32937103 PMID:37951334

NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214

G

ferritin light chain 1

multiple interactions

ISO

[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein]

NCBI chr 1:105,072,858...105,074,705
Ensembl chr X:45,399,355...45,399,915
Ensembl chr 2:45,399,355...45,399,915
Ensembl chr 1:45,399,355...45,399,915

G

GABA type A receptor associated protein like 1

increases expression
multiple interactions

ISO

erastin results in increased expression of GABARAPL1 mRNA
Doxycycline promotes the reaction [erastin results in increased expression of GABARAPL1 mRNA]

NCBI chr 4:164,666,332...164,675,474
Ensembl chr 4:164,666,246...164,674,578

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
increases expression

EXP

NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLC protein]

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

increases expression
multiple interactions

EXP

erastin results in increased expression of GCLM protein
NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLM protein]

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

gap junction protein, alpha 1

multiple interactions

ISO

GJA1 protein affects the reaction [erastin results in decreased expression of GPX4 protein]; GJA1 protein affects the reaction [erastin results in decreased expression of SLC7A11 protein]

NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689

G

glutathione peroxidase 4

decreases expression
multiple interactions

ISO
EXP

erastin results in decreased expression of GPX4 protein
erastin promotes the reaction [Silicon Dioxide results in decreased expression of GPX4 protein]; picein inhibits the reaction [erastin results in decreased expression of GPX4 protein]
astaxanthine inhibits the reaction [erastin results in decreased expression of GPX4 protein]; ferrostatin-1 inhibits the reaction [erastin results in decreased expression of GPX4 protein]; gap 27 peptide inhibits the reaction [erastin results in decreased expression of GPX4 protein]; GJA1 protein affects the reaction [erastin results in decreased expression of GPX4 protein]; SESN1 protein inhibits the reaction [erastin results in decreased expression of GPX4 protein]

PMID:31323261 PMID:32937103 PMID:34785303 PMID:37075931 PMID:37648051 More...

NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629

G

glycogen synthase kinase 3 beta

multiple interactions
increases expression

ISO

cordycepin inhibits the reaction [erastin results in increased expression of GSK3B protein]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

hepatitis A virus cellular receptor 1

multiple interactions

ISO

erastin inhibits the reaction [Quercetin inhibits the reaction [ochratoxin A results in increased expression of HAVCR1 mRNA]]

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268

G

high mobility group AT-hook 2

multiple interactions
increases expression

ISO

Doxycycline promotes the reaction [erastin results in increased expression of HMGA2 mRNA]

NCBI chr 7:57,762,710...57,884,555
Ensembl chr 7:57,765,675...57,880,341

G

heme oxygenase 1

increases expression
multiple interactions
decreases expression
increases response to substance

ISO

erastin results in increased expression of HMOX1 protein
picein inhibits the reaction [erastin results in decreased expression of HMOX1 protein]
HMOX1 protein results in increased susceptibility to erastin
Doxycycline promotes the reaction [erastin results in increased expression of HMOX1 mRNA]
erastin results in increased expression of HMOX1 mRNA; erastin results in increased expression of HMOX1 protein

PMID:30817950 PMID:38115220 PMID:38641223 PMID:38727095

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

HRas proto-oncogene, GTPase

increases response to substance

ISO

HRAS protein modified form results in increased susceptibility to erastin

NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590

G

heat shock protein family A (Hsp70) member 5

increases expression
multiple interactions

ISO

erastin results in increased expression of HSPA5 protein
erastin promotes the reaction [Silicon Dioxide results in increased expression of HSPA5 protein]

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

heat shock protein family B (small) member 1

decreases phosphorylation

EXP

erastin results in decreased phosphorylation of HSPB1 protein

NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301

G

interleukin 1 beta

multiple interactions

ISO

erastin inhibits the reaction [Quercetin inhibits the reaction [ochratoxin A results in increased expression of IL1B mRNA]]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

ISO

erastin inhibits the reaction [Quercetin inhibits the reaction [ochratoxin A results in increased expression of IL6 mRNA]]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

keratin 5

multiple interactions
increases expression

ISO

Doxycycline promotes the reaction [erastin results in increased expression of KRT5 mRNA]

NCBI chr 7:134,724,840...134,730,569
Ensembl chr 7:134,724,840...134,730,569

G

microtubule-associated protein 1 light chain 3 beta

increases expression
multiple interactions

EXP

erastin results in increased expression of MAP1LC3B protein modified form
3-methyladenine inhibits the reaction [erastin results in increased expression of MAP1LC3B protein modified form]; Chloroquine promotes the reaction [erastin results in increased expression of MAP1LC3B protein modified form]

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

ISO

erastin results in increased phosphorylation of MAPK1 protein
GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

ISO

GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 8

increases phosphorylation
multiple interactions

ISO

erastin results in increased phosphorylation of MAPK8 protein
GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

myoglobin

multiple interactions
increases response to substance
increases expression

ISO

Doxycycline promotes the reaction [erastin results in increased expression of MB mRNA]
MB protein results in increased susceptibility to erastin

NCBI chr 7:110,640,511...110,647,742
Ensembl chr 7:110,640,512...110,647,958

G

marker of proliferation Ki-67

decreases expression
multiple interactions

ISO

erastin results in decreased expression of MKI67 protein
Butyric Acid promotes the reaction [erastin results in decreased expression of MKI67 protein]
BGN mRNA alternative form inhibits the reaction [erastin results in decreased expression of MKI67 protein]

PMID:35234341 PMID:37341073

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

mutS homolog 2

increases expression

ISO

erastin results in increased expression of MSH2 mRNA alternative form

NCBI chr 6:12,567,368...12,626,534
Ensembl chr 6:12,567,368...12,626,503

G

nuclear receptor coactivator 4

decreases expression
multiple interactions

EXP
ISO

erastin results in decreased expression of NCOA4 protein
[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]
3-methyladenine inhibits the reaction [erastin results in decreased expression of NCOA4 protein]; Chloroquine inhibits the reaction [erastin results in decreased expression of NCOA4 protein]

PMID:32937103 PMID:37951334

NCBI chr16:7,395,502...7,415,846
Ensembl chr16:7,401,802...7,415,840

G

nuclear factor of activated T-cells 2

multiple interactions

ISO

erastin promotes the reaction [Silicon Dioxide results in increased expression of NFATC2 protein]

NCBI chr 3:177,615,189...177,747,493
Ensembl chr 3:177,618,314...177,747,380

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases expression
affects response to substance
increases expression

ISO
EXP

NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]; picein inhibits the reaction [erastin results in decreased expression of NFE2L2 protein]
NFE2L2 protein affects the susceptibility to erastin
cordycepin inhibits the reaction [erastin results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
erastin results in increased expression of NFE2L2 protein
NFE2L2 protein promotes the reaction [erastin results in increased expression of FTH1 protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLM protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of SLC7A11 mRNA]

PMID:31323261 PMID:32937103 PMID:38014886 PMID:38636790 PMID:38727095

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

netrin 1

multiple interactions

ISO

erastin inhibits the reaction [Quercetin inhibits the reaction [ochratoxin A results in increased expression of NTN1 mRNA]]

NCBI chr10:53,398,852...53,597,595
Ensembl chr10:53,398,852...53,584,060

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

ISO

erastin results in increased cleavage of PARP1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide promotes the reaction [erastin results in increased cleavage of PARP1 protein]

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

platelet and endothelial cell adhesion molecule 1

multiple interactions
decreases expression

ISO

picein inhibits the reaction [erastin results in decreased expression of PECAM1 mRNA]

NCBI chr10:92,090,263...92,152,002
Ensembl chr10:92,090,235...92,151,839

G

protein kinase D2

affects response to substance
multiple interactions

ISO

PRKD2 protein affects the susceptibility to erastin
[PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1]] which affects the abundance of Malondialdehyde; [PRKD2 protein affects the susceptibility to erastin] which affects the abundance of Malondialdehyde; [PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein; [PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein; [PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]; PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1]

NCBI chr 1:86,640,095...86,670,476
Ensembl chr 1:86,642,629...86,670,675

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions
decreases expression

EXP
ISO

erastin results in increased expression of PTGS2 mRNA; erastin results in increased expression of PTGS2 protein
Quercetin inhibits the reaction [erastin results in increased expression of PTGS2 protein]; Quercetin promotes the reaction [erastin results in decreased expression of PTGS2 protein]
Vitamin E inhibits the reaction [erastin analog results in increased expression of PTGS2 mRNA]
erastin analog results in increased expression of PTGS2 mRNA; erastin results in increased expression of PTGS2 mRNA

PMID:24439385 PMID:32937103 PMID:37230155

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

ribonuclease L

increases expression
multiple interactions

ISO

erastin results in increased expression of RNASEL mRNA
Doxycycline promotes the reaction [erastin results in increased expression of RNASEL mRNA]

NCBI chr13:68,446,641...68,460,804
Ensembl chr13:68,446,882...68,459,557

G

ring finger protein 38

multiple interactions

ISO

[Doxycycline co-treated with erastin] results in increased expression of RNF38 mRNA

NCBI chr 5:63,154,507...63,263,138
Ensembl chr 5:63,154,507...63,263,137

G

RUNX family transcription factor 2

decreases expression
multiple interactions

ISO

erastin results in decreased expression of RUNX2 protein
picein inhibits the reaction [erastin results in decreased expression of RUNX2 protein]

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027

G

sterol-C5-desaturase

increases expression

ISO

erastin results in increased expression of SC5D mRNA alternative form

NCBI chr 8:51,526,669...51,538,277
Ensembl chr 8:51,529,346...51,538,277

G

sestrin 1

multiple interactions

ISO

SESN1 protein inhibits the reaction [erastin results in decreased expression of GPX4 protein]

NCBI chr20:46,876,918...46,970,010
Ensembl chr20:46,876,895...46,970,010

G

sestrin 2

multiple interactions
increases expression

ISO

NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
Acetylcysteine inhibits the reaction [erastin results in increased expression of SESN2 protein]; Butylated Hydroxyanisole inhibits the reaction [erastin results in increased expression of SESN2 protein]; Dactinomycin inhibits the reaction [erastin results in increased expression of SESN2 mRNA]; Deferoxamine inhibits the reaction [erastin results in increased expression of SESN2 protein]; diphenyleneiodonium inhibits the reaction [erastin results in increased expression of SESN2 protein]; ferrostatin-1 inhibits the reaction [erastin results in increased expression of SESN2 protein]; NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
erastin results in increased expression of SESN2 mRNA; erastin results in increased expression of SESN2 protein

NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255

G

solute carrier family 11 member 2

increases expression

EXP

erastin results in increased expression of SLC11A2 protein

NCBI chr 7:133,381,878...133,429,921
Ensembl chr 7:133,381,878...133,418,941

G

solute carrier family 40 member 1

decreases expression
multiple interactions
increases expression

EXP
ISO

erastin results in decreased expression of SLC40A1 protein
picein inhibits the reaction [erastin results in decreased expression of SLC40A1 protein]
erastin results in increased expression of SLC40A1 protein

PMID:31323261 PMID:32937103 PMID:38727095

NCBI chr 9:55,525,457...55,633,463
Ensembl chr 9:55,525,532...55,543,460

G

solute carrier family 7 member 11

increases expression
multiple interactions
decreases expression

EXP
ISO

erastin results in increased expression of SLC7A11 mRNA
erastin results in increased expression of SLC7A11 mRNA; erastin results in increased expression of SLC7A11 protein
erastin promotes the reaction [Silicon Dioxide results in decreased expression of SLC7A11 protein]; picein inhibits the reaction [erastin results in decreased expression of SLC7A11 protein]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[indol-3-yl pyruvic acid co-treated with erastin] results in increased expression of SLC7A11 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [erastin results in increased expression of SLC7A11 protein]; [indol-3-yl pyruvic acid co-treated with erastin] results in increased expression of SLC7A11 protein; AHR protein affects the reaction [[indol-3-yl pyruvic acid co-treated with erastin] results in increased expression of SLC7A11 protein]; AHR protein affects the reaction [erastin results in increased expression of SLC7A11 mRNA]; AHR protein affects the reaction [erastin results in increased expression of SLC7A11 protein]; gap 27 peptide inhibits the reaction [erastin results in decreased expression of SLC7A11 protein]; GJA1 protein affects the reaction [erastin results in decreased expression of SLC7A11 protein]
NFE2L2 protein promotes the reaction [erastin results in increased expression of SLC7A11 mRNA]

PMID:32937103 PMID:34785303 PMID:37075931 PMID:38641223 PMID:38727095

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

secretory leukocyte peptidase inhibitor

multiple interactions
increases expression

ISO

Doxycycline promotes the reaction [erastin results in increased expression of SLPI mRNA]

NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822

G

Sp7 transcription factor

multiple interactions
decreases expression

ISO

picein inhibits the reaction [erastin results in decreased expression of SP7 mRNA]

NCBI chr 7:135,363,193...135,373,376
Ensembl chr 7:135,363,199...135,373,559

G

secreted phosphoprotein 1

multiple interactions
decreases expression

ISO

picein inhibits the reaction [erastin results in decreased expression of SPP1 protein]

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820

G

sterol regulatory element binding transcription factor 1

decreases expression

ISO

erastin results in decreased expression of SREBF1 protein

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

TATA-box binding protein associated factor, RNA polymerase I subunit A

decreases expression

ISO

erastin results in decreased expression of TAF1A mRNA alternative form

NCBI chr13:97,543,772...97,579,742
Ensembl chr13:97,560,820...97,579,737

G

transferrin

increases expression
multiple interactions

EXP

erastin results in increased expression of TF mRNA; erastin results in increased expression of TF protein
Quercetin inhibits the reaction [erastin results in increased expression of TF mRNA]; Quercetin inhibits the reaction [erastin results in increased expression of TF protein]

PMID:32937103 PMID:37230155

NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:112,647,642...112,695,400

G

transferrin receptor

increases expression

EXP
ISO

erastin results in increased expression of TFRC protein

PMID:31323261 PMID:32937103

NCBI chr11:81,668,478...81,690,318
Ensembl chr11:81,668,478...81,690,318

G

TIMP metallopeptidase inhibitor 1

decreases expression

ISO

erastin results in decreased expression of TIMP1 mRNA alternative form

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

tumor necrosis factor

multiple interactions

ISO

erastin inhibits the reaction [Quercetin inhibits the reaction [ochratoxin A results in increased expression of TNF mRNA]]; erastin inhibits the reaction [Quercetin inhibits the reaction [ochratoxin A results in increased expression of TNF protein]]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

thioredoxin reductase 1

affects response to substance

ISO

TXNRD1 protein affects the susceptibility to erastin

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817

G

voltage-dependent anion channel 2

decreases expression
affects binding
increases degradation

ISO
EXP

erastin results in decreased expression of VDAC2 protein
erastin analog binds to VDAC2 protein
erastin results in increased degradation of VDAC2 protein

PMID:17568748 PMID:32937103

NCBI chr15:2,512,214...2,526,105
Ensembl chr15:2,512,216...2,532,229

G

voltage-dependent anion channel 3

increases degradation
decreases expression
affects response to substance

EXP
ISO

erastin results in increased degradation of VDAC3 protein
erastin results in decreased expression of VDAC3 protein
VDAC3 protein affects the susceptibility to erastin

PMID:17568748 PMID:32937103

NCBI chr16:76,137,489...76,153,933
Ensembl chr16:76,137,504...76,155,304

G

vascular endothelial growth factor A

decreases expression
multiple interactions

ISO

erastin results in decreased expression of VEGFA mRNA
picein inhibits the reaction [erastin results in decreased expression of VEGFA mRNA]

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

von Willebrand factor

decreases expression
multiple interactions

ISO

erastin results in decreased expression of VWF mRNA
picein inhibits the reaction [erastin results in decreased expression of VWF mRNA]

NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:160,047,982...160,177,757

G

WD repeat domain 41

decreases expression

ISO

erastin results in decreased expression of WDR41 mRNA alternative form

NCBI chr 2:27,957,453...28,008,573
Ensembl chr 2:27,957,492...28,008,573

G

Wnt family member 5A

multiple interactions
increases expression

ISO

erastin promotes the reaction [Silicon Dioxide results in increased expression of WNT5A protein]
erastin results in increased expression of WNT5A protein

NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,703,665...3,724,860

erlotinib hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [ABCG2 gene mutant form results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 results in increased export of Methotrexate]

PMID:18829547 PMID:19232821

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

acetyl-CoA carboxylase alpha

increases phosphorylation

ISO

Erlotinib Hydrochloride results in increased phosphorylation of ACACA protein

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

adhesion G protein-coupled receptor E1

multiple interactions

ISO

[Interleukin 1 Receptor Antagonist Protein co-treated with Erlotinib Hydrochloride] results in decreased expression of ADGRE1 protein

NCBI chr 9:2,329,398...2,484,959
Ensembl chr 9:2,329,438...2,484,959

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

ISO

Erlotinib Hydrochloride results in decreased phosphorylation of AKT1 protein
Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]

PMID:21195724 PMID:30623574

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

apoptotic peptidase activating factor 1

multiple interactions

ISO

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of APAF1 mRNA

NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:27,381,855...27,466,772

G

amphiregulin

affects response to substance

ISO

AREG protein affects the susceptibility to Erlotinib Hydrochloride

NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641

G

ARF GTPase 1

decreases response to substance

ISO

ARF1 mRNA results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr10:44,497,543...44,513,994

G

activating transcription factor 4

increases expression

EXP

Erlotinib Hydrochloride results in increased expression of ATF4 protein

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

autophagy related 5

decreases response to substance
increases expression

ISO

ATG5 protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased expression of ATG5 protein

PMID:21655094 PMID:23917044

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821

G

autophagy related 7

increases expression

ISO

Erlotinib Hydrochloride results in increased expression of ATG7 protein

NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:149,391,390...149,598,319

G

ATM serine/threonine kinase

multiple interactions

ISO

Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATM mRNA]

NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629

G

ATR serine/threonine kinase

multiple interactions
increases expression

ISO

Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATR mRNA]
Erlotinib Hydrochloride results in increased expression of ATR mRNA

NCBI chr 8:105,306,299...105,403,742
Ensembl chr 8:105,306,305...105,403,718

G

Axl receptor tyrosine kinase

decreases response to substance
multiple interactions

ISO

AXL results in decreased susceptibility to Erlotinib Hydrochloride
[amuvatinib results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride; [GSK 1363089 results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride

NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:90,392,864...90,424,009

G

BCL2-associated agonist of cell death

multiple interactions

ISO

Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAD mRNA]

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BCL2 associated X, apoptosis regulator

multiple interactions

ISO

Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAX mRNA]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

Bcl-2 binding component 3

multiple interactions
increases expression

ISO

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of BBC3 mRNA; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of BBC3 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of BBC3 protein]

PMID:25895606 PMID:29274334

NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666

G

BCL2, apoptosis regulator

increases expression
multiple interactions

ISO

Erlotinib Hydrochloride results in increased expression of BCL2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2 protein
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]

PMID:23894143 PMID:29274334

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 11

multiple interactions
increases expression

ISO

Harmine promotes the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L11 protein]

NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695

G

Bcl2-like 2

increases expression
multiple interactions

ISO

Erlotinib Hydrochloride results in increased expression of BCL2L2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2L2 protein
[Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]

NCBI chr15:32,326,686...32,337,834
Ensembl chr15:32,326,020...32,335,379

G

beclin 1

decreases response to substance

ISO

BECN1 protein results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

baculoviral IAP repeat-containing 5

multiple interactions
decreases expression

ISO

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BIRC5 mRNA; Erlotinib Hydrochloride inhibits the reaction [Betulinic Acid results in decreased expression of BIRC5 protein]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in decreased expression of BIRC5 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of BIRC5 protein]

PMID:25895606 PMID:29274334 PMID:30136359

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

BCL2 interacting protein 3

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962

G

B-Raf proto-oncogene, serine/threonine kinase

decreases activity

ISO

Erlotinib Hydrochloride results in decreased activity of BRAF protein mutant form

NCBI chr 4:69,329,772...69,476,931
Ensembl chr 4:69,342,813...69,476,931

G

BRCA1, DNA repair associated

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein

NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763

G

caspase 3

increases cleavage
multiple interactions
increases activity

ISO

Erlotinib Hydrochloride results in increased cleavage of CASP3 protein
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein
Erlotinib Hydrochloride results in increased activity of CASP3 protein
Erlotinib Hydrochloride promotes the reaction [resveratrol results in increased activity of CASP3 protein]; resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased activity of CASP3 protein]

PMID:23125191 PMID:25895606 PMID:30171258

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

C-C motif chemokine ligand 2

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of CCL2 mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

cyclin B1

multiple interactions

ISO

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of CCNB1 mRNA

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin D1

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

Cd69 molecule

decreases expression

ISO

Erlotinib Hydrochloride results in decreased expression of CD69 protein

NCBI chr 4:164,411,485...164,419,403
Ensembl chr 4:164,411,485...164,419,509

G

cadherin 1

multiple interactions
decreases expression

ISO
EXP

Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of CDH1 protein]; Erlotinib Hydrochloride results in decreased glycosylation of and results in increased degradation of CDH1 protein
Erlotinib Hydrochloride results in decreased expression of CDH1 mRNA; Erlotinib Hydrochloride results in decreased expression of CDH1 protein
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]

PMID:22223758 PMID:24768708

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cyclin-dependent kinase 4

decreases phosphorylation

ISO

Erlotinib Hydrochloride results in decreased phosphorylation of CDK4 protein

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163

G

cyclin-dependent kinase 6

multiple interactions
decreases expression

ISO

Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of CDK6 protein]

NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

ISO

Erlotinib Hydrochloride results in increased expression of CDKN1A mRNA
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A mRNA]

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

checkpoint with forkhead and ring finger domains

multiple interactions

ISO

CHFR protein affects the susceptibility to [Cisplatin co-treated with Erlotinib Hydrochloride]

NCBI chr12:52,164,214...52,197,860
Ensembl chr12:52,164,217...52,197,703

G

chordin-like 2

multiple interactions

ISO

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CHRDL2 protein

NCBI chr 1:163,755,316...163,782,758
Ensembl chr 1:163,755,316...163,782,757

G

colony stimulating factor 3

increases secretion

ISO

Erlotinib Hydrochloride results in increased secretion of CSF3 protein

NCBI chr10:84,157,485...84,159,860
Ensembl chr10:84,157,211...84,159,860

G

catenin beta 1

multiple interactions
affects phosphorylation
decreases expression

ISO

[Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of CTNNB1 protein
Erlotinib Hydrochloride affects the phosphorylation of CTNNB1 protein
Erlotinib Hydrochloride results in decreased expression of CTNNB1 protein

PMID:30136359 PMID:34463000

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

C-X-C motif chemokine ligand 11

multiple interactions

ISO

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CXCL11 protein

NCBI chr14:15,973,728...15,976,503
Ensembl chr14:15,973,720...15,976,567

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

ISO

Erlotinib Hydrochloride results in decreased activity of CYP19A1 protein

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

ISO

Erlotinib Hydrochloride results in decreased activity of CYP1A1 protein

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

ISO

Erlotinib Hydrochloride results in decreased activity of CYP1B1 protein

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

ISO

Erlotinib Hydrochloride results in increased expression of CYP2B6 mRNA

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity
increases expression

ISO

Erlotinib Hydrochloride results in decreased activity of CYP3A4 protein
Erlotinib Hydrochloride results in increased expression of CYP3A4 mRNA

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 51

increases response to substance

ISO

CYP51A1 mRNA results in increased susceptibility to Erlotinib Hydrochloride

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

ISO
EXP

Erlotinib Hydrochloride results in increased expression of DDIT3 protein
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

DENN domain containing 6B

decreases expression

ISO

Erlotinib Hydrochloride results in decreased expression of DENND6B mRNA

NCBI chr 7:122,139,159...122,154,720
Ensembl chr 7:122,141,317...122,153,131

G

dual specificity phosphatase 1

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of DUSP1 mRNA

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

epidermal growth factor

multiple interactions

ISO
EXP

Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to Crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]

PMID:21613822 PMID:21787763 PMID:22553343 PMID:25625231 PMID:27427493 More...

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

epidermal growth factor receptor

affects response to substance
decreases expression
decreases phosphorylation
decreases activity
multiple interactions
decreases response to substance

ISO

EGFR protein affects the susceptibility to Erlotinib Hydrochloride; EGFR protein mutant form affects the susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in decreased expression of EGFR protein modified form
Erlotinib Hydrochloride results in decreased phosphorylation of EGFR protein
Erlotinib Hydrochloride results in decreased activity of EGFR protein
[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein; EGFR gene mutant form results in increased susceptibility to [Gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]; Erlotinib Hydrochloride inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]; Erlotinib Hydrochloride results in decreased activity of and results in decreased phosphorylation of EGFR protein; Erlotinib Hydrochloride results in decreased glycosylation of and results in decreased expression of EGFR protein
EGFR protein mutant form results in decreased susceptibility to Erlotinib Hydrochloride

PMID:12907618 PMID:16407879 PMID:16891461 PMID:19168569 PMID:21080748 More...

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

eukaryotic translation initiation factor 2 subunit alpha

increases expression

EXP

Erlotinib Hydrochloride results in increased expression of EIF2S1 protein modified form

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

ETS transcription factor ELK1

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]

PMID:25625231 PMID:30364229

NCBI chr X:3,692,367...3,709,252
Ensembl chr X:3,693,293...3,709,249

G

erb-b2 receptor tyrosine kinase 3

decreases response to substance

ISO

ERBB3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120

G

estrogen receptor 1

multiple interactions

ISO

Erlotinib Hydrochloride affects the expression of and affects the phosphorylation of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

forkhead box G1

multiple interactions
decreases expression

ISO

Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]
Erlotinib Hydrochloride results in decreased expression of FOXG1 protein

NCBI chr 6:72,401,582...72,404,392
Ensembl chr 6:72,394,239...72,427,392

G

forkhead box O3

decreases phosphorylation

ISO

Erlotinib Hydrochloride results in decreased phosphorylation of FOXO3 protein

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845

G

growth differentiation factor 15

multiple interactions

ISO

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of GDF15 protein

NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022

G

guanosine monophosphate reductase

decreases expression

ISO

Erlotinib Hydrochloride results in decreased expression of GMPR mRNA

NCBI chr17:19,357,992...19,395,807
Ensembl chr17:19,357,992...19,431,655

G

glycogen synthase kinase 3 beta

decreases expression

ISO

Erlotinib Hydrochloride results in decreased expression of GSK3B protein modified form

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

H2A.X variant histone

multiple interactions
increases expression

ISO

Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of H2AX protein modified form]

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

heparin-binding EGF-like growth factor

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib]

NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220

G

interferon induced transmembrane protein 3

decreases expression

ISO

Erlotinib Hydrochloride results in decreased expression of IFITM3 mRNA

NCBI chr 1:205,540,649...205,541,758
Ensembl chr 1:205,481,168...205,547,920

G

interferon gamma

decreases secretion

ISO

Erlotinib Hydrochloride results in decreased secretion of IFNG protein

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 17F

increases expression

ISO
EXP

Erlotinib Hydrochloride results in increased expression of IL17F mRNA

NCBI chr 9:30,686,532...30,697,918
Ensembl chr 9:30,686,538...30,697,918

G

interleukin 1 alpha

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1A mRNA

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions
increases secretion

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1B mRNA
Erlotinib Hydrochloride results in increased secretion of IL1B protein

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor type 1

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1R1 mRNA

NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579

G

interleukin 1 receptor type 2

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1R2 mRNA

NCBI chr 9:49,879,928...49,920,374
Ensembl chr 9:49,877,266...49,920,374

G

interleukin 1 receptor accessory protein

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1RAP mRNA

NCBI chr11:87,567,813...87,704,346
Ensembl chr11:87,575,116...87,704,342

G

interleukin 1 receptor antagonist

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased secretion of IL1RN protein

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732

G

interleukin 2

decreases secretion

ISO

Erlotinib Hydrochloride results in decreased secretion of IL2 protein

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 25

increases expression

ISO
EXP

Erlotinib Hydrochloride results in increased expression of IL25 mRNA

NCBI chr15:32,378,750...32,382,141
Ensembl chr15:32,378,750...32,382,141

G

interleukin 2 receptor subunit alpha

decreases expression

ISO

Erlotinib Hydrochloride results in decreased expression of IL2RA protein

NCBI chr17:71,759,802...71,808,475
Ensembl chr17:71,759,802...71,808,507

G

interleukin 6

increases expression
increases secretion
multiple interactions

ISO
EXP

Erlotinib Hydrochloride results in increased expression of IL6 mRNA
Erlotinib Hydrochloride results in increased secretion of IL6 protein
Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein]; Interleukin 1 Receptor Antagonist Protein inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]

PMID:24768708 PMID:27738319 PMID:30623574

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin-1 receptor-associated kinase 1

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IRAK1 mRNA

NCBI chr X:156,919,927...156,929,825
Ensembl chr X:156,920,081...156,929,825

G

integrin subunit beta 1

decreases expression

EXP

Erlotinib Hydrochloride results in decreased expression of ITGB1 mRNA

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269

G

Janus kinase 2

decreases phosphorylation

ISO

Erlotinib Hydrochloride results in decreased phosphorylation of JAK2 protein

NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762

G

potassium voltage-gated channel subfamily H member 2

affects activity
decreases activity

ISO

Erlotinib Hydrochloride affects the activity of KCNH2 protein
Erlotinib Hydrochloride results in decreased activity of KCNH2 protein

PMID:23707608 PMID:35680041

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

KIT ligand

multiple interactions

ISO

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of KITLG protein

NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793

G

KRAS proto-oncogene, GTPase

increases response to substance

ISO

KRAS protein results in increased susceptibility to Erlotinib Hydrochloride

NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320

G

lactate dehydrogenase A

increases secretion

ISO

Erlotinib Hydrochloride results in increased secretion of LDHA protein

NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ISO

Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in increased expression of MAP1LC3B protein modified form]

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen activated protein kinase 1

decreases phosphorylation
multiple interactions

ISO
EXP

Erlotinib Hydrochloride results in decreased phosphorylation of MAPK1 protein
Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK1 protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]
Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK1 protein]

PMID:18787115 PMID:18980991 PMID:21195724 PMID:27427493 PMID:28101945

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

decreases phosphorylation
multiple interactions

ISO
EXP

Erlotinib Hydrochloride results in decreased phosphorylation of MAPK3 protein
Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK3 protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]
Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK3 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK3 protein]

PMID:18787115 PMID:18980991 PMID:21195724 PMID:27427493 PMID:28101945

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression
multiple interactions

ISO

Erlotinib Hydrochloride results in decreased expression of MCL1 protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of MCL1 protein]

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

MET proto-oncogene, receptor tyrosine kinase

multiple interactions
decreases phosphorylation

ISO

[Erlotinib Hydrochloride co-treated with Dasatinib] results in decreased phosphorylation of MET protein
Erlotinib Hydrochloride results in decreased phosphorylation of MET protein

PMID:21106725 PMID:23894143

NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821

G

MHC class I polypeptide-related sequence B

increases expression

ISO

Erlotinib Hydrochloride results in increased expression of MICB protein

NCBI chr 1:87,623,826...87,641,075
Ensembl chr 1:87,623,826...87,640,872

G

matrix metallopeptidase 14

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MMP14 mRNA]

NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893

G

matrix metallopeptidase 2

multiple interactions

ISO

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP2 mRNA

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

multiple interactions

ISO

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP9 mRNA

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

methylsterol monooxygenase 1

decreases response to substance
multiple interactions

ISO

MSMO1 protein results in decreased susceptibility to Erlotinib Hydrochloride
MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form]

NCBI chr16:29,747,113...29,764,360
Ensembl chr16:29,747,137...29,764,445

G

mechanistic target of rapamycin kinase

decreases phosphorylation
multiple interactions

ISO

Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein]

PMID:21655094 PMID:25895606

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MUC5AC mRNA]

PMID:18006877 PMID:19661247

NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006

G

MYC proto-oncogene, bHLH transcription factor

affects expression

ISO

Erlotinib Hydrochloride affects the expression of MYC protein

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

MYD88, innate immune signal transduction adaptor

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of MYD88 mRNA

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230

G

NFKB inhibitor alpha

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of NFKBIA mRNA

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nucleolar protein 10

decreases expression

ISO

Erlotinib Hydrochloride results in decreased expression of NOL10 mRNA

NCBI chr 6:45,861,773...45,954,067
Ensembl chr 6:45,872,960...45,954,066

G

NADPH oxidase 4

multiple interactions
decreases response to substance
increases expression

ISO

Erlotinib Hydrochloride results in increased expression of and results in increased stability of NOX4 mRNA
NOX4 protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased expression of NOX4 protein

NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

ISO

Erlotinib Hydrochloride binds to and results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 1, group I, member 3

affects localization

ISO

Erlotinib Hydrochloride affects the localization of NR1I3 protein mutant form

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370

G

NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL

decreases response to substance

ISO

NSDHL protein results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr X:155,817,301...155,848,224
Ensembl chr X:155,817,340...155,848,220

G

oncostatin M

multiple interactions

ISO

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of OSM protein

NCBI chr14:83,327,202...83,332,073
Ensembl chr14:83,327,554...83,331,827

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions
increases expression

ISO

Erlotinib Hydrochloride results in increased cleavage of PARP1 protein
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; Harmine promotes the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]

PMID:23125191 PMID:25895606 PMID:30171258

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [carvacrol results in increased phosphorylation of PIK3CA protein]

NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:117,143,468...117,177,411

G

PML nuclear body scaffold

increases expression
decreases response to substance
increases localization

ISO

Erlotinib Hydrochloride results in increased expression of PML protein
PML protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased localization of PML protein

NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:67,523,164...67,576,083

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of PTGS2 mRNA

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

protein tyrosine phosphatase, non-receptor type 9

decreases expression
decreases response to substance

ISO

Erlotinib Hydrochloride results in decreased expression of PTPN9 protein
PTPN9 mutant form results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr 8:66,286,771...66,368,306
Ensembl chr 8:66,287,284...66,368,294

G

RAD50 double strand break repair protein

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein

NCBI chr10:38,310,147...38,362,100
Ensembl chr10:38,310,147...38,362,100

G

RAD51 recombinase

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein

NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469

G

Raf-1 proto-oncogene, serine/threonine kinase

decreases phosphorylation
multiple interactions

ISO

Erlotinib Hydrochloride results in decreased phosphorylation of RAF1 protein
Erlotinib Hydrochloride inhibits the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased phosphorylation of RAF1 protein]

PMID:21195724 PMID:36442402

NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:150,352,160...150,412,813

G

RB transcriptional corepressor 1

decreases phosphorylation
multiple interactions
decreases expression

ISO

Erlotinib Hydrochloride results in decreased phosphorylation of RB1 protein
Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of RB1 protein modified form]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form]

PMID:21195724 PMID:30136359

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [carvacrol results in increased phosphorylation of RELA protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased acetylation of RELA protein]

PMID:28101945 PMID:32535744

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

ribosomal protein S6

decreases phosphorylation
decreases expression
multiple interactions

ISO

Erlotinib Hydrochloride results in decreased phosphorylation of RPS6 protein
Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form
MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form]

PMID:23125191 PMID:23440206

NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566

G

ribosomal protein S6 kinase B1

decreases phosphorylation
multiple interactions

ISO

Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein]

PMID:21655094 PMID:25895606

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238

G

selenium binding protein 1

decreases expression

ISO

Erlotinib Hydrochloride results in decreased expression of SELENBP1 mRNA

NCBI chr 2:185,183,022...185,193,612
Ensembl chr 2:185,183,004...185,194,295

G

siah E3 ubiquitin protein ligase 2

decreases expression

ISO

Erlotinib Hydrochloride results in decreased expression of SIAH2 mRNA

NCBI chr 2:145,063,847...145,081,675
Ensembl chr 2:145,063,857...145,081,873

G

snail family transcriptional repressor 1

multiple interactions

ISO

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI1 mRNA

NCBI chr 3:176,667,476...176,671,965

G

snail family transcriptional repressor 2

multiple interactions

ISO

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI2 mRNA

NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349

G

suppressor of cytokine signaling 3

increases expression

EXP

Erlotinib Hydrochloride results in increased expression of SOCS3 mRNA

NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825

G

SRY-box transcription factor 9

multiple interactions
decreases expression

ISO

Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]
Erlotinib Hydrochloride results in decreased expression of SOX9 protein

NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250

G

sequestosome 1

increases expression

ISO

Erlotinib Hydrochloride results in increased expression of SQSTM1 protein

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

SRC proto-oncogene, non-receptor tyrosine kinase

decreases phosphorylation

ISO

Erlotinib Hydrochloride results in decreased phosphorylation of SRC protein

NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462

G

signal transducer and activator of transcription 3

increases phosphorylation
decreases expression
increases response to substance
decreases response to substance
multiple interactions

ISO

Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein
Erlotinib Hydrochloride results in decreased expression of STAT3 protein modified form
STAT3 mutant form results in increased susceptibility to Erlotinib Hydrochloride
STAT3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride
[Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of STAT3 protein modified form; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]

PMID:23125191 PMID:23894143 PMID:30136359

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

terminal nucleotidyltransferase 5C

decreases expression

ISO

Erlotinib Hydrochloride results in decreased expression of TENT5C mRNA

NCBI chr 2:190,541,668...190,563,902
Ensembl chr 2:190,540,650...190,565,995

G

transcription factor AP-2 alpha

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]

PMID:21499124 PMID:21951556

NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219

G

transforming growth factor alpha

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib]

NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339

G

transforming growth factor, beta 1

multiple interactions

ISO

Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transmembrane p24 trafficking protein 2

decreases response to substance

ISO

TMED2 mRNA results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr12:37,713,522...37,722,606
Ensembl chr12:37,713,529...37,722,606

G

TNF superfamily member 8

multiple interactions

ISO

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of TNFSF8 protein

NCBI chr 5:82,266,436...82,292,858
Ensembl chr 5:82,266,436...82,292,858

G

toll interacting protein

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of TOLLIP mRNA

NCBI chr 1:206,391,120...206,413,809
Ensembl chr 1:206,380,308...206,411,988

G

tumor protein p53

multiple interactions
increases expression

ISO

Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of TP53 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of TP53 protein]

PMID:25895606 PMID:29274334

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

TNF receptor associated factor 6

multiple interactions

ISO

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of TRAF6 mRNA

NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328

G

twist family bHLH transcription factor 1

increases expression
decreases response to substance
multiple interactions

ISO

Erlotinib Hydrochloride results in increased expression of TWIST1 protein
TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein

NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:56,398,061...56,404,965

G

thymidylate synthetase

decreases expression
multiple interactions

ISO

Erlotinib Hydrochloride results in decreased expression of TYMS protein
Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of TYMS protein]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]

NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097

G

UL16 binding protein 1

increases expression
multiple interactions

ISO

Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA; Erlotinib Hydrochloride results in increased expression of ULBP1 protein
Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA]

PMID:21499124 PMID:21951556

NCBI chr 1:3,506,106...3,527,982

G

X-box binding protein 1

increases expression

EXP

Erlotinib Hydrochloride results in increased expression of XBP1 protein modified form

NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

24-dehydrocholesterol reductase

decreases expression

ISO

febrifugine results in decreased expression of DHCR24 mRNA

NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:126,573,338...126,599,936

G

7-dehydrocholesterol reductase

decreases expression

ISO

febrifugine results in decreased expression of DHCR7 mRNA; febrifugine results in decreased expression of DHCR7 protein

NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:208,444,434...208,461,382

G

low density lipoprotein receptor

decreases expression

ISO

febrifugine results in decreased expression of LDLR mRNA

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675

G

lanosterol synthase

decreases expression

ISO

febrifugine results in decreased expression of LSS mRNA

NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,073,543...12,118,253

G

marker of proliferation Ki-67

decreases expression

ISO

febrifugine results in decreased expression of MKI67 protein

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

squalene epoxidase

decreases expression

ISO

febrifugine results in decreased expression of SQLE mRNA; febrifugine results in decreased expression of SQLE protein

NCBI chr 7:92,758,175...92,773,049
Ensembl chr 7:92,757,409...92,773,050

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ornithine decarboxylase 1

increases activity

ISO

fenazaquin results in increased activity of ODC1 protein

NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146

G

Parkinsonism associated deglycase

increases response to substance

ISO

PARK7 mutant form results in increased susceptibility to fenazaquin

NCBI chr 5:166,636,551...166,659,825
Ensembl chr 5:166,636,552...166,659,825

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

ISO

gefitinib results in decreased activity of ABCB11 protein

PMID:20829430 PMID:23956101

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily G member 2

multiple interactions

ISO

[[gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; gefitinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Doxorubicin]

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

actin alpha 2, smooth muscle

multiple interactions
decreases expression

ISO

[Gefitinib co-treated with CCL2 protein] results in increased expression of ACTA2 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of ACTA2 protein
Gefitinib results in decreased expression of ACTA2 protein

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

adenosine A1 receptor

decreases expression

ISO

gefitinib results in decreased expression of ADORA1 mRNA

NCBI chr13:48,210,922...48,247,826
Ensembl chr13:48,213,273...48,247,190

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation
decreases phosphorylation
decreases expression

ISO
EXP

Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of AKT1 protein]; Methionine inhibits the reaction [Gefitinib results in increased phosphorylation of AKT1 protein]
Gefitinib results in decreased expression of AKT1 mRNA
Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of AKT1 protein]; Gefitinib promotes the reaction [Urethane results in increased phosphorylation of AKT1 protein]; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of AKT1 protein]]

PMID:17805209 PMID:19233551 PMID:23255615 PMID:23948867 PMID:24568969 More...

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

androgen receptor

multiple interactions

ISO

Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

amphiregulin

affects response to substance
multiple interactions
decreases response to substance

ISO

AREG protein affects the susceptibility to gefitinib
Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of AREG mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of AREG mRNA]
AREG protein results in decreased susceptibility to gefitinib

PMID:15496427 PMID:15723263 PMID:16230376 PMID:18980991 PMID:21258428

NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641

G

autophagy related 5

increases expression

ISO

gefitinib results in increased expression of ATG5 protein

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821

G

autophagy related 7

increases expression

ISO

gefitinib results in increased expression of ATG7 protein

NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:149,391,390...149,598,319

G

aurora kinase A

decreases response to substance
multiple interactions

ISO

AURKA results in decreased susceptibility to gefitinib
[AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to Gefitinib; [TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771

G

apoptosis and caspase activation inhibitor

affects response to substance

ISO

AVEN protein affects the susceptibility to gefitinib

NCBI chr 3:119,753,395...119,886,009
Ensembl chr 3:119,872,661...119,886,008

G

BCL2-associated agonist of cell death

multiple interactions

ISO

[cucurbitacin B co-treated with Gefitinib] results in increased expression of BAD mRNA

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BCL2-antagonist/killer 1

multiple interactions

ISO

[cucurbitacin B co-treated with Gefitinib] results in increased expression of BAK1 mRNA; [cucurbitacin B co-treated with Gefitinib] results in increased expression of BAK1 protein

NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

EXP
ISO

Gefitinib results in increased expression of BAX mRNA; Gefitinib results in increased expression of BAX protein
[cucurbitacin B co-treated with Gefitinib] results in increased expression of BAX mRNA; [cucurbitacin B co-treated with Gefitinib] results in increased expression of BAX protein

PMID:26183715 PMID:32370496

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

ISO

[cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2 mRNA; [cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

multiple interactions

ISO

[cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2L1 mRNA

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

Bcl2-like 11

increases response to substance
multiple interactions

ISO

BCL2L11 protein results in increased susceptibility to gefitinib
[cucurbitacin B co-treated with Gefitinib] results in increased expression of BCL2L11 mRNA

PMID:20237869 PMID:26183715

NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695

G

beclin 1

multiple interactions

ISO

[MIR578 affects the susceptibility to Gefitinib] which affects the expression of BECN1 protein; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of BECN1 protein]

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

baculoviral IAP repeat-containing 5

increases expression
decreases expression
multiple interactions

ISO

gefitinib results in increased expression of BIRC5 protein
Gefitinib results in decreased expression of BIRC5 protein
leptomycin B promotes the reaction [Gefitinib results in decreased expression of BIRC5 protein]; tyrphostin AG 1024 inhibits the reaction [Gefitinib results in increased expression of BIRC5 protein]

PMID:17473213 PMID:28942004 PMID:36807944

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

BCL2 interacting protein 3

multiple interactions

ISO

gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962

G

caspase 1

increases activity
multiple interactions

ISO

Gefitinib metabolite results in increased activity of CASP1 protein
N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [Gefitinib metabolite results in increased activity of CASP1 protein]

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 3

increases expression
increases cleavage
multiple interactions

EXP
ISO

gefitinib results in increased expression of CASP3 mRNA; gefitinib results in increased expression of CASP3 protein
Gefitinib results in increased cleavage of CASP3 protein
Gefitinib results in increased expression of CASP3 protein modified form
[Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of CASP3 protein modified form]
[cucurbitacin B co-treated with Gefitinib] results in increased cleavage of CASP3 protein; EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein

PMID:23523951 PMID:26183715 PMID:27084042 PMID:27639429 PMID:33248157

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases cleavage

ISO

Gefitinib results in increased cleavage of CASP8 protein

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caveolin 1

increases expression

ISO

gefitinib results in increased expression of CAV1 mRNA; gefitinib results in increased expression of CAV1 protein

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740

G

C-C motif chemokine ligand 2

increases secretion
increases expression
multiple interactions

ISO

Gefitinib results in increased secretion of CCL2 protein
Gefitinib results in increased expression of CCL2 mRNA
[Gefitinib co-treated with CCL2 protein] results in increased expression of ACTA2 protein; [Gefitinib co-treated with CCL2 protein] results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of CASP3 protein modified form]; [Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of PARP1 protein modified form]; [Gefitinib results in increased secretion of CCL2 protein] which results in decreased expression of CDH1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of ACTA2 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of FN1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of VIM protein; cucurbitacin B inhibits the reaction [Gefitinib results in increased expression of CCL2 mRNA]

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

cyclin B1

multiple interactions

ISO

Gefitinib results in decreased expression of and affects the localization of CCNB1 protein

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin D1

decreases expression
multiple interactions

ISO

Gefitinib results in decreased expression of CCND1 protein
[cucurbitacin B co-treated with Gefitinib] results in decreased expression of CCND1 mRNA; [cucurbitacin B co-treated with Gefitinib] results in decreased expression of CCND1 protein
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 protein]

PMID:16740687 PMID:17513607 PMID:23948867 PMID:26183715

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin D3

decreases expression

ISO

gefitinib results in decreased expression of CCND3 protein

NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033

G

CD14 molecule

multiple interactions

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]]; [gefitinib promotes the reaction arsenic trioxide] which results in increased expression of CD14 mRNA; gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]; SB 203580 inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]]

NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292

G

cadherin 1

multiple interactions
increases expression

ISO

[Gefitinib results in increased secretion of CCL2 protein] which results in decreased expression of CDH1 protein
Gefitinib results in increased expression of CDH1 protein

PMID:33248157 PMID:38517198

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cyclin-dependent kinase 1

increases phosphorylation

ISO

Gefitinib results in increased phosphorylation of CDK1 protein

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin-dependent kinase 6

multiple interactions
decreases expression

ISO

Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of CDK6 protein]

NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions
decreases expression

ISO

gefitinib results in increased expression of CDKN1A protein
leptomycin B inhibits the reaction [gefitinib results in decreased expression of CDKN1A protein]

PMID:17513607 PMID:28942004

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression
decreases expression

ISO

[cucurbitacin B co-treated with Gefitinib] results in increased expression of CDKN1B protein; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of CDKN1B protein]
Gefitinib results in increased expression of CDKN1B protein
gefitinib results in decreased expression of CDKN1B

PMID:14679152 PMID:16322342 PMID:16740687 PMID:17513607 PMID:26183715

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

cyclin-dependent kinase inhibitor 2B

increases expression

ISO

gefitinib results in increased expression of CDKN2B mRNA; gefitinib results in increased expression of CDKN2B protein

NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:109,114,322...109,134,855

G

ceramide transporter 1

affects response to substance

ISO

CERT1 protein affects the susceptibility to Gefitinib

NCBI chr 2:29,617,202...29,721,734
Ensembl chr 2:29,617,023...29,721,729

G

cell growth regulator with ring finger domain 1

increases expression

ISO

gefitinib results in increased expression of CGRRF1 mRNA

NCBI chr15:22,560,902...22,588,815
Ensembl chr15:22,568,332...22,588,811

G

claudin 2

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of CLDN2 mRNA

NCBI chr X:108,248,383...108,258,847
Ensembl chr X:108,237,676...108,262,377

G

collagen type I alpha 1 chain

decreases expression
multiple interactions

ISO

Gefitinib results in decreased expression of COL1A1 protein
[Gefitinib co-treated with CCL2 protein] results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of COL1A1 protein

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

coronin 1C

affects response to substance

ISO

CORO1C protein affects the susceptibility to gefitinib

NCBI chr12:48,373,573...48,445,718
Ensembl chr12:48,373,597...48,445,716

G

cytochrome c, somatic

affects localization

ISO

gefitinib affects the localization of CYCS protein

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases response to substance
decreases activity
increases expression

ISO
EXP

CYP1A1 protein results in increased susceptibility to gefitinib
Gefitinib results in decreased activity of CYP1A1 protein
Gefitinib results in increased expression of CYP1A1 mRNA

PMID:28652202 PMID:32370496 PMID:33814510

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

ISO

Gefitinib results in decreased activity of CYP1B1 protein

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects metabolic processing

ISO

CYP2D6 protein affects the metabolism of Gefitinib; CYP2D6 protein polymorphism affects the metabolism of Gefitinib

PMID:15788367 PMID:34936353

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily f, polypeptide 4

decreases expression

ISO

gefitinib results in decreased expression of CYP2F1 mRNA

NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:91,543,768...91,557,553

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects metabolic processing

ISO

CYP3A4 protein affects the metabolism of Gefitinib

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 9

affects metabolic processing

ISO

CYP3A5 protein affects the metabolism of gefitinib

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

DnaJ heat shock protein family (Hsp40) member B1

increases secretion

ISO

Gefitinib metabolite results in increased secretion of DNAJB1 protein

NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416

G

dual specificity phosphatase 3

affects response to substance

ISO

DUSP3 protein affects the susceptibility to gefitinib

NCBI chr10:87,420,213...87,434,202
Ensembl chr10:87,419,494...87,434,063

G

dual specificity phosphatase 9

decreases expression

ISO

gefitinib results in decreased expression of DUSP9 mRNA

NCBI chr X:156,503,237...156,507,162
Ensembl chr X:156,503,190...156,507,161

G

E2F transcription factor 1

decreases expression

ISO

gefitinib results in decreased expression of E2F1 mRNA; gefitinib results in decreased expression of E2F1 protein

PMID:17094457 PMID:18347146

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563

G

endothelin receptor type B

multiple interactions

ISO

gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA]

NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765

G

epidermal growth factor

multiple interactions

ISO

Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]
gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]

PMID:15841081 PMID:16243822 PMID:17805209 PMID:17898861 PMID:18927496 More...

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

epidermal growth factor receptor

decreases response to substance
decreases activity
multiple interactions
decreases phosphorylation
decreases expression
increases response to substance
affects response to substance

ISO
EXP

EGFR gene mutant form results in decreased susceptibility to Gefitinib; EGFR protein mutant form results in decreased susceptibility to Gefitinib
Gefitinib results in decreased activity of EGFR protein
Gefitinib inhibits the reaction [astragaloside VI results in increased expression of and results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]
Gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased expression of EGFR protein modified form
[Gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene; Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of EGFR protein]; Gefitinib promotes the reaction [Urethane results in increased phosphorylation of EGFR protein]; Gefitinib results in decreased phosphorylation of and results in decreased activity of EGFR protein; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of EGFR protein]]
Gefitinib results in decreased expression of EGFR protein modified form
[[Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [cucurbitacin B co-treated with Gefitinib] results in decreased phosphorylation of EGFR protein; [Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [Gefitinib co-treated with Oxaliplatin] results in decreased phosphorylation of EGFR protein; [Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]] which results in decreased activity of EGFR protein; [Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to Gefitinib; [Methionine co-treated with Gefitinib] results in decreased phosphorylation of EGFR protein; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form]; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein]; EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to Docetaxel]; Gefitinib inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of EGFR mRNA]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of EGFR protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]; Gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of EGFR protein; KRAS protein affects the reaction [EGFR protein affects the susceptibility to Gefitinib]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]
EGFR gene mutant form results in increased susceptibility to gefitinib; EGFR gene polymorphism results in increased susceptibility to gefitinib; EGFR protein mutant form results in increased susceptibility to gefitinib
EGFR gene mutant form affects the susceptibility to Gefitinib; EGFR protein affects the susceptibility to Gefitinib; EGFR protein mutant form affects the susceptibility to Gefitinib

PMID:13680161 PMID:14679152 PMID:15660382 PMID:15723263 PMID:15841081 More...

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

erythropoietin receptor

increases expression

ISO

gefitinib results in increased expression of EPOR mRNA

NCBI chr 8:28,765,738...28,770,371
Ensembl chr 8:28,765,746...28,770,322

G

epidermal growth factor receptor pathway substrate 15

increases expression

ISO

gefitinib results in increased expression of EPS15 mRNA

NCBI chr 5:129,274,487...129,374,856
Ensembl chr 5:129,274,502...129,374,856

G

erb-b2 receptor tyrosine kinase 2

multiple interactions
decreases phosphorylation

ISO

gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]
gefitinib results in decreased phosphorylation of ERBB2 protein

PMID:16243822 PMID:17898861

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

ERCC excision repair 1, endonuclease non-catalytic subunit

multiple interactions
affects response to substance

ISO

ERCC1 gene polymorphism affects the susceptibility to [gefitinib co-treated with Cisplatin]
ERCC1 gene polymorphism affects the susceptibility to gefitinib

NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:88,118,891...88,139,120

G

estrogen receptor 1

decreases phosphorylation

ISO

gefitinib results in decreased phosphorylation of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

increases expression
multiple interactions

ISO

gefitinib results in increased expression of ESR2 protein
Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]

PMID:20005069 PMID:29383186

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

Fas ligand

multiple interactions
increases response to substance

ISO

benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Gefitinib results in increased susceptibility to FASLG protein]

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

fibroblast growth factor 6

increases expression

ISO

gefitinib results in increased expression of FGF6 mRNA

NCBI chr 4:161,541,089...161,549,624
Ensembl chr 4:161,541,089...161,553,521

G

fibroblast growth factor receptor 3

decreases expression

ISO

Gefitinib results in decreased expression of FGFR3 mRNA

NCBI chr14:81,211,800...81,227,215
Ensembl chr14:81,211,800...81,227,209

G

fibronectin 1

multiple interactions

ISO

[Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of FN1 protein

NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ISO

Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of FOS mRNA]

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

forkhead box F1

multiple interactions

ISO

gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA]

NCBI chr19:66,062,635...66,066,427
Ensembl chr19:66,062,369...66,066,428

G

forkhead box O3

increases response to substance
increases expression
multiple interactions

ISO
EXP

FOXO3 protein results in increased susceptibility to gefitinib
Gefitinib results in increased expression of FOXO3 mRNA; Gefitinib results in increased expression of FOXO3 protein; Gefitinib results in increased expression of FOXO3 protein modified form
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of FOXO3 mRNA]
gefitinib results in decreased phosphorylation of and affects the localization of FOXO3 protein

PMID:18089711 PMID:32370496

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845

G

growth arrest and DNA-damage-inducible, alpha

increases expression

ISO

gefitinib results in increased expression of GADD45A mRNA

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

growth arrest and DNA-damage-inducible, gamma

decreases expression

ISO

gefitinib results in decreased expression of GADD45G mRNA

NCBI chr17:13,528,606...13,530,351
Ensembl chr17:13,528,610...13,530,369

G

glycyl-tRNA synthetase 1

increases expression

ISO

Gefitinib results in increased expression of GARS1 mRNA

NCBI chr 4:85,484,939...85,542,876
Ensembl chr 4:85,493,753...85,542,876

G

glutamate-cysteine ligase, catalytic subunit

affects response to substance

ISO

GCLC protein affects the susceptibility to gefitinib

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glial fibrillary acidic protein

multiple interactions

EXP

gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]]

NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685

G

G protein subunit beta 2

decreases expression

ISO

gefitinib results in decreased expression of GNB2 mRNA

NCBI chr12:24,795,505...24,800,796
Ensembl chr12:24,795,827...24,800,796

G

glycine N-methyltransferase

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of GNMT mRNA

NCBI chr 9:21,752,235...21,756,368
Ensembl chr 9:21,752,266...21,755,692

G

G protein-coupled estrogen receptor 1

multiple interactions

ISO

Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of GPER1 mRNA]

NCBI chr12:20,331,073...20,336,527
Ensembl chr12:20,327,679...20,337,144

G

glutamic--pyruvic transaminase

increases secretion

ISO

Gefitinib results in increased secretion of GPT protein

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glycogen synthase kinase 3 beta

decreases expression

ISO

Gefitinib results in decreased expression of GSK3B protein modified form

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

guanylate cyclase 2E

decreases expression

ISO

gefitinib results in decreased expression of GUCY2D mRNA

NCBI chr10:54,453,753...54,478,639
Ensembl chr10:54,457,844...54,472,898

G

hepatitis A virus cellular receptor 1

multiple interactions

ISO

Gefitinib promotes the reaction [Folic Acid results in increased expression of HAVCR1 protein]

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268

G

heparin-binding EGF-like growth factor

multiple interactions

ISO
EXP

gefitinib inhibits the reaction [irinotecan metabolite results in increased expression of HBEGF mRNA]; gefitinib inhibits the reaction [irinotecan results in increased expression of HBEGF mRNA]
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased secretion of HBEGF protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]

PMID:15723263 PMID:29228391

NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

ISO

gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of HIF1A protein]

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

high mobility group box 1

increases secretion

ISO

Gefitinib metabolite results in increased secretion of HMGB1 protein

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

heme oxygenase 1

increases expression
multiple interactions

EXP
ISO

gefitinib results in increased expression of HMOX1 mRNA; gefitinib results in increased expression of HMOX1 protein
[Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of HMOX1 mRNA

PMID:27084042 PMID:32741899

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heat shock protein 90 alpha family class A member 1

increases secretion

ISO

Gefitinib metabolite results in increased secretion of HSP90AA1 protein

NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499

G

heat shock protein family A (Hsp70) member 1A

increases secretion

ISO

Gefitinib metabolite results in increased secretion of HSPA1A protein

NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979

G

HtrA serine peptidase 1

increases expression
multiple interactions

ISO

Gefitinib results in increased expression of HTRA1 mRNA
Arsenic inhibits the reaction [Gefitinib results in increased expression of HTRA1 mRNA]

NCBI chr 1:194,928,069...194,977,619
Ensembl chr 1:194,927,687...194,977,620

G

insulin-like growth factor 1

decreases secretion

ISO

Gefitinib results in decreased secretion of IGF1 protein

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor 1 receptor

multiple interactions
increases phosphorylation

ISO

gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; tyrphostin AG 1024 inhibits the reaction [gefitinib results in increased phosphorylation of IGF1R protein]

NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664

G

interleukin 1 beta

multiple interactions
increases expression

ISO

gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B protein]
Gefitinib metabolite results in increased expression of IL1B protein

PMID:23948867 PMID:33132241

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

integrin subunit alpha M

multiple interactions

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein]]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM mRNA]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein]

NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943

G

integrin subunit alpha V

multiple interactions

ISO

gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA]

NCBI chr 3:89,245,382...89,333,512
Ensembl chr 3:89,245,095...89,333,511

G

integrin subunit beta 1

multiple interactions

ISO

[ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to gefitinib

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269

G

kinase insert domain receptor

multiple interactions

ISO

gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA]

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192

G

Kelch-like ECH-associated protein 1

increases expression

ISO

gefitinib results in increased expression of KEAP1 mRNA

NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042

G

KRAS proto-oncogene, GTPase

affects response to substance
decreases response to substance
multiple interactions

ISO

KRAS protein mutant form affects the susceptibility to gefitinib
KRAS protein results in decreased susceptibility to gefitinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to gefitinib]

PMID:17270025 PMID:28739874

NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320

G

lipocalin 2

multiple interactions

ISO

Gefitinib promotes the reaction [Folic Acid results in increased expression of LCN2 protein]

NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842

G

leptin receptor

decreases expression

ISO

gefitinib results in decreased expression of LEPR mRNA

NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215

G

galectin 9

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of LGALS9 mRNA

NCBI chr10:64,405,044...64,428,249
Ensembl chr10:64,405,044...64,428,070

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ISO

[MIR578 affects the susceptibility to Gefitinib] which affects the lipidation of MAP1LC3B protein; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the lipidation of MAP1LC3B protein]

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation
decreases phosphorylation
decreases expression

ISO
EXP

Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK1 mRNA]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK1 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]; Methionine promotes the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]
Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK1 protein]; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK1 protein]]
gefitinib results in increased phosphorylation of MAPK1 protein
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK1 protein]
gefitinib results in decreased expression of MAPK1 protein modified form

PMID:15660382 PMID:16322342 PMID:17145836 PMID:17805209 PMID:17898861 More...

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation
decreases expression
decreases phosphorylation

ISO
EXP

Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK3 mRNA]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK3 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK3 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK3 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK3 protein]; Methionine promotes the reaction [Gefitinib results in decreased phosphorylation of MAPK3 protein]
Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK3 protein]; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK3 protein]]
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK3 protein]
gefitinib results in increased phosphorylation of MAPK3 protein
gefitinib results in decreased expression of MAPK3 protein modified form

PMID:15660382 PMID:16322342 PMID:17145836 PMID:17805209 PMID:17898861 More...

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 6

multiple interactions

ISO

Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK6 mRNA]

NCBI chr 8:85,027,141...85,050,236
Ensembl chr 8:85,027,144...85,050,236

G

mitogen-activated protein kinase 8

increases phosphorylation
multiple interactions
decreases phosphorylation

ISO

gefitinib results in increased phosphorylation of MAPK8 protein
Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK8 mRNA]
Gefitinib results in decreased phosphorylation of MAPK8 protein

PMID:20846305 PMID:35317323 PMID:36190352

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

MARVEL domain containing 1

decreases response to substance

ISO

MARVELD1 protein results in decreased susceptibility to Gefitinib

NCBI chr 1:250,903,342...250,907,393
Ensembl chr 1:250,903,342...250,907,393

G

midkine

multiple interactions

ISO

gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA]

NCBI chr 3:98,356,789...98,358,960
Ensembl chr 3:98,356,789...98,358,743

G

MHC class I polypeptide-related sequence B

increases expression

ISO

Gefitinib results in increased expression of MICB protein

NCBI chr 1:87,623,826...87,641,075
Ensembl chr 1:87,623,826...87,640,872

G

MHC I like leukocyte 1

increases expression

ISO

Gefitinib results in increased expression of MICA protein

NCBI chr 1:87,500,591...87,526,983
Ensembl chr 1:87,500,676...87,526,981

G

marker of proliferation Ki-67

multiple interactions

ISO

[Gefitinib co-treated with betulin] results in decreased expression of MKI67 protein

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

mutL homolog 1

decreases expression

ISO

gefitinib results in decreased expression of MLH1 mRNA

NCBI chr 8:120,074,871...120,112,109
Ensembl chr 8:120,065,900...120,112,011

G

matrix metallopeptidase 1

decreases expression

ISO

Gefitinib results in decreased expression of MMP1 mRNA

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

matrix metallopeptidase 9

multiple interactions
decreases expression

ISO
EXP

gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
Gefitinib results in decreased expression of MMP9 mRNA; Gefitinib results in decreased expression of MMP9 protein
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]
gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]

PMID:15841081 PMID:23127547 PMID:27087131 PMID:29228391 PMID:35317323 More...

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

major histocompatibility complex, class I-related

affects expression

ISO

gefitinib affects the expression of MR1 mRNA

NCBI chr13:69,850,420...69,868,302
Ensembl chr13:69,850,420...69,868,502

G

metallothionein 2

multiple interactions

ISO

[Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of MT2 mRNA

NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709

G

mechanistic target of rapamycin kinase

decreases phosphorylation

ISO

gefitinib results in decreased phosphorylation of MTOR protein

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

ISO

gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC mRNA]; gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC protein]

NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006

G

murinoglobulin 1

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of MUG1 mRNA

NCBI chr 4:156,748,351...156,802,132

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

ISO

gefitinib results in decreased expression of MYC protein

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

myosin heavy chain 7

increases expression

EXP

gefitinib results in increased expression of MYH7 mRNA; gefitinib results in increased expression of MYH7 protein

NCBI chr15:32,416,525...32,439,851
Ensembl chr15:32,416,527...32,438,194

G

NADH:ubiquinone oxidoreductase complex assembly factor 4

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of NDUFAF4 mRNA

NCBI chr 5:43,401,795...43,406,967

G

nestin

multiple interactions

EXP

Gefitinib inhibits the reaction [astragaloside VI results in increased expression of NES protein]

NCBI chr 2:175,735,715...175,745,631
Ensembl chr 2:175,736,551...175,746,228

G

nuclear factor kappa B subunit 1

decreases expression

ISO

gefitinib results in decreased expression of NFKB1 mRNA

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

NFKB inhibitor alpha

multiple interactions

ISO

[AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to gefitinib

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

natriuretic peptide A

increases expression
multiple interactions

EXP

Gefitinib results in increased expression of NPPA mRNA; Gefitinib results in increased expression of NPPA protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of NPPA mRNA]

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

natriuretic peptide B

increases expression

EXP

gefitinib results in increased expression of NPPB mRNA; gefitinib results in increased expression of NPPB protein

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310

G

neuronal pentraxin 2

decreases expression

ISO

gefitinib results in decreased expression of NPTX2 mRNA

NCBI chr12:15,151,136...15,162,045
Ensembl chr12:15,151,136...15,162,045

G

neural retina leucine zipper

decreases expression

ISO

gefitinib results in decreased expression of NRL mRNA

NCBI chr15:32,977,023...32,981,442
Ensembl chr15:32,977,035...32,981,442

G

oncostatin M receptor

affects response to substance

ISO

OSMR protein affects the susceptibility to gefitinib

NCBI chr 2:57,634,517...57,688,802
Ensembl chr 2:57,634,517...57,688,561

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases expression
increases cleavage

ISO

Betulinic Acid promotes the reaction [Gefitinib results in increased cleavage of PARP1 protein]; Gefitinib affects the reaction [Oxaliplatin results in increased cleavage of PARP1 protein]
[Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of PARP1 protein modified form]
gefitinib results in increased cleavage of PARP1 protein

PMID:16243822 PMID:23523951 PMID:30136359 PMID:33248157

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

proliferating cell nuclear antigen

multiple interactions

ISO

Gefitinib inhibits the reaction [Folic Acid results in increased expression of PCNA protein]

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

pericentrin

decreases response to substance

ISO

PCNT protein results in decreased susceptibility to gefitinib

NCBI chr20:12,189,767...12,278,179
Ensembl chr20:12,192,353...12,278,178

G

PDZ domain containing 1

multiple interactions

ISO

Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of PDZK1 mRNA]

NCBI chr 2:187,064,995...187,096,348
Ensembl chr 2:187,065,013...187,096,806

G

platelet and endothelial cell adhesion molecule 1

multiple interactions
decreases expression

ISO

gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]
Gefitinib results in decreased expression of PECAM1 protein

PMID:18424623 PMID:35317323

NCBI chr10:92,090,263...92,152,002
Ensembl chr10:92,090,235...92,151,839

G

progesterone receptor membrane component 1

decreases response to substance

ISO

PGRMC1 protein results in decreased susceptibility to gefitinib

NCBI chr X:120,698,610...120,706,805
Ensembl chr X:120,698,610...120,706,805

G

pleckstrin homology-like domain, family A, member 2

affects response to substance

ISO

PHLDA2 protein affects the susceptibility to gefitinib

NCBI chr 1:208,126,302...208,127,241
Ensembl chr 1:208,126,302...208,127,920

G

plasminogen activator, urokinase

multiple interactions

ISO

gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]

NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030

G

phospholipase B domain containing 1

affects response to substance

ISO

PLBD1 protein affects the susceptibility to gefitinib

NCBI chr 4:171,204,198...171,260,488
Ensembl chr 4:171,204,198...171,260,488

G

phosphatase and tensin homolog

multiple interactions
increases expression

EXP

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of PTEN mRNA]
Gefitinib results in increased expression of PTEN mRNA; Gefitinib results in increased expression of PTEN protein; Gefitinib results in increased expression of PTEN protein modified form

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

gefitinib promotes the reaction [[zoledronic acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of PTGS2 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 protein]

PMID:16322342 PMID:23948867

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

PTTG1 regulator of sister chromatid separation, securin

multiple interactions
decreases response to substance

ISO

gefitinib results in decreased stability of and results in decreased expression of PTTG1 protein
PTTG1 protein results in decreased susceptibility to gefitinib

NCBI chr10:28,394,940...28,406,410
Ensembl chr10:28,394,814...28,406,309

G

quiescin sulfhydryl oxidase 1

increases expression

ISO

gefitinib results in increased expression of QSOX1 mRNA

NCBI chr13:70,500,060...70,537,711
Ensembl chr13:70,500,060...70,537,733

G

RAD51 recombinase

affects response to substance

ISO

RAD51 protein affects the susceptibility to Gefitinib

NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469

G

RB transcriptional corepressor 1

multiple interactions
decreases expression

ISO

Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of RB1 protein modified form]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form]

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

RNA binding motif protein 7

affects response to substance

ISO

RBM7 protein affects the susceptibility to gefitinib

NCBI chr 8:57,728,413...57,734,833
Ensembl chr 8:57,728,423...57,734,968

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
decreases response to substance

ISO

gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]
RELA protein results in decreased susceptibility to gefitinib

PMID:19318490 PMID:21216229

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

replication protein A1

increases expression

ISO

gefitinib results in increased expression of RPA1 mRNA

NCBI chr10:60,647,185...60,698,279
Ensembl chr10:60,647,185...60,698,279

G

ribosomal protein S6 kinase B1

decreases phosphorylation

ISO

gefitinib results in decreased phosphorylation of RPS6KB1 protein

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238

G

ribonucleotide reductase catalytic subunit M1

affects response to substance

ISO

RRM1 gene polymorphism affects the susceptibility to gefitinib

NCBI chr 1:166,235,904...166,260,206
Ensembl chr 1:166,235,900...166,260,944

G

RT1 class I, locus CE5

affects expression

ISO

gefitinib affects the expression of HLA-F mRNA

NCBI chr20:3,407,880...3,484,130

G

RT1 class II, locus Db1

affects expression

ISO

gefitinib affects the expression of HLA-DRB1 mRNA

NCBI chr20:4,550,594...4,560,182
Ensembl chr20:4,550,596...4,560,165

G

RT1 class II, locus DOa

affects expression

ISO

gefitinib affects the expression of HLA-DOA mRNA

NCBI chr20:4,755,287...4,758,491
Ensembl chr20:4,755,499...4,758,478

G

S100 calcium binding protein A6

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of S100A6 mRNA

NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:178,398,481...178,399,762

G

S100 calcium binding protein A8

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of S100A8 mRNA; [gefitinib co-treated with naphthalene] affects the expression of S100A8 protein

NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:178,464,702...178,465,221

G

serpin family F member 1

multiple interactions

ISO

gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA]

NCBI chr10:60,748,504...60,760,898
Ensembl chr10:60,748,506...60,760,898

G

stratifin

decreases expression

ISO

gefitinib results in decreased expression of SFN mRNA

NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:151,110,530...151,111,995

G

Ski proto-oncogene

increases expression

ISO

gefitinib results in increased expression of SKI mRNA

NCBI chr 5:170,995,851...171,064,957
Ensembl chr 5:170,995,851...171,064,957

G

solute carrier family 10, member 3

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of SLC10A3 mRNA

NCBI chr X:157,306,043...157,309,849
Ensembl chr X:157,303,915...157,309,793

G

snail family transcriptional repressor 2

affects response to substance

ISO

SNAI2 protein affects the susceptibility to gefitinib

NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349

G

suppressor of cytokine signaling 2

decreases expression
multiple interactions

ISO

Gefitinib results in decreased expression of SOCS2 mRNA
SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of BECN1 protein]; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of SQSTM1 protein]; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the lipidation of MAP1LC3B protein]; SOCS2 protein affects the reaction [MIR578 affects the susceptibility to Gefitinib]

NCBI chr 7:31,890,564...31,932,092
Ensembl chr 7:31,874,463...31,930,423

G

SRY-box transcription factor 17

decreases localization

ISO

gefitinib results in decreased localization of SOX17 protein

NCBI chr 5:19,814,345...19,819,859
Ensembl chr 5:19,814,360...19,819,854

G

sequestosome 1

multiple interactions
decreases expression

ISO

[Gefitinib co-treated with Cisplatin] results in decreased expression of SQSTM1 protein; [MIR578 affects the susceptibility to Gefitinib] which affects the expression of SQSTM1 protein; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein]; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of SQSTM1 protein]

PMID:25979647 PMID:27639429 PMID:37948135

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

sterol regulatory element binding transcription factor 1

multiple interactions

ISO

[Gefitinib co-treated with betulin] results in decreased expression of SREBF1 protein

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

serum response factor

multiple interactions

ISO

Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of SRF mRNA]

NCBI chr 9:21,924,050...21,933,338
Ensembl chr 9:21,924,076...21,933,337

G

signal transducer and activator of transcription 3

multiple interactions

ISO

[cucurbitacin B co-treated with Gefitinib] results in decreased phosphorylation of STAT3 protein; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of STAT3 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of STAT3 protein]

PMID:19318490 PMID:21787763 PMID:23948867 PMID:26183715

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

synaptopodin

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of SYNPO mRNA

NCBI chr18:56,326,369...56,347,359
Ensembl chr18:56,319,571...56,353,306

G

TEK receptor tyrosine kinase

multiple interactions

ISO

gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA]

NCBI chr 5:114,722,815...114,849,535
Ensembl chr 5:114,723,006...114,849,991

G

telomerase reverse transcriptase

decreases expression

ISO

gefitinib results in decreased expression of TERT mRNA

NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111

G

transcription factor AP-2 alpha

multiple interactions

ISO

gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]

PMID:21499124 PMID:21951556

NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219

G

transforming growth factor alpha

decreases response to substance
multiple interactions

ISO

TGFA protein results in decreased susceptibility to gefitinib
gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; gefitinib inhibits the reaction [irinotecan metabolite results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [irinotecan results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]

PMID:15723263 PMID:16230376 PMID:18424623 PMID:21266357

NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339

G

tumor necrosis factor

multiple interactions
decreases expression

ISO

Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF mRNA]; Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF protein]; Gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA]; Gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
Gefitinib results in decreased expression of TNF mRNA
Gefitinib results in decreased expression of and results in decreased secretion of TNF protein

PMID:15841081 PMID:23948867 PMID:35317323

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor superfamily member 1B

decreases expression

ISO

gefitinib results in decreased expression of TNFRSF1B mRNA

NCBI chr 5:162,356,250...162,387,411
Ensembl chr 5:162,353,848...162,387,411

G

troponin I3, cardiac type

increases secretion

EXP

Gefitinib results in increased secretion of TNNI3 protein

NCBI chr 1:78,342,571...78,346,255
Ensembl chr 1:78,342,592...78,346,253

G

tumor protein p53

multiple interactions
increases expression
affects response to substance

ISO
EXP

[TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein]
gefitinib results in increased expression of TP53 mRNA; gefitinib results in increased expression of TP53 protein
TP53 protein affects the susceptibility to gefitinib

PMID:21216229 PMID:27084042 PMID:29383186

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

tripartite motif-containing 23

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of TRIM23 mRNA

NCBI chr 2:37,036,193...37,069,024
Ensembl chr 2:37,035,477...37,069,526

G

TSC22 domain family, member 1

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of TSC22D1 mRNA

NCBI chr15:58,159,612...58,260,244
Ensembl chr15:58,159,952...58,183,322

G

twist family bHLH transcription factor 1

affects response to substance

ISO

TWIST1 protein affects the susceptibility to Gefitinib

NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:56,398,061...56,404,965

G

thymidylate synthetase

decreases expression
multiple interactions

ISO

Gefitinib results in decreased expression of TYMS mRNA; Gefitinib results in decreased expression of TYMS protein
Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of TYMS protein]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]; TYMS protein affects the susceptibility to [Gefitinib co-treated with S 1 (combination)]

PMID:18347146 PMID:30136359

NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097

G

UL16 binding protein 1

multiple interactions
increases expression

ISO

Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib results in increased expression of ULBP1 mRNA]
Gefitinib results in increased expression of ULBP1 mRNA; Gefitinib results in increased expression of ULBP1 protein

PMID:21499124 PMID:21951556

NCBI chr 1:3,506,106...3,527,982

G

vascular endothelial growth factor A

multiple interactions
decreases secretion
decreases expression

ISO
EXP

gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]
Gefitinib results in decreased secretion of VEGFA protein
Gefitinib results in decreased expression of VEGFA mRNA; Gefitinib results in decreased expression of VEGFA protein
gefitinib results in decreased expression of VEGFA protein

PMID:15660382 PMID:18424623 PMID:35317323 PMID:38517198

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vimentin

multiple interactions
decreases expression

ISO

[Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of VIM protein; Gefitinib inhibits the reaction [Folic Acid results in increased expression of VIM protein]
Gefitinib results in decreased expression of VIM protein

PMID:23255615 PMID:33248157 PMID:38517198

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746

G

X-ray repair cross complementing 1

affects response to substance

ISO

XRCC1 protein polymorphism affects the susceptibility to gefitinib

NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613

G

zinc finger CCCH type containing 3

multiple interactions

ISO

[gefitinib co-treated with naphthalene] affects the expression of ZC3H3 mRNA

NCBI chr 7:109,321,423...109,406,241
Ensembl chr 7:109,321,423...109,406,172

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

ISO

IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of AKT1 protein]
IC 87114 results in decreased phosphorylation of AKT1 protein

PMID:16179367 PMID:19176369

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

colony stimulating factor 2

multiple interactions

ISO

IC 87114 inhibits the reaction [PTPN11 protein mutant form results in increased susceptibility to CSF2 protein]

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

forkhead box O3

multiple interactions
decreases phosphorylation

ISO

IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of FOXO3 protein]
IC 87114 results in decreased phosphorylation of FOXO3 protein

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845

G

glycogen synthase kinase 3 alpha

decreases phosphorylation

ISO

IC 87114 results in decreased phosphorylation of GSK3A protein

NCBI chr 1:89,943,669...89,953,514
Ensembl chr 1:89,943,669...89,953,593

G

glycogen synthase kinase 3 beta

decreases phosphorylation

ISO

IC 87114 results in decreased phosphorylation of GSK3B protein

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

interleukin 10

multiple interactions

ISO

IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in decreased secretion of IL10 protein]

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 18

multiple interactions

ISO

IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL18 protein]

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 4

multiple interactions

ISO

IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of AKT1 protein]; IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of FOXO3 protein]; IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK1 protein]; IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK3 protein]; IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL4 protein]

PMID:16179367 PMID:33711354

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 5

multiple interactions

ISO

IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL5 protein]

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

multiple interactions

ISO

IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

ISO

IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK1 protein]
IC 87114 results in decreased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

ISO

IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK3 protein]
IC 87114 results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta

decreases activity
multiple interactions

ISO

IC 87114 results in decreased activity of PIK3CD protein
IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of PIK3CD protein]

PMID:16179367 PMID:33711354

NCBI chr 5:165,377,994...165,426,620
Ensembl chr 5:165,377,994...165,403,968

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma

multiple interactions

ISO

IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of PIK3CG protein]

NCBI chr 6:54,494,247...54,529,563
Ensembl chr 6:54,478,603...54,529,509

G

protein tyrosine phosphatase, non-receptor type 11

multiple interactions
increases response to substance

ISO

IC 87114 inhibits the reaction [PTPN11 protein mutant form results in increased susceptibility to CSF2 protein]
PTPN11 protein mutant form results in increased susceptibility to IC 87114

NCBI chr12:41,026,079...41,085,577
Ensembl chr12:41,043,785...41,085,577

G

ribosomal protein S6 kinase B1

decreases phosphorylation

ISO

IC 87114 results in decreased phosphorylation of RPS6KB1 protein

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

ISO

[idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein; AKT activator SC79 inhibits the reaction [[idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein]; palbociclib promotes the reaction [idelalisib results in decreased phosphorylation of AKT1 protein]

PMID:23676220 PMID:31445927

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

BCL2 associated X, apoptosis regulator

multiple interactions

ISO

[FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

ISO

[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

multiple interactions

ISO

[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein]

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

BH3 interacting domain death agonist

multiple interactions

ISO

[FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein]

NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275

G

caspase 3

multiple interactions

ISO

[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

multiple interactions

ISO

[TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein]; AKT activator SC79 inhibits the reaction [idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]]; idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

CASP8 and FADD-like apoptosis regulator

multiple interactions

ISO

[FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein]

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434

G

C-X-C motif chemokine ligand 1

decreases expression

ISO

idelalisib decreases expression of Cxcl1 protein in liver and spleen

RGD

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811

G

Fas cell surface death receptor

affects response to substance
multiple interactions

ISO

idelalisib affects the susceptibility to FAS protein
FAS protein affects the reaction [idelalisib results in increased expression of ALT protein]

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

multiple interactions

ISO

[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein; [FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein; [FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein; [FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein; [idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein]; AKT activator SC79 inhibits the reaction [[idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein]; AKT activator SC79 inhibits the reaction [idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]]; AKT activator SC79 inhibits the reaction [idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]]; idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]; idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

glutamic--pyruvic transaminase

multiple interactions
affects expression
increases expression

ISO

[Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; FAS protein affects the reaction [idelalisib results in increased expression of ALT protein]
idelalisib affects the expression of GPT protein

PMID:31445927 PMID:31501888

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

hypoxia inducible factor 1 subunit alpha

increases expression
multiple interactions

ISO

idelalisib results in increased expression of HIF1A protein
idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of HIF1A protein]

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

interferon gamma

decreases expression

ISO

idelalisib decreases expression of Ifng protein in liver, spleen and lymph node

RGD

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 10

decreases expression

ISO

idelalisib decreases expression of Il10 protein in liver, lymph node and spleen

RGD

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 4

decreases expression

ISO

idelalisib decreases expression of Il4 protein in lymph node

RGD

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 6

decreases expression

ISO

idelalisib decreases expression of Il6 protein in liver and spleen

RGD

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

microRNA 122

affects expression

ISO

idelalisib affects the expression of MIR122 mRNA

NCBI chr18:61,028,817...61,028,901

G

matrix metallopeptidase 9

multiple interactions
decreases expression

ISO

idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA]
idelalisib results in decreased expression of MMP9 protein

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

mechanistic target of rapamycin kinase

multiple interactions

ISO

idelalisib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MTOR protein]
idelalisib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MTOR protein]; idelalisib promotes the reaction [Lipopolysaccharides results in increased expression of MTOR mRNA]

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

N-acetyltransferase 10

increases expression

ISO

idelalisib results in increased expression of NAT10 mRNA

NCBI chr 3:110,566,582...110,604,829
Ensembl chr 3:110,566,582...110,604,836

G

poly (ADP-ribose) polymerase 1

multiple interactions

ISO

[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

increases expression
multiple interactions

ISO

idelalisib results in increased expression of PIK3CA mRNA
idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA]

NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:117,143,468...117,177,411

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta

increases expression
multiple interactions

ISO

idelalisib results in increased expression of PIK3CB mRNA
idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA]

NCBI chr 8:108,474,017...108,579,140
Ensembl chr 8:108,474,019...108,579,331

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta

multiple interactions
increases expression

ISO

idelalisib inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA]
idelalisib results in increased expression of PIK3CD mRNA

NCBI chr 5:165,377,994...165,426,620
Ensembl chr 5:165,377,994...165,403,968

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma

decreases expression

ISO

idelalisib results in decreased expression of PIK3CG mRNA

NCBI chr 6:54,494,247...54,529,563
Ensembl chr 6:54,478,603...54,529,509

G

phosphoinositide-3-kinase interacting protein 1

increases expression

ISO

idelalisib results in increased expression of PIK3IP1 mRNA

NCBI chr14:82,428,315...82,440,261
Ensembl chr14:82,428,248...82,440,260

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

AKT activator SC79 inhibits the reaction [idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]]; idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

transforming growth factor, beta 1

multiple interactions

ISO

idelalisib inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA]; idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA]; idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

tumor necrosis factor

increases response to substance
multiple interactions

ISO

idelalisib results in increased susceptibility to TNF protein
[TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

vascular endothelial growth factor A

multiple interactions

ISO

idelalisib promotes the reaction [Lipopolysaccharides results in increased expression of VEGFA mRNA]
idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of VEGFA mRNA]; idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of VEGFA protein]

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor alpha 1A

multiple interactions

ISO
EXP

Ketanserin inhibits the reaction [Prazosin binds to ADRA1A protein]
Ketanserin binds to and results in decreased activity of ADRA1A protein

PMID:11937776 PMID:16545797

NCBI chr15:45,005,648...45,111,416
Ensembl chr15:45,005,799...45,102,534

G

adrenoceptor alpha 1B

multiple interactions

ISO

Ketanserin inhibits the reaction [Prazosin binds to ADRA1B protein]

NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347

G

adrenoceptor alpha 1D

multiple interactions

ISO

Ketanserin inhibits the reaction [Prazosin binds to ADRA1D protein]

NCBI chr 3:139,246,333...139,262,331
Ensembl chr 3:139,246,323...139,262,331

G

AKT serine/threonine kinase 1

multiple interactions

ISO

[[Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]] which results in increased ubiquitination of and results in increased degradation of IRS1 protein; [Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]; Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

brain-derived neurotrophic factor

multiple interactions

EXP

[Fluoxetine co-treated with Ketanserin] results in increased expression of BDNF mRNA

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

catenin beta 1

multiple interactions

EXP

[Fluoxetine co-treated with Ketanserin] results in increased expression of CTNNB1 mRNA

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

dopa decarboxylase

increases activity

ISO

Ketanserin results in increased activity of DDC protein

NCBI chr14:90,592,304...90,682,830
Ensembl chr14:90,592,304...90,682,806

G

5-hydroxytryptamine receptor 2A

multiple interactions
decreases activity
affects binding

ISO
EXP

Aripiprazole inhibits the reaction [Ketanserin binds to HTR2A protein]; Clozapine inhibits the reaction [Ketanserin binds to HTR2A protein]; Ketanserin binds to and results in decreased activity of HTR2A protein; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Ketanserin binds to HTR2A protein]; Quetiapine Fumarate inhibits the reaction [Ketanserin binds to HTR2A protein]; Spiperone inhibits the reaction [Ketanserin binds to HTR2A protein]; ziprasidone inhibits the reaction [Ketanserin binds to HTR2A protein]
Ketanserin results in decreased activity of HTR2A protein
8-fluoro-12-(4-methylpiperazin-1-yl)-6H-(1)benzothieno(2,3-b)(1,5)benzodiazepine inhibits the reaction [Ketanserin binds to HTR2A protein]; [Ketanserin binds to and results in decreased activity of HTR2A protein] inhibits the reaction [Methamphetamine results in decreased abundance of Serotonin]; [Ketanserin binds to and results in decreased activity of HTR2A protein] inhibits the reaction [Methamphetamine results in increased secretion of Corticosterone]; [Ketanserin binds to and results in decreased activity of HTR2A protein] which results in decreased susceptibility to Serotonin; Diazinon promotes the reaction [Ketanserin binds to HTR2A protein]; Ketanserin binds to and results in decreased activity of HTR2A protein; Ketanserin inhibits the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]]; Ketanserin inhibits the reaction [Tramadol results in increased activity of HTR2A protein]; Risperidone inhibits the reaction [Ketanserin binds to HTR2A protein]
4-iodo-2,5-dimethoxyphenylisopropylamine inhibits the reaction [Ketanserin binds to HTR2A protein]; cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Ketanserin binds to HTR2A protein]; HU 211 inhibits the reaction [Ketanserin binds to HTR2A protein]; Ketanserin binds to and results in decreased activity of HTR2A protein

PMID:2891550 PMID:10773215 PMID:10978843 PMID:11927170 PMID:16314884 More...

NCBI chr15:56,360,647...56,428,703
Ensembl chr15:56,359,596...56,431,619

G

5-hydroxytryptamine receptor 7

multiple interactions

ISO

[Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]

NCBI chr 1:243,049,064...243,173,636
Ensembl chr 1:243,049,081...243,173,230

G

interleukin 6

multiple interactions

ISO

Ketanserin inhibits the reaction [Serotonin results in increased expression of and results in increased secretion of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin receptor substrate 1

multiple interactions

ISO

[[Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]] which results in increased ubiquitination of and results in increased degradation of IRS1 protein; [Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]

NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538

G

mitogen activated protein kinase 1

multiple interactions

ISO

Ketanserin inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions

ISO

Ketanserin inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO

Ketanserin inhibits the reaction [Tobacco Smoke Pollution affects the localization of NFE2L2 protein]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

protein phosphatase 1, regulatory (inhibitor) subunit 1B

multiple interactions

ISO

Ketanserin inhibits the reaction [Serotonin results in increased phosphorylation of PPP1R1B protein]

NCBI chr10:83,843,948...83,853,063
Ensembl chr10:83,844,036...83,853,063

G

solute carrier family 6 member 4

affects binding
multiple interactions

ISO

Ketanserin binds to SLC6A4 protein
methamidophos inhibits the reaction [Ketanserin binds to SLC6A4 protein]

NCBI chr10:62,322,688...62,357,060
Ensembl chr10:62,324,254...62,357,056

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta

multiple interactions

ISO

[[Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]] which results in increased ubiquitination of and results in increased degradation of IRS1 protein; [Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]

NCBI chr 3:173,078,904...173,101,508
Ensembl chr 3:173,079,041...173,101,854

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

ISO

lapatinib results in decreased activity of ABCB11 protein

PMID:20829430 PMID:23956101 PMID:28437613

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily B member 1A

multiple interactions

ISO

lapatinib inhibits the reaction [ABCB1 protein results in increased export of and results in decreased susceptibility to Doxorubicin]; lapatinib inhibits the reaction [azidoprazosin binds to ABCB1 protein]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily B member 4

decreases activity

ISO

lapatinib results in decreased activity of ABCB4 protein

NCBI chr 4:26,106,895...26,164,440

G

ATP binding cassette subfamily G member 2

multiple interactions

ISO

lapatinib inhibits the reaction [ABCG2 gene mutant form results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Topotecan]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; lapatinib inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]; lapatinib inhibits the reaction [azidoprazosin binds to ABCG2 protein]; lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

actin alpha 2, smooth muscle

multiple interactions

ISO

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation
decreases activity
decreases expression

ISO

[Bortezomib co-treated with Lapatinib] results in decreased phosphorylation of AKT1 protein; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of AKT1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein]
Lapatinib results in decreased phosphorylation of AKT1 protein
lapatinib results in decreased activity of AKT1 protein
lapatinib results in decreased expression of AKT1 protein; lapatinib results in decreased expression of AKT1 protein modified form

PMID:15665275 PMID:16091755 PMID:19435893 PMID:19509167 PMID:20701607 More...

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldehyde dehydrogenase 1 family, member A1

multiple interactions

ISO

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ALDH1A1 protein

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

ISO

Lapatinib results in increased expression of BAX protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased expression of BAX protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]]

PMID:29387217 PMID:32890875

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

ISO

Lapatinib results in decreased expression of BCL2 protein
AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]

PMID:29387217 PMID:32890875

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

baculoviral IAP repeat-containing 5

decreases expression

ISO

lapatinib results in decreased expression of BIRC5 protein

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

BCL2 interacting protein 3

multiple interactions

ISO

Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of BNIP3 mRNA]

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962

G

caspase 3

increases cleavage
increases activity
multiple interactions

ISO

Lapatinib results in increased cleavage of CASP3 protein
Lapatinib results in increased activity of CASP3 protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP3 protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]

PMID:29387217 PMID:32890875 PMID:37788138

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 7

increases activity

ISO

Lapatinib results in increased activity of CASP7 protein

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512

G

caspase 9

multiple interactions
increases activity
increases cleavage

ISO

2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP9 protein]
Lapatinib results in increased activity of CASP9 protein

PMID:29387217 PMID:37788138

Ensembl chr 5:159,391,188...159,409,648

G

cyclin A2

decreases expression

ISO

lapatinib results in decreased expression of CCNA2 protein

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin D1

multiple interactions
decreases expression

ISO

[afimoxifene co-treated with Lapatinib] results in decreased expression of CCND1 protein; [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]
lapatinib results in decreased expression of CCND1 protein

PMID:15665275 PMID:25221644 PMID:32890875 PMID:33396024

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin E1

multiple interactions

ISO

[afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

CD24 molecule

multiple interactions

ISO

[lapatinib results in decreased susceptibility to lapatinib] which results in decreased expression of CD24 protein

NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785

G

CD44 molecule

multiple interactions

ISO

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of CD44 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]]

PMID:26643609 PMID:33396024

NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424

G

cadherin 1

multiple interactions

ISO

[Genistein co-treated with Lapatinib] promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein]

PMID:26643609 PMID:32890875 PMID:33396024

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cadherin 2

multiple interactions

ISO

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein]

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288

G

cyclin dependent kinase 2

multiple interactions

ISO

[afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

ISO

Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein]

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression

ISO

[afimoxifene co-treated with Lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; [afimoxifene co-treated with Lapatinib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]
lapatinib results in increased expression of CDKN1B protein

PMID:15665275 PMID:20701607 PMID:32890875

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity
increases metabolic processing

ISO

Lapatinib results in decreased activity of CYP1A1 protein
CYP1A1 protein results in increased metabolism of Lapatinib

PMID:33814510 PMID:37788138

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

ISO

Lapatinib results in decreased activity of CYP1B1 protein

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing
multiple interactions

ISO

CYP3A4 protein results in increased metabolism of Lapatinib
[CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of HMOX1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of NQO1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD2 mRNA

PMID:26958860 PMID:33259822 PMID:37788138

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases metabolic processing
multiple interactions

ISO

CYP3A5 protein results in increased metabolism of Lapatinib
[CYP3A5 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; CYP3A5 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]

PMID:26958860 PMID:37788138

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

epidermal growth factor receptor

decreases activity
affects response to substance
multiple interactions

ISO

lapatinib results in decreased activity of EGFR protein
EGFR protein affects the susceptibility to lapatinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]; lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]

PMID:15665275 PMID:17192538 PMID:19509167 PMID:20549698 PMID:28739874

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

erb-b2 receptor tyrosine kinase 2

multiple interactions
decreases phosphorylation
decreases expression
decreases activity

ISO

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of ERBB2 protein; Bortezomib promotes the reaction [Lapatinib results in decreased phosphorylation of ERBB2 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of MCM7 protein]; Lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein]
lapatinib results in decreased phosphorylation of ERBB2 protein
lapatinib results in decreased expression of ERBB2 protein
lapatinib results in decreased activity of ERBB2 protein

PMID:15665275 PMID:16091755 PMID:17192538 PMID:19509167 PMID:20197467 More...

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

erb-b2 receptor tyrosine kinase 3

decreases expression
decreases activity

ISO

lapatinib results in decreased expression of ERBB3 protein modified form
lapatinib results in decreased activity of ERBB3 protein

PMID:19435893 PMID:19509167

NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120

G

estrogen receptor 1

decreases activity
multiple interactions

ISO

lapatinib results in decreased activity of ESR1 protein
[lapatinib co-treated with afimoxifene] results in decreased activity of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

glutamic--pyruvic transaminase

increases secretion

ISO

Lapatinib results in increased secretion of GPT protein

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

H2A.X variant histone

increases expression
multiple interactions

ISO

Lapatinib results in increased expression of H2AX protein
CYP3A5 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]; CYP3A7 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

ISO

AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]

PMID:25981168 PMID:32890875

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

heme oxygenase 1

multiple interactions
increases expression

ISO

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of HMOX1 mRNA
lapatinib metabolite results in increased expression of HMOX1 mRNA

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

Janus kinase 2

multiple interactions

ISO

Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of JAK2 protein]

NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762

G

KRAS proto-oncogene, GTPase

decreases response to substance
multiple interactions

ISO

KRAS protein results in decreased susceptibility to lapatinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]

NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320

G

lactate dehydrogenase A

increases secretion

ISO

Lapatinib results in increased secretion of LDHA protein

NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation
decreases expression
decreases activity

ISO

ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]
lapatinib results in decreased phosphorylation of MAPK1 protein
lapatinib results in decreased expression of MAPK1 protein
lapatinib results in decreased activity of MAPK1 protein

PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More...

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen-activated protein kinase 12

multiple interactions

ISO

lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]

NCBI chr 7:122,085,647...122,096,307
Ensembl chr 7:122,085,913...122,096,307

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation
decreases expression
decreases activity

ISO

ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]
lapatinib results in decreased phosphorylation of MAPK3 protein
lapatinib results in decreased expression of MAPK3 protein
lapatinib results in decreased activity of MAPK3 protein

PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More...

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

minichromosome maintenance complex component 7

multiple interactions
decreases expression

ISO

ERBB2 protein affects the reaction [lapatinib results in decreased expression of MCM7 protein]

NCBI chr12:22,155,921...22,163,320
Ensembl chr12:22,155,921...22,163,771

G

mechanistic target of rapamycin kinase

multiple interactions

ISO

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein]

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases activity

ISO

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein
lapatinib metabolite results in increased activity of NFE2L2 protein

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

ISO

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of NQO1 mRNA
lapatinib metabolite results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

ISO

2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of PARP1 protein]; [Lapatinib co-treated with bafilomycin A] results in increased cleavage of PARP1 protein; [Lapatinib co-treated with concanamycin A] results in increased cleavage of PARP1 protein; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]

PMID:25221644 PMID:25981168 PMID:29387217 PMID:32890875

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

proliferating cell nuclear antigen

multiple interactions

ISO

[Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]

PMID:32890875 PMID:33396024

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

protein tyrosine phosphatase, non-receptor type 3

multiple interactions

ISO

lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]

NCBI chr 5:76,703,687...76,822,584
Ensembl chr 5:76,703,687...76,860,470

G

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions

ISO

Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of RAF1 protein]

NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:150,352,160...150,412,813

G

RB transcriptional corepressor 1

multiple interactions

ISO

Lapatinib inhibits the reaction [sodium arsenite results in decreased phosphorylation of RB1 protein]

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

snail family transcriptional repressor 1

multiple interactions
decreases response to substance

ISO

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of SNAI1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein]
SNAI1 protein results in decreased susceptibility to lapatinib

PMID:26643609 PMID:32890875 PMID:33396024

NCBI chr 3:176,667,476...176,671,965

G

snail family transcriptional repressor 2

multiple interactions

ISO

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]]

NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349

G

superoxide dismutase 1

multiple interactions

ISO

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD1 mRNA

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

superoxide dismutase 2

multiple interactions
increases expression

ISO

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD2 mRNA
lapatinib metabolite results in increased expression of SOD2 mRNA

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

SRY-box transcription factor 2

multiple interactions

ISO

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of SOX2 protein

NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

ISO

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of SRC protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein]

PMID:26643609 PMID:32890875

NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462

G

signal transducer and activator of transcription 3

multiple interactions

ISO

Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of STAT3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of STAT3 protein]

PMID:32890875 PMID:33396024

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

transforming growth factor, beta 1

decreases response to substance

ISO

TGFB1 protein results in decreased susceptibility to lapatinib

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

DNA topoisomerase I

decreases expression

ISO

Lapatinib results in decreased expression of TOP1 protein

NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327

G

DNA topoisomerase II alpha

decreases expression

ISO

Lapatinib results in decreased expression of TOP2A protein

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366

G

twist family bHLH transcription factor 1

multiple interactions

ISO

Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]]

NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:56,398,061...56,404,965

G

UDP glucuronosyltransferase 1 family, polypeptide A2

decreases activity
multiple interactions

ISO

Lapatinib results in decreased activity of UGT1A3 protein
[Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of obeticholic acid; [Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of Ursodeoxycholic Acid

NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

vascular endothelial growth factor A

multiple interactions

ISO

AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]]

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vimentin

multiple interactions

ISO

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VIM protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein]

PMID:26643609 PMID:32890875 PMID:33396024

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

EXP

Linagliptin inhibits the reaction [Cisplatin results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

caspase 3

multiple interactions

ISO

Linagliptin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

cystatin C

multiple interactions

EXP

Linagliptin inhibits the reaction [Cisplatin results in increased expression of CST3 protein]

NCBI chr 3:156,790,061...156,794,116
Ensembl chr 3:156,790,079...156,793,937

G

DNA-damage inducible transcript 3

multiple interactions

ISO

Linagliptin inhibits the reaction [Cisplatin results in increased expression of DDIT3 mRNA]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

dipeptidylpeptidase 4

decreases activity

EXP

Linagliptin results in decreased activity of DPP4 protein

NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422

G

dual specificity phosphatase 1

multiple interactions

EXP

Linagliptin inhibits the reaction [Acetic Acid results in decreased expression of DUSP1 mRNA]

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

forkhead box O3

multiple interactions

EXP

Linagliptin inhibits the reaction [Cisplatin results in decreased expression of FOXO3 protein]

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845

G

heme oxygenase 1

multiple interactions

EXP

indole-3-carbinol promotes the reaction [Linagliptin inhibits the reaction [letrozole results in decreased expression of HMOX1 protein]]; Linagliptin inhibits the reaction [letrozole results in decreased expression of HMOX1 protein]; Linagliptin promotes the reaction [indole-3-carbinol inhibits the reaction [letrozole results in decreased expression of HMOX1 protein]]

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heat shock protein family A (Hsp70) member 5

multiple interactions

ISO

Linagliptin inhibits the reaction [Cisplatin results in increased expression of HSPA5 mRNA]

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

interleukin 10

multiple interactions

EXP

indole-3-carbinol promotes the reaction [Linagliptin inhibits the reaction [Letrozole results in increased expression of IL10 protein]]; Linagliptin inhibits the reaction [Acetic Acid results in decreased expression of IL10 protein]; Linagliptin inhibits the reaction [Letrozole results in increased expression of IL10 protein]; Linagliptin promotes the reaction [indole-3-carbinol inhibits the reaction [Letrozole results in increased expression of IL10 protein]]

PMID:28619389 PMID:35122774

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 6

multiple interactions

EXP

Linagliptin inhibits the reaction [Acetic Acid results in increased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin 1

multiple interactions

EXP

indole-3-carbinol promotes the reaction [Linagliptin inhibits the reaction [Letrozole results in increased expression of INS1 protein]]; Linagliptin inhibits the reaction [Letrozole results in increased expression of INS1 protein]; Linagliptin promotes the reaction [indole-3-carbinol inhibits the reaction [Letrozole results in increased expression of INS1 protein]]

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

Janus kinase 2

multiple interactions

ISO
EXP

Linagliptin inhibits the reaction [Cuprizone results in increased expression of JAK2 protein modified form]
Linagliptin inhibits the reaction [Acetic Acid results in increased phosphorylation of JAK2 protein]

PMID:29864483 PMID:35122774

NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762

G

luteinizing hormone subunit beta

multiple interactions

EXP

indole-3-carbinol promotes the reaction [Linagliptin inhibits the reaction [letrozole results in increased expression of LHB protein]]; Linagliptin inhibits the reaction [letrozole results in increased expression of LHB protein]; Linagliptin promotes the reaction [indole-3-carbinol inhibits the reaction [letrozole results in increased expression of LHB protein]]

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

mitogen activated protein kinase 1

multiple interactions

EXP

Linagliptin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions

EXP

Linagliptin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

myelin basic protein

multiple interactions

ISO

Linagliptin inhibits the reaction [Cuprizone results in decreased expression of MBP mRNA]

NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174

G

mechanistic target of rapamycin kinase

multiple interactions

EXP

Linagliptin inhibits the reaction [Acetic Acid results in increased expression of MTOR mRNA]

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

NFE2 like bZIP transcription factor 2

multiple interactions

EXP

indole-3-carbinol promotes the reaction [Linagliptin inhibits the reaction [letrozole results in decreased expression of NFE2L2 protein]]; Linagliptin inhibits the reaction [letrozole results in decreased expression of NFE2L2 protein]; Linagliptin promotes the reaction [indole-3-carbinol inhibits the reaction [letrozole results in decreased expression of NFE2L2 protein]]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions

EXP

Linagliptin inhibits the reaction [Acetic Acid results in decreased expression of NR0B2 mRNA]

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

oligodendrocyte transcription factor 2

multiple interactions

ISO

Linagliptin inhibits the reaction [Cuprizone results in decreased expression of OLIG2 mRNA]

NCBI chr11:43,961,585...43,964,961
Ensembl chr11:43,958,940...43,968,634

G

PTEN induced kinase 1

multiple interactions

EXP

Linagliptin inhibits the reaction [Cisplatin results in decreased expression of PINK1]

NCBI chr 5:155,813,838...155,825,950
Ensembl chr 5:155,813,838...155,825,950

G

proteolipid protein 1

multiple interactions

ISO

Linagliptin inhibits the reaction [Cuprizone results in decreased expression of PLP1 mRNA]

NCBI chr X:104,933,921...104,993,317
Ensembl chr X:104,975,780...104,993,314

G

PPARG coactivator 1 alpha

multiple interactions

ISO
EXP

Linagliptin inhibits the reaction [Cisplatin results in decreased expression of PPARGC1A protein]
Linagliptin inhibits the reaction [Acetic Acid results in decreased expression of PPARGC1A mRNA]; Linagliptin inhibits the reaction [Cisplatin results in decreased expression of PPARGC1A]

PMID:32567747 PMID:35122774 PMID:39102946

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions

EXP

Linagliptin inhibits the reaction [Cisplatin results in decreased expression of PRKN]

NCBI chr 1:51,236,410...52,430,242
Ensembl chr 1:51,210,330...52,430,304

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

EXP
ISO

indole-3-carbinol promotes the reaction [Linagliptin inhibits the reaction [Letrozole affects the localization of RELA protein]]; Linagliptin inhibits the reaction [Acetic Acid results in increased expression of RELA protein]; Linagliptin inhibits the reaction [Letrozole affects the localization of RELA protein]; Linagliptin promotes the reaction [indole-3-carbinol inhibits the reaction [Letrozole affects the localization of RELA protein]]
Linagliptin inhibits the reaction [Cuprizone results in increased expression of RELA protein]

PMID:28619389 PMID:29864483 PMID:35122774

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

sirtuin 1

multiple interactions

ISO
EXP

Linagliptin inhibits the reaction [Cuprizone results in decreased expression of SIRT1 mRNA]
Linagliptin inhibits the reaction [Acetic Acid results in decreased expression of SIRT1 mRNA]

PMID:29864483 PMID:35122774

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

sirtuin 3

multiple interactions

EXP

Linagliptin inhibits the reaction [Cisplatin results in decreased expression of SIRT3 mRNA]

NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076

G

suppressor of cytokine signaling 3

multiple interactions

EXP

Linagliptin inhibits the reaction [Acetic Acid results in increased expression of SOCS3 mRNA]

NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825

G

sequestosome 1

multiple interactions

EXP

Linagliptin inhibits the reaction [Cisplatin results in increased expression of SQSTM1]

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

signal transducer and activator of transcription 3

multiple interactions

ISO
EXP

Linagliptin inhibits the reaction [Cuprizone results in increased expression of STAT3 protein modified form]
Linagliptin inhibits the reaction [Acetic Acid results in increased phosphorylation of STAT3 protein]

PMID:29864483 PMID:35122774

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

transforming growth factor, beta 1

multiple interactions

EXP

indole-3-carbinol promotes the reaction [Linagliptin inhibits the reaction [letrozole results in increased expression of TGFB1 protein]]; Linagliptin inhibits the reaction [letrozole results in increased expression of TGFB1 protein]; Linagliptin promotes the reaction [indole-3-carbinol inhibits the reaction [letrozole results in increased expression of TGFB1 protein]]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

tumor necrosis factor

multiple interactions

EXP
ISO

indole-3-carbinol promotes the reaction [Linagliptin inhibits the reaction [Letrozole results in increased expression of TNF protein]]; Linagliptin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Linagliptin inhibits the reaction [Letrozole results in increased expression of TNF protein]; Linagliptin promotes the reaction [indole-3-carbinol inhibits the reaction [Letrozole results in increased expression of TNF protein]]
Linagliptin inhibits the reaction [Cuprizone results in increased expression of TNF protein]

PMID:28619389 PMID:29864483 PMID:35122774

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

ISO

[Metolazone results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

nuclear receptor subfamily 1, group I, member 2

increases activity
multiple interactions

ISO

Metolazone results in increased activity of NR1I2 protein
[Metolazone results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ERCC excision repair 6, chromatin remodeling factor

multiple interactions
affects response to substance

ISO

NU 1025 inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]
ERCC6 gene mutant form affects the susceptibility to NU 1025

NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

multiple interactions

EXP

PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

AKT serine/threonine kinase 1

multiple interactions

EXP

PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

BCL2-associated agonist of cell death

multiple interactions

ISO

[PD168393 co-treated with Paclitaxel] results in increased expression of BAD protein

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

caspase 3

multiple interactions

ISO

[PD168393 co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

ISO

PD168393 results in increased expression of and results in increased secretion of CCL2 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

ISO

[PD168393 co-treated with Paclitaxel] results in increased expression of CDKN1A protein

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

C-X-C motif chemokine ligand 10

multiple interactions
increases expression

ISO

acteoside inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]; PD168393 results in increased expression of and results in increased secretion of CXCL10 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

cytochrome c, somatic

multiple interactions

ISO

[PD168393 co-treated with Paclitaxel] affects the localization of CYCS protein

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

epidermal growth factor receptor

affects localization
multiple interactions
decreases phosphorylation

ISO
EXP

PD168393 affects the localization of EGFR protein; PD168393 affects the localization of EGFR protein modified form
PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]
[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of EGFR protein]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein]
PD168393 results in decreased phosphorylation of EGFR protein

PMID:16413505 PMID:21967610 PMID:23527233 PMID:25398788

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

Janus kinase 3

multiple interactions

ISO

PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of JAK3 protein]

NCBI chr16:18,418,807...18,432,515
Ensembl chr16:18,420,415...18,433,222

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

ISO

[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK1 protein]; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK1 protein]
PD168393 results in decreased phosphorylation of MAPK1 protein

PMID:16413505 PMID:16778083 PMID:23527233

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

ISO

[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK3 protein]; PD168393 inhibits the reaction [resveratrol results in increased phosphorylation of MAPK3 protein]
PD168393 results in decreased phosphorylation of MAPK3 protein

PMID:16413505 PMID:16778083 PMID:23527233

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 8

multiple interactions

ISO

PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

matrix metallopeptidase 3

multiple interactions

ISO

PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased expression of MMP3 mRNA]

NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826

G

Sp1 transcription factor

multiple interactions

EXP

PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]

NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513

G

sterol regulatory element binding transcription factor 1

multiple interactions

EXP

PD168393 inhibits the reaction [Glucose results in increased activity of and results in increased cleavage of SREBF1 protein]

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

transforming growth factor alpha

multiple interactions

ISO

PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein]

NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339

G

transforming growth factor, beta 1

multiple interactions

EXP

PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

tumor protein p53

multiple interactions

ISO

[PD168393 co-treated with Paclitaxel] results in increased expression of TP53 protein

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

affects response to substance
affects transport

ISO

ABCB1A protein affects the susceptibility to Prazosin
ABCB1A protein affects the transport of Prazosin
ABCB1 protein affects the transport of Prazosin

PMID:15502009 PMID:15616150 PMID:18322075

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP-binding cassette, sub-family B member 1B

affects response to substance

ISO

ABCB1B protein affects the susceptibility to Prazosin

NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:26,106,903...26,279,567

G

ATP binding cassette subfamily G member 2

multiple interactions
increases export
affects transport

ISO

3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased export of Prazosin]; Elacridar inhibits the reaction [ABCG2 protein results in increased export of Prazosin]
6-OH-BDE-47 inhibits the reaction [ABCG2 protein results in increased export of Prazosin]
ABCG2 protein affects the transport of Prazosin

PMID:18322075 PMID:19056916 PMID:28031414

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

actin, alpha 1, skeletal muscle

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine results in increased expression of ACTA1 mRNA]

NCBI chr19:68,781,168...68,784,194
Ensembl chr19:68,781,168...68,786,178

G

adenosine A1 receptor

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine results in increased expression of ADORA1 protein]

NCBI chr13:48,210,922...48,247,826
Ensembl chr13:48,213,273...48,247,190

G

adenosine A2a receptor

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]

NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,270...13,332,802

G

adenosine A3 receptor

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]

NCBI chr 2:196,077,042...196,080,686
Ensembl chr 2:196,077,042...196,080,686

G

adrenoceptor alpha 1A

multiple interactions
affects binding
increases expression
decreases activity

ISO
EXP

1-(2-(3-methoxyphenyl)ethyl)phenoxy-3-(dimethylamino)-2-propanol inhibits the reaction [Prazosin binds to ADRA1A protein]; alfuzosin inhibits the reaction [Prazosin binds to ADRA1A protein]; Epinephrine inhibits the reaction [ADRA1A protein binds to Prazosin]; Ketanserin inhibits the reaction [Prazosin binds to ADRA1A protein]; Norepinephrine inhibits the reaction [ADRA1A protein binds to Prazosin]; Oxymetazoline inhibits the reaction [ADRA1A protein binds to Prazosin]; Oxymetazoline inhibits the reaction [Prazosin binds to ADRA1A protein]; Prazosin binds to and results in decreased activity of ADRA1A protein; Prazosin inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in decreased transport of Potassium]; sarpogrelate inhibits the reaction [Prazosin binds to ADRA1A protein]; xylometazoline inhibits the reaction [ADRA1A protein binds to Prazosin]
ADRA1A protein binds to Prazosin; Prazosin binds to ADRA1A protein
Prazosin results in increased expression of ADRA1A mRNA; Prazosin results in increased expression of ADRA1A protein
Prazosin binds to and affects the activity of ADRA1A protein; Prazosin binds to and results in decreased activity of ADRA1A protein; Prazosin inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]; Prazosin inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]
Prazosin results in decreased activity of ADRA1A protein

PMID:6310690 PMID:7536677 PMID:8183249 PMID:8196478 PMID:9639061 More...

NCBI chr15:45,005,648...45,111,416
Ensembl chr15:45,005,799...45,102,534

G

adrenoceptor alpha 1B

multiple interactions
increases expression
affects binding

ISO
EXP

1-(2-(3-methoxyphenyl)ethyl)phenoxy-3-(dimethylamino)-2-propanol inhibits the reaction [Prazosin binds to ADRA1B protein]; Epinephrine inhibits the reaction [ADRA1B protein binds to Prazosin]; Ketanserin inhibits the reaction [Prazosin binds to ADRA1B protein]; Norepinephrine inhibits the reaction [ADRA1B protein binds to Prazosin]; Oxymetazoline inhibits the reaction [ADRA1B protein binds to Prazosin]; sarpogrelate inhibits the reaction [Prazosin binds to ADRA1B protein]; xylometazoline inhibits the reaction [ADRA1B protein binds to Prazosin]
Prazosin results in increased expression of ADRA1B protein
Prazosin binds to and affects the activity of ADRA1B protein
ADRA1B protein binds to Prazosin; Prazosin binds to ADRA1B protein

PMID:8183249 PMID:9639061 PMID:11934817 PMID:11937776 PMID:20030735

NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347

G

adrenoceptor alpha 1D

multiple interactions
affects binding

ISO
EXP

1-(2-(3-methoxyphenyl)ethyl)phenoxy-3-(dimethylamino)-2-propanol inhibits the reaction [Prazosin binds to ADRA1D protein]; Epinephrine inhibits the reaction [ADRA1D protein binds to Prazosin]; Ketanserin inhibits the reaction [Prazosin binds to ADRA1D protein]; Norepinephrine inhibits the reaction [ADRA1D protein binds to Prazosin]; Oxymetazoline inhibits the reaction [ADRA1D protein binds to Prazosin]; sarpogrelate inhibits the reaction [Prazosin binds to ADRA1D protein]; xylometazoline inhibits the reaction [ADRA1D protein binds to Prazosin]
ADRA1D protein binds to Prazosin; Prazosin binds to ADRA1D protein
Prazosin binds to and affects the activity of ADRA1D protein

PMID:8183249 PMID:9294627 PMID:9639061 PMID:11937776 PMID:15493479 More...

NCBI chr 3:139,246,333...139,262,331
Ensembl chr 3:139,246,323...139,262,331

G

adrenoceptor alpha 2A

multiple interactions

ISO
EXP

Prazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Prazosin inhibits the reaction [Phenylephrine promotes the reaction [Brimonidine Tartrate binds to and results in increased activity of ADRA2A protein]]
Prazosin binds to and results in decreased activity of ADRA2A protein

PMID:8397342 PMID:10742289

NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:263,065,278...263,069,871

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine results in decreased expression of ATP2A2 mRNA]

PMID:11577024 PMID:17592507

NCBI chr12:39,733,519...39,782,942
Ensembl chr12:39,733,458...39,782,934

G

arginine vasopressin

increases expression

EXP

Prazosin results in increased expression of AVP protein

NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:138,246,554...138,248,522

G

caspase 8

increases activity

ISO

Prazosin results in increased activity of CASP8 protein

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

increases activity

ISO

Prazosin results in increased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

C-C motif chemokine ligand 5

multiple interactions

ISO

Prazosin inhibits the reaction [Norepinephrine results in increased secretion of CCL5 protein]

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

cAMP responsive element binding protein 1

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

ISO

Prazosin promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
Prazosin results in increased expression of CYP1A1 mRNA

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]]; Prazosin promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]; Prazosin promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 protein]

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

endothelin 1

multiple interactions

EXP

Prazosin inhibits the reaction [EDN1 protein results in increased expression of NPPA protein]; Prazosin inhibits the reaction [Phenylephrine results in increased expression of EDN1 protein]

PMID:12513686 PMID:15007106

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

fibronectin 1

multiple interactions

ISO

[Norepinephrine co-treated with Prazosin] results in decreased expression of FN1 protein

NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ISO
EXP

Prazosin inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of FOS protein]
Prazosin inhibits the reaction [Amphetamine results in increased expression of FOS protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]

PMID:12560108 PMID:12955385 PMID:19225867

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

glucose-6-phosphate dehydrogenase

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased activity of G6PD protein]; Prazosin inhibits the reaction [norfenefrine results in increased activity of G6PD protein]

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

ISO

Prazosin inhibits the reaction [Acetaminophen results in increased expression of GCLC mRNA]

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

heme oxygenase 1

multiple interactions

ISO

Prazosin inhibits the reaction [Acetaminophen results in increased expression of HMOX1 mRNA]

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

insulin-like growth factor 1

multiple interactions

EXP

Prazosin inhibits the reaction [IGF1 protein results in decreased susceptibility to Norepinephrine]

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

luteinizing hormone subunit beta

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein]

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

lipoprotein lipase

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA]

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107

G

mitogen activated protein kinase 1

multiple interactions
affects activity

ISO
EXP

Prazosin inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]
Prazosin affects the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Prazosin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Prazosin inhibits the reaction [Phenylephrine results in increased activity of MAPK1 protein]; Prazosin inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]
Prazosin affects the activity of MAPK1 protein

PMID:11693273 PMID:11804996 PMID:11880281 PMID:12513686 PMID:17306214 More...

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

affects activity
multiple interactions

EXP
ISO

Prazosin affects the activity of MAPK3 protein
Prazosin inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK3 protein]
Prazosin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Prazosin inhibits the reaction [Phenylephrine results in increased activity of MAPK3 protein]; Prazosin inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK3 protein]

PMID:11693273 PMID:11804996 PMID:11880281 PMID:12513686 PMID:17306214 More...

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

matrix metallopeptidase 2

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

myosin heavy chain 6

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine results in decreased expression of MYH6 mRNA]

PMID:11577024 PMID:17592507

NCBI chr15:32,388,102...32,413,663
Ensembl chr15:32,387,487...32,411,333

G

myosin heavy chain 7

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine results in increased expression of MYH7 mRNA]

PMID:11577024 PMID:17592507

NCBI chr15:32,416,525...32,439,851
Ensembl chr15:32,416,527...32,438,194

G

neutrophil cytosolic factor 1

multiple interactions

EXP

Prazosin inhibits the reaction [Cocaine results in increased phosphorylation of NCF1 protein]

NCBI chr12:28,121,816...28,131,080
Ensembl chr12:28,121,366...28,131,079

G

NFE2 like bZIP transcription factor 2

decreases activity

ISO

Prazosin results in decreased activity of NFE2L2 protein

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nitric oxide synthase 2

multiple interactions

ISO
EXP

Prazosin inhibits the reaction [carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Prazosin inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Prazosin inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Prazosin inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
Prazosin inhibits the reaction [Phenylephrine results in increased expression of NOS2 mRNA]; Prazosin inhibits the reaction [Phenylephrine results in increased expression of NOS2 protein]

PMID:15753950 PMID:19439816

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

natriuretic peptide A

multiple interactions

EXP

Prazosin inhibits the reaction [EDN1 protein results in increased expression of NPPA protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Prazosin inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; Prazosin inhibits the reaction [Phenylephrine results in increased expression of NPPA protein]

PMID:12513686 PMID:15240149 PMID:16714034 PMID:17592507

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

neuropeptide Y

multiple interactions

EXP

[Prazosin co-treated with SCH 23390] inhibits the reaction [Phenylpropanolamine results in decreased expression of NPY protein]

NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310

G

oxytocin/neurophysin I prepropeptide

increases expression

EXP

Prazosin results in increased expression of OXT protein

NCBI chr 3:138,235,754...138,236,594
Ensembl chr 3:138,235,754...138,236,594

G

phospholipase C beta 1

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCB1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]

PMID:16714034 PMID:19225867

NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:142,513,033...143,225,646

G

phospholipase C beta 3

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCB3 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]

PMID:16714034 PMID:19225867

NCBI chr 1:213,572,499...213,589,585
Ensembl chr 1:213,574,166...213,589,583

G

phospholipase C, delta 1

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCD1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]

PMID:16714034 PMID:19225867

NCBI chr 8:127,672,955...127,695,939
Ensembl chr 8:127,672,980...127,695,939

G

phospholipase C, gamma 1

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCG1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]

PMID:16714034 PMID:19225867

NCBI chr 3:169,805,299...169,836,040
Ensembl chr 3:169,804,846...169,836,050

G

PPARG coactivator 1 alpha

multiple interactions

ISO

[Propranolol co-treated with Prazosin] inhibits the reaction [Norepinephrine results in increased expression of PPARGC1A mRNA]

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

renin

decreases activity
increases activity
multiple interactions
increases transport

ISO
EXP

Prazosin results in decreased activity of REN protein
Prazosin results in increased activity of REN protein
Propranolol inhibits the reaction [Prazosin results in increased transport of REN protein]

PMID:3539430 PMID:6173514 PMID:6258839 PMID:7023672

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

ribosomal protein S6 kinase B1

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine results in increased activity of RPS6KB1 protein]

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238

G

ribosomal protein S6 kinase B2

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine results in increased activity of RPS6KB2 protein]

NCBI chr 1:210,880,824...210,887,556
Ensembl chr 1:210,880,825...210,887,562

G

SHC adaptor protein 1

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]

NCBI chr 2:177,135,649...177,147,257
Ensembl chr 2:177,135,659...177,147,914

G

solute carrier family 22 member 1

decreases activity
multiple interactions

ISO

Prazosin results in decreased activity of SLC22A1 protein
Prazosin inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr 1:50,624,339...50,651,437
Ensembl chr 1:50,624,377...50,651,436

G

solute carrier family 22 member 2

multiple interactions

ISO

Prazosin inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

solute carrier family 22 member 3

multiple interactions
decreases activity

ISO

Prazosin inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]
Prazosin results in decreased activity of SLC22A3 protein

NCBI chr 1:50,783,218...50,872,358
Ensembl chr 1:50,783,218...50,872,353

G

sialophorin

decreases response to substance

ISO

SPN protein results in decreased susceptibility to Prazosin

NCBI chr 1:191,177,449...191,190,115
Ensembl chr 1:191,178,096...191,187,852

G

transforming growth factor, beta 1

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB1 mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta 2

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB2 mRNA]

NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856

G

transforming growth factor, beta 3

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB3 mRNA]

NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:111,435,170...111,456,946

G

TIMP metallopeptidase inhibitor 2

multiple interactions

EXP

Prazosin inhibits the reaction [Norepinephrine results in increased expression of TIMP2 mRNA]

NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214

G

TNF superfamily member 11

multiple interactions

ISO

Prazosin inhibits the reaction [Phenylephrine results in increased expression of TNFSF11 mRNA]

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

G

tyrosinase

multiple interactions

EXP

Prazosin inhibits the reaction [Phenylephrine results in increased activity of TYR protein]

NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:150,527,687...150,622,857

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caveolin 1

multiple interactions

EXP

saracatinib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CAV1 protein]

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740

G

C-terminal Src kinase

decreases activity
multiple interactions

ISO

saracatinib results in decreased activity of CSK protein
saracatinib inhibits the reaction [CSK protein results in decreased expression of CYP7A1 mRNA]

NCBI chr 8:66,925,650...66,944,861
Ensembl chr 8:66,925,651...66,930,274

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases oxidation

ISO

CYP1A2 protein results in increased oxidation of saracatinib

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 24, subfamily a, polypeptide 1

multiple interactions

ISO

saracatinib inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]; saracatinib inhibits the reaction [lithocholic acid acetate results in increased expression of CYP24A1 mRNA]

NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases oxidation

ISO

CYP2D6 protein results in increased oxidation of saracatinib

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases oxidation

ISO

CYP3A4 protein results in increased oxidation of saracatinib

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450 family 7 subfamily A member 1

increases expression
multiple interactions

ISO

saracatinib results in increased expression of CYP7A1 mRNA
saracatinib inhibits the reaction [Calcitriol results in decreased expression of CYP7A1 mRNA]; saracatinib inhibits the reaction [CSK protein results in decreased expression of CYP7A1 mRNA]; saracatinib inhibits the reaction [lithocholic acid acetate results in decreased expression of CYP7A1 mRNA]

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

L1 cell adhesion molecule

decreases phosphorylation

ISO

saracatinib results in decreased phosphorylation of L1CAM protein

NCBI chr X:156,748,597...156,775,116
Ensembl chr X:156,748,597...156,775,077

G

protein kinase, membrane associated tyrosine/threonine 1

decreases activity

ISO

saracatinib results in decreased activity of PKMYT1 protein

NCBI chr10:13,252,805...13,263,584
Ensembl chr10:13,252,816...13,264,263

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

ISO

saracatinib binds to and affects the activity of SRC protein

NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462

G

vitamin D receptor

multiple interactions

ISO

saracatinib inhibits the reaction [Calcitriol results in increased phosphorylation of VDR protein]; saracatinib inhibits the reaction [lithocholic acid acetate results in increased phosphorylation of VDR protein]

NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:130,866,745...130,916,757

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arginine vasopressin

multiple interactions

ISO

sotrastaurin inhibits the reaction [Raloxifene Hydrochloride results in decreased expression of AVP mRNA]; sotrastaurin inhibits the reaction [Selective Estrogen Receptor Modulators results in decreased expression of AVP mRNA]

NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:138,246,554...138,248,522

G

mitogen activated protein kinase 1

multiple interactions

ISO

sotrastaurin inhibits the reaction [Raloxifene Hydrochloride results in increased phosphorylation of MAPK1 protein]; sotrastaurin inhibits the reaction [Selective Estrogen Receptor Modulators results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions

ISO

sotrastaurin inhibits the reaction [Raloxifene Hydrochloride results in increased phosphorylation of MAPK3 protein]; sotrastaurin inhibits the reaction [Selective Estrogen Receptor Modulators results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

protein kinase C, beta

decreases activity
multiple interactions

ISO

sotrastaurin results in decreased activity of PRKCB protein
sotrastaurin inhibits the reaction [docetaxel results in increased phosphorylation of PRKCB protein]

NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor alpha 1A

affects binding

EXP
ISO

Terazosin binds to ADRA1A protein

PMID:7536677 PMID:8183249 PMID:21544540

NCBI chr15:45,005,648...45,111,416
Ensembl chr15:45,005,799...45,102,534

G

adrenoceptor alpha 1B

affects binding

ISO

Terazosin binds to ADRA1B protein

NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347

G

adrenoceptor alpha 1D

affects binding

ISO
EXP

Terazosin binds to ADRA1D protein

PMID:8183249 PMID:9294627

NCBI chr 3:139,246,333...139,262,331
Ensembl chr 3:139,246,323...139,262,331

G

BCL2 associated X, apoptosis regulator

increases expression

ISO

Terazosin results in increased expression of BAX protein

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

decreases expression

ISO

Terazosin results in decreased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

cyclin-dependent kinase inhibitor 1B

increases expression

ISO

Terazosin results in increased expression of CDKN1B protein

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

interleukin 24

increases expression

ISO

Terazosin results in increased expression of IL24 mRNA

NCBI chr13:44,905,362...44,910,760
Ensembl chr13:44,905,363...44,910,760

G

matrix metallopeptidase 2

increases activity

EXP

Terazosin increases activity of Mmp2 protein in the prostate

RGD

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

EXP

Tetrodotoxin inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

amyloid beta precursor protein

multiple interactions

ISO

Tetrodotoxin inhibits the reaction [DDT results in increased expression of APP mRNA]
Tetrodotoxin inhibits the reaction [DDT results in increased expression of APP mRNA]; Tetrodotoxin inhibits the reaction [DDT results in increased expression of APP protein]

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

activity-regulated cytoskeleton-associated protein

multiple interactions

ISO

Tetrodotoxin inhibits the reaction [ciguatoxin 3C results in increased expression of ARC mRNA]

NCBI chr 7:108,444,959...108,448,413
Ensembl chr 7:108,444,692...108,451,220

G

brain-derived neurotrophic factor

multiple interactions

ISO
EXP

Tetrodotoxin inhibits the reaction [Azacitidine results in decreased methylation of BDNF promoter]; Tetrodotoxin inhibits the reaction [Azacitidine results in increased expression of BDNF mRNA]
Tetrodotoxin inhibits the reaction [decamethrin results in increased expression of BDNF mRNA]; Tetrodotoxin inhibits the reaction [Veratridine results in increased expression of BDNF mRNA]
3,5-dichloro-N-(1-(2,2-dimethyltetrahydropyran-4-ylmethyl)-4-fluoropiperidin-4-ylmethyl)benzamide promotes the reaction [Tetrodotoxin inhibits the reaction [Oxygen deficiency promotes the reaction [BDNF protein results in increased transport of Calcium]]]; Tetrodotoxin inhibits the reaction [Oxygen deficiency promotes the reaction [BDNF protein results in increased transport of Calcium]]

PMID:16166269 PMID:18184782 PMID:26095976

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

calcium/calmodulin-dependent protein kinase IV

multiple interactions

EXP

Tetrodotoxin inhibits the reaction [Tetrachlorodibenzodioxin affects the localization of CAMK4 protein]

NCBI chr18:24,857,152...25,076,054
Ensembl chr18:24,857,146...25,077,193

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

EXP

Tetrodotoxin inhibits the reaction [[3-(4-hydroxy-2-methoxybenzylidene)anabaseine co-treated with 5-hydroxyindole] results in increased activity of CHRNA7 protein]

NCBI chr 1:126,123,425...126,249,181
Ensembl chr 1:126,123,425...126,446,858

G

cAMP responsive element binding protein 1

multiple interactions

EXP

Tetrodotoxin inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [CREB1 protein binds to CYP1A1 promoter]]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

corticotropin releasing hormone

decreases activity

ISO

Tetrodotoxin results in decreased activity of CRH protein

NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386

G

cytochrome b-245 beta chain

multiple interactions

ISO

[Tetrodotoxin co-treated with cariporide] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CYBB mRNA]; [Tetrodotoxin co-treated with cariporide] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CYBB protein]; Tetrodotoxin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CYBB mRNA]; Tetrodotoxin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CYBB protein]

NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

EXP

Tetrodotoxin inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]]; Tetrodotoxin inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [CREB1 protein binds to CYP1A1 promoter]]

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

EXP

[Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

early growth response 1

multiple interactions

ISO

Tetrodotoxin inhibits the reaction [ciguatoxin 3C results in increased expression of EGR1 mRNA]

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

ectonucleoside triphosphate diphosphohydrolase 4

multiple interactions

EXP

[Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of ENTPD4 mRNA

NCBI chr15:51,040,665...51,068,450
Ensembl chr15:51,040,673...51,068,441

G

glutamate-rich 5

increases expression

ISO

Tetrodotoxin results in increased expression of ERICH5 mRNA

NCBI chr 7:67,538,154...67,569,433
Ensembl chr 7:67,536,588...67,563,989

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression

EXP

Tetrodotoxin results in decreased expression of FOS mRNA; Tetrodotoxin results in decreased expression of FOS protein

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

gonadotropin releasing hormone 1

decreases secretion

ISO

Tetrodotoxin results in decreased secretion of GNRH1 protein

NCBI chr15:46,147,878...46,152,086
Ensembl chr15:46,148,301...46,148,977
Ensembl chr15:46,148,301...46,148,977

G

glutamate ionotropic receptor AMPA type subunit 1

increases localization
increases expression
multiple interactions

EXP

Tetrodotoxin results in increased localization of GRIA1 protein
tetrodotoxin increases expression of Gria1 protein in nucleus accumbens cultured cells
[Lead co-treated with Tetrodotoxin] results in increased expression of [GRIA1 protein binds to GRIA2 protein]

CTD
RGD

PMID:19674091 PMID:29939358 PMID:19674091

NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309

G

glutamate ionotropic receptor AMPA type subunit 2

increases localization
increases expression
multiple interactions

EXP
ISO

Tetrodotoxin results in increased localization of GRIA2 protein
tetrodotoxin increases expression of Gria2 protein in nucleus accumbens cultured cells
[Lead co-treated with Tetrodotoxin] results in increased expression of [GRIA1 protein binds to GRIA2 protein]
Tetrodotoxin results in increased expression of GRIA2 protein
Tetrodotoxin inhibits the reaction [ciguatoxin 3C results in decreased expression of GRIA2 protein]

CTD
RGD

PMID:19674091 PMID:25945544 PMID:29939358 PMID:19674091

NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:168,247,496...168,367,616

G

glutamate ionotropic receptor NMDA type subunit 2A

multiple interactions

ISO

Tetrodotoxin inhibits the reaction [ciguatoxin 3C results in decreased expression of GRIN2A protein]

NCBI chr10:6,136,458...6,560,003
Ensembl chr10:6,138,037...6,551,378

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

ISO

Tetrodotoxin inhibits the reaction [ciguatoxin 3C results in decreased expression of GRIN2B protein]

NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:170,322,617...170,773,570

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

EXP

Tetrodotoxin inhibits the reaction [4-OH-2',3,3',4',5'-pentachlorobiphenyl results in increased expression of JUN protein]

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

potassium voltage-gated channel subfamily C member 1

decreases expression

EXP

Tetrodotoxin results in decreased expression of KCNC1 mRNA

NCBI chr 1:106,039,247...106,081,034
Ensembl chr 1:106,039,237...106,081,033

G

potassium voltage-gated channel subfamily C member 2

decreases expression

EXP

Tetrodotoxin results in decreased expression of KCNC2 mRNA; Tetrodotoxin results in decreased expression of KCNC2 protein

NCBI chr 7:49,586,274...49,770,212
Ensembl chr 7:49,586,136...49,770,212

G

KiSS-1 metastasis-suppressor

multiple interactions

ISO

Tetrodotoxin inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]; Tetrodotoxin promotes the reaction [2-aminoethyl diphenylborinate inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]]

NCBI chr13:47,327,159...47,332,759
Ensembl chr13:47,327,004...47,332,906

G

KISS1 receptor

multiple interactions

ISO

Tetrodotoxin inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]; Tetrodotoxin promotes the reaction [2-aminoethyl diphenylborinate inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]]

NCBI chr 7:10,435,766...10,439,424
Ensembl chr 7:10,435,766...10,439,424

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

ISO
EXP

Tetrodotoxin inhibits the reaction [Permethrin results in increased phosphorylation of MAPK1 protein]
Tetrodotoxin results in decreased phosphorylation of MAPK1 protein
Tetrodotoxin inhibits the reaction [Bmk NT1 toxin, Buthus martensii Karsch results in increased phosphorylation of MAPK1 protein]

PMID:15086530 PMID:30205134 PMID:30940546

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

decreases phosphorylation
multiple interactions

ISO
EXP

Tetrodotoxin results in decreased phosphorylation of MAPK3 protein
Tetrodotoxin inhibits the reaction [Bmk NT1 toxin, Buthus martensii Karsch results in increased phosphorylation of MAPK3 protein]
Tetrodotoxin inhibits the reaction [Permethrin results in increased phosphorylation of MAPK3 protein]

PMID:15086530 PMID:30205134 PMID:30940546

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

MBL associated serine protease 2

increases expression

ISO

Tetrodotoxin results in increased expression of MASP2 mRNA

NCBI chr 5:164,319,017...164,332,686
Ensembl chr 5:164,308,991...164,332,705

G

neuropeptide Y

multiple interactions

EXP

Tetrodotoxin inhibits the reaction [Veratridine results in increased expression of NPY mRNA]

NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310

G

protein kinase C, beta

multiple interactions

EXP

[Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of PRKCB mRNA

NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740

G

parvalbumin

decreases expression

EXP

Tetrodotoxin results in decreased expression of PVALB mRNA

NCBI chr 7:111,653,820...111,668,469
Ensembl chr 7:111,653,111...111,668,446

G

rhomboid like 2

increases expression

ISO

Tetrodotoxin results in increased expression of RHBDL2 mRNA

NCBI chr 5:141,322,246...141,376,702
Ensembl chr 5:141,322,354...141,366,747

G

sodium voltage-gated channel beta subunit 1

multiple interactions

EXP

Tetrodotoxin results in decreased activity of [SCN2A protein binds to SCN1B protein]; Tetrodotoxin results in decreased activity of [SCN8A protein binds to SCN1B protein binds to SCN2B protein]

PMID:9236205 PMID:21983428

NCBI chr 1:95,481,298...95,491,211
Ensembl chr 1:95,481,298...95,491,197

G

sodium voltage-gated channel alpha subunit 2

multiple interactions
decreases activity

EXP
ISO

Tetrodotoxin results in decreased activity of [SCN2A protein binds to SCN1B protein]
Tetrodotoxin results in decreased activity of SCN2A protein
Tetrodotoxin inhibits the reaction [decamethrin results in decreased expression of SCN2A mRNA]

PMID:9236205 PMID:22972919 PMID:25358543

NCBI chr 3:70,710,862...70,845,569
Ensembl chr 3:70,710,954...70,845,279

G

sodium voltage-gated channel beta subunit 2

multiple interactions

EXP

Tetrodotoxin results in decreased activity of [SCN8A protein binds to SCN1B protein binds to SCN2B protein]

NCBI chr 8:54,322,383...54,334,519
Ensembl chr 8:54,322,383...54,334,519

G

sodium voltage-gated channel alpha subunit 3

multiple interactions

ISO

Tetrodotoxin inhibits the reaction [decamethrin results in decreased expression of SCN3A mRNA]

NCBI chr 3:70,554,496...70,666,198
Ensembl chr 3:70,556,224...70,666,198

G

sodium voltage-gated channel alpha subunit 5

decreases activity

EXP

Tetrodotoxin results in decreased activity of SCN5A protein

NCBI chr 8:128,098,613...128,196,515
Ensembl chr 8:128,098,613...128,196,470

G

sodium voltage-gated channel alpha subunit 8

multiple interactions
decreases activity

ISO
EXP

[Tetrodotoxin results in decreased activity of [SCN8A protein co-treated with SCN9A protein]] which affects the transport of Sodium; Tetrodotoxin affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of SCN8A protein]; Tetrodotoxin inhibits the reaction [SCN8A protein results in increased transport of Sodium]
Tetrodotoxin results in decreased activity of [SCN8A protein binds to SCN1B protein binds to SCN2B protein]
Tetrodotoxin results in decreased activity of SCN8A protein

PMID:16020462 PMID:17522141 PMID:21983428 PMID:23382806 PMID:24070585

NCBI chr 7:133,860,901...134,034,809
Ensembl chr 7:133,861,227...134,030,026

G

sodium voltage-gated channel alpha subunit 9

decreases activity
multiple interactions

ISO

Tetrodotoxin results in decreased activity of SCN9A protein
[Tetrodotoxin results in decreased activity of [SCN8A protein co-treated with SCN9A protein]] which affects the transport of Sodium; Tetrodotoxin inhibits the reaction [SCN9A protein results in increased transport of Sodium]

PMID:16020462 PMID:17522141 PMID:23382806

NCBI chr 3:71,553,185...71,701,377
Ensembl chr 3:71,553,189...71,701,377

G

secretin

multiple interactions

EXP

Tetrodotoxin inhibits the reaction [Potassium Chloride results in increased secretion of SCT protein]

PMID:15963647 PMID:16888165

NCBI chr 1:205,812,435...205,813,246
Ensembl chr 1:205,812,435...205,813,246

G

solute carrier family 9 member A1

multiple interactions

ISO

[cariporide co-treated with Tetrodotoxin] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SLC9A1 protein]; Tetrodotoxin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SLC9A1 protein]

NCBI chr 5:150,859,412...150,913,525
Ensembl chr 5:150,860,228...150,913,517

G

TCF25 ribosome quality control complex subunit

increases expression

ISO

Tetrodotoxin results in increased expression of TCF25 mRNA

NCBI chr19:68,323,789...68,358,226
Ensembl chr19:68,323,867...68,358,240

G

tumor necrosis factor

multiple interactions

ISO

cariporide promotes the reaction [Tetrodotoxin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]]; Tetrodotoxin inhibits the reaction [decamethrin results in increased secretion of TNF protein]; Tetrodotoxin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Tetrodotoxin inhibits the reaction [Permethrin results in increased secretion of TNF protein]; Tetrodotoxin promotes the reaction [cariporide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]]

PMID:24070585 PMID:27655349

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

dihydrofolate reductase

decreases response to substance

ISO

DHFR protein polymorphism results in decreased susceptibility to Trimetrexate

NCBI chr 2:25,320,895...25,346,004

G

glutathione S-transferase alpha 3

decreases response to substance

EXP

GSTA3 protein results in decreased susceptibility to Trimetrexate

NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:31,154,989...31,180,654

G

KRAS proto-oncogene, GTPase

increases response to substance

ISO

KRAS gene mutant form results in increased susceptibility to Trimetrexate

NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320

G

solute carrier family 19 member 1

decreases response to substance

ISO

SLC19A1 protein results in decreased susceptibility to Trimetrexate

NCBI chr20:11,583,928...11,601,959
Ensembl chr20:11,583,929...11,601,488

tyrphostin AG 1478

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

multiple interactions

EXP

RTKI cpd inhibits the reaction [estradiol-17 beta-glucuronide affects the localization of and results in decreased activity of ABCC2 protein]

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

angiotensin I converting enzyme

multiple interactions

EXP

RTKI cpd inhibits the reaction [Aldosterone results in increased expression of ACE mRNA]

NCBI chr10:91,410,129...91,430,246
Ensembl chr10:91,409,819...91,430,942

G

actin alpha 2, smooth muscle

multiple interactions
decreases expression

ISO

RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of ACTA2 protein]
RTKI cpd results in decreased expression of ACTA2 protein

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

adrenoceptor beta 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]

NCBI chr 1:265,777,103...265,780,114
Ensembl chr 1:265,766,079...265,849,237

G

angiotensinogen

multiple interactions

EXP

RTKI cpd inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; RTKI cpd inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]

PMID:15849355 PMID:25398788

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

AKT serine/threonine kinase 1

multiple interactions

EXP
ISO

RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of AKT1 protein]]; RTKI cpd inhibits the reaction [Zinc Sulfate results in increased phosphorylation of AKT1 protein]
RTKI cpd inhibits the reaction [Cadmium Chloride results in increased cleavage of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of AKT1 protein]

PMID:11309286 PMID:15177934 PMID:15849355 PMID:19233221 PMID:19946718 More...

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

albumin

multiple interactions

ISO

RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CXCL8 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK3 protein]

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

arachidonate 5-lipoxygenase

multiple interactions

ISO

[RTKI cpd co-treated with AG 1879] inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]; RTKI cpd inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]
RTKI cpd inhibits the reaction [Acrolein results in increased expression of ALOX5 protein]

PMID:14569062 PMID:20153347

NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126

G

angiopoietin 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [Iloprost results in increased expression of ANGPT1 mRNA]

NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:75,418,218...75,668,696

G

angiopoietin 2

multiple interactions

ISO

RTKI cpd inhibits the reaction [Iloprost results in increased expression of ANGPT2 mRNA]

NCBI chr16:77,790,760...77,841,241
Ensembl chr16:77,790,563...77,841,239

G

androgen receptor

multiple interactions

ISO

RTKI cpd inhibits the reaction [EGF protein results in decreased expression of AR protein]; RTKI cpd inhibits the reaction [Particulate Matter results in increased secretion of AR protein]; RTKI cpd inhibits the reaction [Vehicle Emissions results in increased secretion of AR protein]

PMID:16472761 PMID:24555532

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

amphiregulin

multiple interactions
decreases activity

ISO

RTKI cpd inhibits the reaction [[AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein]
RTKI cpd results in decreased activity of AREG protein

PMID:15706222 PMID:21185374

NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641

G

activating transcription factor 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of ATF1 protein]

NCBI chr 7:133,240,774...133,283,488
Ensembl chr 7:133,241,197...133,283,485

G

ATPase Na+/K+ transporting subunit alpha 2

multiple interactions

ISO

RTKI cpd inhibits the reaction [Ammonia results in increased expression of ATP1A2 mRNA]; RTKI cpd inhibits the reaction [Ammonia results in increased expression of ATP1A2 protein]

NCBI chr13:87,261,964...87,286,911
Ensembl chr13:87,261,968...87,286,911

G

BCL2 associated X, apoptosis regulator

multiple interactions

EXP
ISO

RTKI cpd results in increased expression of and results in increased activity of BAX protein
RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BAX mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BAX protein]]
ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in decreased expression of BAX protein]]; RTKI cpd inhibits the reaction [Estradiol results in decreased expression of BAX protein]

PMID:18371937 PMID:34724321 PMID:35716406

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

ISO

ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]; RTKI cpd inhibits the reaction [Estradiol results in increased expression of BCL2 protein]
RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 protein]]

PMID:34724321 PMID:35716406

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

decreases expression

EXP

RTKI cpd results in decreased expression of BCL2L1 mRNA; RTKI cpd results in decreased expression of BCL2L1 protein

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

baculoviral IAP repeat-containing 5

multiple interactions
decreases expression

ISO

[RTKI cpd results in decreased activity of EGFR protein] which results in decreased expression of BIRC5 protein
RTKI cpd results in decreased expression of BIRC5 protein

PMID:21268125 PMID:29974605

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

bone morphogenetic protein 4

multiple interactions

ISO

RTKI cpd inhibits the reaction [antimonite results in decreased expression of BMP4 mRNA]; RTKI cpd inhibits the reaction [arsenite results in decreased expression of BMP4 mRNA]

NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172

G

caspase 3

multiple interactions

EXP
ISO

RTKI cpd promotes the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]
RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of CASP3 mRNA]]
ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in decreased cleavage of CASP3 protein]]; RTKI cpd inhibits the reaction [Estradiol results in decreased cleavage of CASP3 protein]

PMID:19233221 PMID:34724321 PMID:35716406

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caveolin 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [Rosiglitazone results in increased expression of CAV1]

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740

G

cyclin B1

multiple interactions

ISO

RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CCNB1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNB1 protein]

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin D1

multiple interactions
decreases expression

ISO

RTKI cpd inhibits the reaction [[Fulvestrant co-treated with bisphenol A] results in decreased expression of CCND1 mRNA]
RTKI cpd results in decreased expression of CCND1 protein

PMID:28446726 PMID:29974605

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin E1

multiple interactions
decreases expression

ISO

RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CCNE1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNE1 protein]
RTKI cpd results in decreased expression of CCNE1 protein

PMID:15923621 PMID:26385184

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

cadherin 1

increases expression

ISO

RTKI cpd results in increased expression of CDH1 protein

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cyclin-dependent kinase 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CDK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK1 protein]

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin dependent kinase 2

multiple interactions

ISO

RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CDK2 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK2 protein]

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

ISO

RTKI cpd inhibits the reaction [Arsenic Trioxide results in increased expression of CDKN1A protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein]

PMID:15734884 PMID:16283431

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cAMP responsive element binding protein 1

multiple interactions

ISO
EXP

RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of CREB1 protein]
RTKI cpd inhibits the reaction [Metribolone results in increased phosphorylation of CREB1 protein]
RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of CREB1 protein]; RTKI cpd inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]

PMID:16671086 PMID:17272394 PMID:17322281

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

colony stimulating factor 2

multiple interactions

ISO

RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; RTKI cpd inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]

PMID:16908450 PMID:19460412 PMID:22581348

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

catenin beta 1

multiple interactions
decreases expression

ISO

RTKI cpd inhibits the reaction [arsenite affects the localization of CTNNB1 protein]
RTKI cpd results in decreased expression of CTNNB1 protein

PMID:17400267 PMID:29974605

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

CYLD lysine 63 deubiquitinase

increases expression

ISO

[RTKI cpd results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein; RTKI cpd results in increased expression of CYLD mRNA; RTKI cpd results in increased expression of CYLD protein

NCBI chr19:34,487,491...34,547,311
Ensembl chr19:34,488,583...34,547,118

G

DNA methyltransferase 3 alpha

multiple interactions

ISO

RTKI cpd inhibits the reaction [lead nitrate results in decreased expression of DNMT3A mRNA]

NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970

G

endothelin 1

multiple interactions

ISO
EXP

RTKI cpd inhibits the reaction [Doxorubicin results in increased expression of EDN1 mRNA]
RTKI cpd inhibits the reaction [Doxorubicin results in increased expression of EDN1 mRNA]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]]

PMID:16261333 PMID:17974986

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

epidermal growth factor

multiple interactions

ISO
EXP

RTKI cpd inhibits the reaction [EGF protein affects the localization of FOXO3 protein]; RTKI cpd inhibits the reaction [EGF protein results in decreased expression of and results in decreased secretion of KLK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in decreased expression of AR protein]; RTKI cpd inhibits the reaction [EGF protein results in increased abundance of Calcium]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of STAT3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNB1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNE1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK2 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of GPER1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of SRC protein]; RTKI cpd inhibits the reaction [EGF protein results in increased secretion of MMP1 protein]; RTKI cpd inhibits the reaction [Estradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]]; RTKI cpd promotes the reaction [Amiodarone inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]]
RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK7 protein]
RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased susceptibility to Desoxycorticosterone]

PMID:10516208 PMID:11309286 PMID:11527950 PMID:11751714 PMID:14737115 More...

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

epidermal growth factor receptor

multiple interactions
decreases expression
decreases phosphorylation
decreases activity

ISO
EXP

[NFE2L2 protein results in increased expression of EGFR protein] which results in decreased susceptibility to RTKI cpd; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased chemical synthesis of Oxygen]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of STAT5B protein]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to FSHB protein; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to Hexachlorobenzene; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to Topotecan; RTKI cpd inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [[AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Cadmium results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [EGFR protein binds to GPER1 protein]; RTKI cpd inhibits the reaction [Estradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [lead nitrate results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]; RTKI cpd promotes the reaction [Amiodarone inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]]
RTKI cpd results in decreased expression of EGFR protein modified form
RTKI cpd results in decreased phosphorylation of EGFR protein
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Genistein results in increased secretion of Testosterone]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [estradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [sodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein]]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]
[[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased expression of MT2 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased expression of BIRC5 protein; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased phosphorylation of STAT3 protein; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to butaprost; RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Arsenic affects the localization of EGFR protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein]; RTKI cpd results in decreased phosphorylation of and results in decreased activity of EGFR protein

PMID:9710602 PMID:12794006 PMID:15177934 PMID:15459120 PMID:15504454 More...

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

early growth response 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of EGR1 protein]

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

ISO

[RTKI cpd co-treated with AG-879] results in decreased phosphorylation of ERBB2 protein
RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of ERBB2 mRNA]]

PMID:18618485 PMID:35716406

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

ISO

RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of ERBB4 mRNA]]

NCBI chr 9:76,973,386...78,045,633
Ensembl chr 9:76,973,227...78,045,772

G

ERBB receptor feedback inhibitor 1

decreases expression

ISO

RTKI cpd results in decreased expression of ERRFI1 protein

NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:166,606,834...166,620,432

G

estrogen receptor 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of ESR1 protein]
ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in decreased cleavage of CASP3 protein]]; ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in decreased expression of BAX protein]]; ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]

PMID:21813366 PMID:34724321

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

F11 receptor

multiple interactions

ISO

RTKI cpd inhibits the reaction [Poly I-C results in decreased expression of F11R protein]

NCBI chr13:86,406,229...86,429,819
Ensembl chr13:86,406,218...86,429,816

G

fibroblast growth factor 2

multiple interactions

ISO

RTKI cpd inhibits the reaction [Iloprost results in increased expression of FGF2 mRNA]

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493

G

Fms related receptor tyrosine kinase 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased secretion of FLT1 protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased secretion of FLT1 protein]

NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ISO
EXP

RTKI cpd inhibits the reaction [afimoxifene results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [afimoxifene results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Atrazine results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Estradiol results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Genistein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Quercetin results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of FOS protein]
RTKI cpd inhibits the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [[Fulvestrant co-treated with bisphenol A] results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [bisphenol A promotes the reaction [FOS protein binds to GPER1 promoter]]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [Estradiol results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOS mRNA]
RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of FOS mRNA]

PMID:9710602 PMID:10516208 PMID:12154012 PMID:15090535 PMID:18758753 More...

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

FosB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ISO

RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOSB mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOSB protein]

NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477

G

forkhead box O3

multiple interactions

ISO

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein]; RTKI cpd inhibits the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone affects the localization of FOXO3 protein]; RTKI cpd inhibits the reaction [EGF protein affects the localization of FOXO3 protein]; RTKI cpd inhibits the reaction [Estradiol affects the localization of FOXO3 protein]

PMID:23673518 PMID:26470790

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845

G

follicle stimulating hormone subunit beta

multiple interactions

ISO
EXP

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to FSHB protein
RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane inhibits the reaction [FSHB protein results in increased expression of LHCGR mRNA]]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of AKT1 protein]]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd promotes the reaction [FSHB protein results in increased expression of LHCGR mRNA]

PMID:21520325 PMID:24071787

NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072

G

gastrin

multiple interactions

ISO

RTKI cpd inhibits the reaction [lead acetate results in increased expression of GAST mRNA]

NCBI chr10:85,765,216...85,767,881
Ensembl chr10:85,765,216...85,767,880

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
decreases expression

EXP

Doxorubicin promotes the reaction [RTKI cpd results in decreased expression of GCLC protein]

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

G protein subunit alpha q

multiple interactions

EXP

RTKI cpd inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]

NCBI chr 1:222,852,453...223,098,754
Ensembl chr 1:222,852,097...223,126,742

G

G protein-coupled estrogen receptor 1

multiple interactions

ISO
EXP

RTKI cpd inhibits the reaction [EGF protein results in increased expression of GPER1 protein]; RTKI cpd inhibits the reaction [EGFR protein binds to GPER1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of GPER1 protein]
RTKI cpd inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]
RTKI cpd inhibits the reaction [bisphenol A promotes the reaction [FOS protein binds to GPER1 promoter]]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of GPER1 mRNA]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of GPER1 protein]

PMID:19749156 PMID:22645130 PMID:23274518

NCBI chr12:20,331,073...20,336,527
Ensembl chr12:20,327,679...20,337,144

G

hyaluronan synthase 2

multiple interactions

EXP

RTKI cpd inhibits the reaction [LHB protein results in increased expression of HAS2 mRNA]

NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:90,002,929...90,018,535

G

heparin-binding EGF-like growth factor

multiple interactions
increases expression
decreases expression

ISO
EXP

RTKI cpd inhibits the reaction [vanadium pentoxide results in increased expression of HBEGF mRNA]
RTKI cpd results in increased expression of HBEGF mRNA
RTKI cpd results in decreased expression of HBEGF mRNA; RTKI cpd results in decreased expression of HBEGF protein

PMID:11159045 PMID:22048644 PMID:26800359

NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220

G

hes family bHLH transcription factor 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [arsenite results in decreased expression of HES1 mRNA]

NCBI chr11:84,210,632...84,213,045
Ensembl chr11:84,210,633...84,213,061

G

heme oxygenase 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [arsenite results in increased expression of HMOX1 protein]

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

5-hydroxytryptamine receptor 2B

multiple interactions

ISO

RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]

NCBI chr 9:94,184,442...94,206,851
Ensembl chr 9:94,190,109...94,204,087

G

interleukin 6

multiple interactions
decreases expression

ISO

RTKI cpd affects the reaction [Capsaicin results in increased secretion of IL6 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane results in increased expression of IL6 protein]; RTKI cpd inhibits the reaction [pentabromodiphenyl ether results in increased expression of IL6 protein]; RTKI cpd inhibits the reaction [Silicon Dioxide analog results in increased secretion of IL6 protein]; RTKI cpd inhibits the reaction [tetrabromobisphenol A results in increased expression of IL6 protein]
RTKI cpd results in decreased expression of IL6 protein

PMID:20619260 PMID:24184330 PMID:24844442 PMID:26718265

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

involucrin

multiple interactions
increases expression

ISO

RTKI cpd inhibits the reaction [arsenite results in decreased expression of IVL mRNA]
RTKI cpd results in increased expression of IVL protein

NCBI chr 2:180,842,307...180,854,646
Ensembl chr 2:180,842,307...180,846,578

G

jagged canonical Notch ligand 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [arsenite results in decreased expression of JAG1 mRNA]; RTKI cpd inhibits the reaction [arsenite results in decreased expression of JAG1 protein]

NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:144,859,453...144,894,872

G

Janus kinase 3

multiple interactions

ISO

RTKI cpd results in decreased phosphorylation of and results in decreased activity of JAK3 protein

NCBI chr16:18,418,807...18,432,515
Ensembl chr16:18,420,415...18,433,222

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ISO
EXP

RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of JUN protein]
RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of JUN mRNA]
RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of JUN mRNA]

PMID:9710602 PMID:11329622 PMID:12154012

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

kallikrein 1-related peptidase C10

multiple interactions

ISO

RTKI cpd inhibits the reaction [EGF protein results in decreased expression of and results in decreased secretion of KLK3 protein]

NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586

G

keratin 1

increases expression

ISO

RTKI cpd results in increased expression of KRT1 protein

NCBI chr 7:134,855,311...134,860,537
Ensembl chr 7:134,855,313...134,860,537

G

keratin 10

multiple interactions

ISO

RTKI cpd inhibits the reaction [arsenite results in decreased expression of KRT10 mRNA]; RTKI cpd inhibits the reaction [arsenite results in decreased expression of KRT10 protein]

NCBI chr10:84,834,865...84,839,160
Ensembl chr10:84,834,840...84,839,160

G

luteinizing hormone subunit beta

multiple interactions

ISO
EXP

RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]
RTKI cpd inhibits the reaction [LHB protein results in increased expression of HAS2 mRNA]; RTKI cpd inhibits the reaction [LHB protein results in increased expression of PTGS2 mRNA]; RTKI cpd inhibits the reaction [LHB protein results in increased expression of TNFAIP6 mRNA]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of EGFR protein]

PMID:15459120 PMID:21220312

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

luteinizing hormone/choriogonadotropin receptor

multiple interactions

EXP

RTKI cpd inhibits the reaction [hexabromocyclododecane inhibits the reaction [FSHB protein results in increased expression of LHCGR mRNA]]; RTKI cpd promotes the reaction [FSHB protein results in increased expression of LHCGR mRNA]

NCBI chr 6:11,415,361...11,480,834
Ensembl chr 6:11,415,415...11,478,061

G

mitogen activated protein kinase kinase 1

multiple interactions

EXP

RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAP2K1 protein]

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184

G

mitogen activated protein kinase kinase 2

multiple interactions

EXP

RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAP2K2 protein]

NCBI chr 7:9,241,449...9,264,216
Ensembl chr 7:9,241,310...9,260,940

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

ISO
EXP

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [arsenic acid results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [arsenite results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Atrazine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Calcitriol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Diacetyl results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Histamine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Iloprost results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [lead nitrate results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Lead results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Thrombin results in increased phosphorylation of MAPK1 protein]; RTKI cpd results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein]
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Metribolone results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Zinc Sulfate results in increased phosphorylation of MAPK1 protein]
RTKI cpd results in decreased phosphorylation of MAPK1 protein

PMID:9710602 PMID:10516208 PMID:11309286 PMID:11329622 PMID:12761878 More...

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 14

multiple interactions

ISO

RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK14 protein]

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

ISO
EXP

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [arsenic acid results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [arsenite results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Atrazine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Calcitriol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Diacetyl results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Histamine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Iloprost results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [lead nitrate results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Lead results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Thrombin results in increased phosphorylation of MAPK3 protein]; RTKI cpd results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein]
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Metribolone results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Zinc Sulfate results in increased phosphorylation of MAPK3 protein]
RTKI cpd results in decreased phosphorylation of MAPK3 protein

PMID:9710602 PMID:10516208 PMID:11309286 PMID:11329622 PMID:12761878 More...

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 7

multiple interactions

ISO

RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK7 protein]

NCBI chr10:46,669,721...46,675,768
Ensembl chr10:46,669,721...46,675,806

G

mitogen-activated protein kinase 8

multiple interactions

ISO
EXP

RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK8 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK8 protein]
RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK8 protein]

PMID:11329622 PMID:15574683 PMID:26514923

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

mitogen-activated protein kinase 9

multiple interactions

ISO

RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression

EXP

RTKI cpd results in decreased expression of MCL1 mRNA; RTKI cpd results in decreased expression of MCL1 protein

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

microRNA 126a

multiple interactions

ISO

RTKI cpd promotes the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA]

NCBI chr 3:29,813,150...29,813,267

G

microRNA 21

multiple interactions

ISO

RTKI cpd inhibits the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone results in increased expression of MIR21 mRNA]; RTKI cpd inhibits the reaction [Dehydroepiandrosterone results in increased expression of MIR21 mRNA]

NCBI chr10:71,902,600...71,902,691

G

microRNA 222

multiple interactions

ISO

RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR222 mRNA]

NCBI chr X:6,022,621...6,022,723
Ensembl chr X:6,022,621...6,022,723

G

matrix metallopeptidase 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [EGF protein results in increased secretion of MMP1 protein]; RTKI cpd inhibits the reaction [Histamine results in increased expression of MMP1 mRNA]; RTKI cpd inhibits the reaction [Histamine results in increased secretion of MMP1 protein]

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

matrix metallopeptidase 13

multiple interactions

ISO

RTKI cpd inhibits the reaction [Asbestos, Serpentine results in increased expression of MMP13 mRNA]

NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105

G

matrix metallopeptidase 14

multiple interactions

ISO

RTKI cpd inhibits the reaction [Acrolein results in increased expression of MMP14 mRNA]

NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893

G

matrix metallopeptidase 2

multiple interactions

ISO

RTKI cpd inhibits the reaction [bisphenol A results in increased expression of MMP2 protein]; RTKI cpd inhibits the reaction [Hexachlorobenzene results in increased expression of MMP2 protein]

PMID:23462309 PMID:25312822

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 7

multiple interactions

ISO

RTKI cpd inhibits the reaction [antimonite results in increased expression of MMP7 mRNA]; RTKI cpd inhibits the reaction [arsenite results in increased expression of MMP7 mRNA]

NCBI chr 8:13,133,043...13,140,761
Ensembl chr 8:13,133,043...13,140,755

G

matrix metallopeptidase 9

multiple interactions

ISO

RTKI cpd inhibits the reaction [Acrolein results in increased expression of MMP9 mRNA]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of MMP9 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased expression of MMP9 mRNA]; RTKI cpd inhibits the reaction [Hexachlorobenzene results in increased secretion of and results in increased activity of MMP9 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased secretion of MMP9 protein]

PMID:15504454 PMID:18006877 PMID:23462309 PMID:25312822 PMID:26514923

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

metallothionein 2

multiple interactions

ISO

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased expression of MT2 protein]

NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709

G

mechanistic target of rapamycin kinase

multiple interactions

EXP

RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MTOR protein]; RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MTOR protein]

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

ISO

RTKI cpd inhibits the reaction [[Smoke results in increased abundance of Particulate Matter] which results in increased expression of MUC5AC mRNA]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased expression of MUC5AC mRNA]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased expression of MUC5AC protein]; RTKI cpd inhibits the reaction [Particulate Matter results in increased expression of MUC5AC mRNA]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MUC5AC mRNA]

PMID:10640773 PMID:20971882 PMID:22820758 PMID:31944254

NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases phosphorylation

ISO

[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with RTKI cpd] inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; [NFE2L2 protein results in increased expression of EGFR protein] which results in decreased susceptibility to RTKI cpd; RTKI cpd inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]
RTKI cpd results in decreased phosphorylation of NFE2L2 protein

PMID:24015256 PMID:33148531 PMID:39179137

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

NFKB inhibitor alpha

increases expression

ISO

[RTKI cpd results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nitric oxide synthase 3

multiple interactions

ISO

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein]

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664

G

notch receptor 1

multiple interactions
increases expression

ISO

RTKI cpd inhibits the reaction [arsenite results in decreased expression of NOTCH1 protein modified form]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased cleavage of NOTCH1 protein]
RTKI cpd results in increased expression of NOTCH1 protein modified form

PMID:18633435 PMID:25118938

NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613

G

NADPH oxidase 4

multiple interactions
increases expression

EXP

Doxorubicin promotes the reaction [RTKI cpd results in increased expression of NOX4 mRNA]

NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483

G

natriuretic peptide A

multiple interactions

EXP

RTKI cpd inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

neuregulin 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 protein]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of ERBB2 mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of ERBB4 mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of PIK3R1 mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BAX mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BAX protein]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of CASP3 mRNA]]

NCBI chr16:65,954,084...67,007,484
Ensembl chr16:65,953,865...66,999,849

G

neurotensin

multiple interactions

ISO

RTKI cpd inhibits the reaction [NTS protein results in increased expression of CXCL8 mRNA]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased secretion of CXCL8 protein]

PMID:15177934 PMID:15247267

NCBI chr 7:39,451,484...39,460,888
Ensembl chr 7:39,451,073...39,460,961

G

proliferating cell nuclear antigen

decreases expression

ISO

RTKI cpd results in decreased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of PIK3R1 mRNA]]

NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347

G

phospholipase A2 group 4A

multiple interactions

ISO

RTKI cpd inhibits the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of PLA2G4A mRNA]
RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A protein]

PMID:19662385 PMID:20850495

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641

G

peroxisome proliferator-activated receptor delta

multiple interactions

ISO

RTKI cpd inhibits the reaction [antimonite results in increased expression of PPARD mRNA]; RTKI cpd inhibits the reaction [arsenite results in increased expression of PPARD mRNA]

NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

RTKI cpd inhibits the reaction [bisphenol A results in increased expression of PPARG mRNA]

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

protein kinase C, alpha

multiple interactions

ISO

RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of PRKCA protein]

NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572

G

protein kinase C, delta

multiple interactions

ISO

RTKI cpd inhibits the reaction [sodium arsenite affects the expression of PRKCD protein]; RTKI cpd inhibits the reaction [sodium arsenite results in decreased phosphorylation of PRKCD protein]

NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO
EXP

RTKI cpd inhibits the reaction [[lead nitrate results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of PTGS2 mRNA]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of PTGS2 protein]
RTKI cpd inhibits the reaction [LHB protein results in increased expression of PTGS2 mRNA]
RTKI cpd inhibits the reaction [TRPV1 gene mutant form promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of PTGS2 protein]]

PMID:15459120 PMID:20660715 PMID:20850495 PMID:24639330

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

protein tyrosine kinase 2

multiple interactions

ISO

[RTKI cpd co-treated with bisphenol A] results in increased phosphorylation of PTK2 protein

NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:107,015,733...107,172,091

G

RB transcriptional corepressor 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [lead nitrate results in increased expression of RB1 mRNA]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of RB1 protein]

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

RUNX family transcription factor 2

decreases expression

EXP

RTKI cpd results in decreased expression of RUNX2 mRNA

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027

G

SHC adaptor protein 1

multiple interactions

EXP

RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of SHC1 protein alternative form]; RTKI cpd inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; RTKI cpd inhibits the reaction [sodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein]]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of SHC1 protein]

PMID:9710602 PMID:19168439

NCBI chr 2:177,135,649...177,147,257
Ensembl chr 2:177,135,659...177,147,914

G

solute carrier family 1 member 2

multiple interactions

EXP

RTKI cpd inhibits the reaction [2,3-bis(4-hydroxyphenyl)-propionitrile results in increased expression of SLC1A2 protein]; RTKI cpd inhibits the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol results in increased expression of SLC1A2 protein]; RTKI cpd inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]; RTKI cpd inhibits the reaction [Raloxifene Hydrochloride results in increased expression of SLC1A2 mRNA]; RTKI cpd inhibits the reaction [Raloxifene Hydrochloride results in increased expression of SLC1A2 protein]

PMID:22645130 PMID:24782323

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

Sp1 transcription factor

multiple interactions

EXP

RTKI cpd inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; RTKI cpd inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]

NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

ISO
EXP

[[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]
RTKI cpd inhibits the reaction [estradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of SRC protein]
RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of SRC protein]; RTKI cpd inhibits the reaction [Nicotine results in increased phosphorylation of SRC protein]

PMID:14569062 PMID:23376140 PMID:25813982 PMID:25856345

NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462

G

sterol regulatory element binding transcription factor 1

multiple interactions

EXP

RTKI cpd inhibits the reaction [Glucose results in increased activity of and results in increased cleavage of SREBF1 protein]

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

steroidogenic acute regulatory protein

multiple interactions

ISO

RTKI cpd inhibits the reaction [bisphenol A results in increased expression of STAR mRNA]

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

signal transducer and activator of transcription 3

multiple interactions
decreases expression

ISO

RTKI cpd inhibits the reaction [bisphenol A results in increased expression of STAT3 mRNA]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of STAT3 protein]
RTKI cpd results in decreased expression of STAT3 protein modified form
[[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased phosphorylation of STAT3 protein

PMID:21268125 PMID:21909620 PMID:23376140 PMID:25841994 PMID:29974605

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

signal transducer and activator of transcription 5B

multiple interactions

ISO

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of STAT5B protein]

NCBI chr10:86,205,148...86,276,178
Ensembl chr10:86,207,293...86,275,990

G

tachykinin, precursor 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546

G

transcription factor AP-2 alpha

multiple interactions

ISO

RTKI cpd inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein]; RTKI cpd inhibits the reaction [Dibutyl Phthalate affects the localization of TFAP2A protein]

NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219

G

transforming growth factor alpha

multiple interactions

ISO

RTKI cpd inhibits the reaction [Particulate Matter results in increased secretion of TGFA protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of GPER1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Vehicle Emissions results in increased secretion of TGFA protein]

PMID:11309286 PMID:19749156 PMID:24555532

NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339

G

transforming growth factor, beta 1

multiple interactions
decreases expression

EXP
ISO

RTKI cpd inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]
RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of TGFB1 protein]
RTKI cpd results in decreased expression of TGFB1 protein

PMID:25398788 PMID:35850069

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

tumor necrosis factor

multiple interactions

ISO

RTKI cpd inhibits the reaction [Poly I-C results in increased secretion of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF alpha induced protein 6

multiple interactions

EXP

RTKI cpd inhibits the reaction [LHB protein results in increased expression of TNFAIP6 mRNA]

NCBI chr 3:56,911,398...56,930,797
Ensembl chr 3:56,911,252...56,930,796

G

tumor protein p53

multiple interactions

ISO

RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of TP53 protein]

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

ISO

RTKI cpd inhibits the reaction [TRPV1 gene mutant form promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of PTGS2 protein]]

NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021

G

vascular endothelial growth factor A

multiple interactions

ISO

RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased secretion of VEGFA protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased secretion of VEGFA protein]

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vimentin

decreases expression
multiple interactions

ISO

RTKI cpd results in decreased expression of VIM protein
RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of VIM protein]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VIM protein]

PMID:25856345 PMID:26971374 PMID:35850069

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

epidermal growth factor

multiple interactions

ISO

UNC0642 inhibits the reaction [EGF protein results in increased expression of POU5F1 protein]

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

euchromatic histone lysine methyltransferase 1

decreases activity

ISO

UNC0642 results in decreased activity of EHMT1 protein

NCBI chr 3:27,978,888...28,127,178
Ensembl chr 3:27,978,888...28,127,349

G

euchromatic histone lysine methyltransferase 2

decreases activity

ISO

UNC0642 results in decreased activity of EHMT2 protein

NCBI chr20:3,924,263...3,941,238
Ensembl chr20:3,924,263...3,941,384

G

POU class 5 homeobox 1

multiple interactions

ISO

UNC0642 inhibits the reaction [EGF protein results in increased expression of POU5F1 protein]

NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenomedullin

increases expression
increases expression

ISO

vandetanib results in increased expression of ADM mRNA
vandetanib increases expression of ADM mRNA in gastric tumors of human cells in mouse model

CTD
RGD

PMID:16052530 PMID:16052530

NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

ISO

vandetanib results in decreased phosphorylation of AKT1 protein
INS protein inhibits the reaction [vandetanib results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

angiopoietin-like 4

increases expression

ISO

vandetanib results in increased expression of ANGPTL4 mRNA

NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681

G

BCL2 interacting protein 3 like

increases expression

ISO

vandetanib results in increased expression of BNIP3L mRNA

NCBI chr15:45,350,081...45,373,213
Ensembl chr15:45,334,537...45,373,282

G

calbindin 1

increases expression

ISO

vandetanib results in increased expression of CALB1 mRNA

NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:34,172,664...34,200,160

G

caspase 3

multiple interactions

ISO

[3-methyladenine co-treated with vandetanib] results in increased activity of CASP3 protein; [Chloroquine co-treated with vandetanib] results in increased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 9

multiple interactions

ISO

[3-methyladenine co-treated with vandetanib] results in increased activity of CASP9 protein; [Chloroquine co-treated with vandetanib] results in increased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

collagen type IV alpha 3 chain

increases expression

ISO

vandetanib results in increased expression of COL4A3 mRNA

NCBI chr 9:91,323,990...91,453,088
Ensembl chr 9:91,323,990...91,453,077

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects metabolic processing
multiple interactions

ISO

CYP3A4 protein alternative form affects the metabolism of vandetanib
Ketoconazole affects the reaction [CYP3A4 protein alternative form affects the metabolism of vandetanib]

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

dual specificity phosphatase 1

increases expression

ISO

vandetanib results in increased expression of DUSP1 mRNA

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

epidermal growth factor receptor

affects response to substance
decreases phosphorylation
decreases activity

ISO

EGFR affects the susceptibility to vandetanib
vandetanib results in decreased phosphorylation of EGFR protein
vandetanib results in decreased activity of EGFR protein

PMID:15596048 PMID:15604279 PMID:21350000

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

eukaryotic translation initiation factor 4E binding protein 1

decreases phosphorylation

ISO

vandetanib results in decreased phosphorylation of EIF4EBP1 protein

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

enolase 2

increases expression

ISO

vandetanib results in increased expression of ENO2 mRNA

NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220

G

family with sequence similarity 13, member A

increases expression

ISO

vandetanib results in increased expression of FAM13A mRNA

NCBI chr 4:89,386,685...89,485,940
Ensembl chr 4:89,388,569...89,485,988

G

glutamic--pyruvic transaminase

increases secretion

ISO

vandetanib results in increased secretion of GPT protein

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

H1.2 linker histone, cluster member

increases expression

ISO

vandetanib results in increased expression of H1-2 mRNA

NCBI chr17:41,818,962...41,820,453
Ensembl chr17:41,779,051...41,822,317

G

hypoxia inducible lipid droplet-associated

increases expression

ISO

vandetanib results in increased expression of HILPDA mRNA

NCBI chr 4:58,836,463...58,839,423
Ensembl chr 4:58,836,463...58,839,423

G

insulin-like growth factor binding protein 1

increases expression

ISO

vandetanib results in increased expression of IGFBP1 mRNA

NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344

G

insulin-like growth factor binding protein 3

increases expression
increases expression

ISO

vandetanib results in increased expression of IGFBP3 mRNA
vandetanib increases expression of IGFBP-3 mRNA in gastric tumors of human cells in mouse model

CTD
RGD

PMID:16052530 PMID:16052530

NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944

G

insulin 2

multiple interactions

ISO

INS protein inhibits the reaction [vandetanib results in decreased phosphorylation of AKT1 protein]; INS protein inhibits the reaction [vandetanib results in decreased phosphorylation of RPS6 protein]

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

insulin induced gene 1

increases expression

ISO

vandetanib results in increased expression of INSIG1 mRNA

NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:8,049,556...8,057,778

G

insulin induced gene 2

increases expression

ISO

vandetanib results in increased expression of INSIG2 mRNA

NCBI chr13:35,025,160...35,052,937
Ensembl chr13:35,025,164...35,047,658

G

potassium voltage-gated channel subfamily H member 2

affects binding
decreases expression
multiple interactions

ISO

vandetanib binds to KCNH2 protein
vandetanib results in decreased expression of KCNH2 protein modified form
Brefeldin A promotes the reaction [vandetanib results in decreased expression of KCNH2 protein modified form]; N-butanoylsphingosine inhibits the reaction [vandetanib results in decreased expression of KCNH2 protein modified form]; vandetanib results in decreased expression of and results in decreased activity of KCNH2 protein

PMID:29630634 PMID:35680041

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

lysine demethylase 3A

increases expression

ISO

vandetanib results in increased expression of KDM3A mRNA

NCBI chr 4:105,189,208...105,233,526
Ensembl chr 4:105,189,208...105,233,370

G

mutS homolog 3

decreases expression

ISO

vandetanib results in decreased expression of MSH3 mRNA

NCBI chr 2:25,179,400...25,320,857
Ensembl chr 2:25,179,400...25,321,102

G

mucin 1, cell surface associated

increases expression

ISO

vandetanib results in increased expression of MUC1 mRNA

NCBI chr 2:176,933,312...176,938,497
Ensembl chr 2:176,933,047...176,938,491

G

N-myc downstream regulated 1

increases expression

ISO

vandetanib results in increased expression of NDRG1 mRNA

NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:100,573,523...100,614,913

G

phosphoglycerate kinase 1

increases expression

ISO

vandetanib results in increased expression of PGK1 mRNA

NCBI chr X:75,336,988...75,352,962
Ensembl chr X:75,336,687...75,352,959

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

increases expression

ISO

vandetanib results in increased expression of PLOD2 mRNA

NCBI chr 8:101,964,318...102,047,022
Ensembl chr 8:101,964,318...102,047,022

G

prothymosin alpha

decreases expression

ISO

vandetanib results in decreased expression of PTMA mRNA

NCBI chr 9:94,624,194...94,628,276
Ensembl chr 9:94,624,196...94,628,276

G

ret proto-oncogene

decreases phosphorylation

ISO

vandetanib results in decreased phosphorylation of RET protein

NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556

G

ribosomal protein S6

decreases phosphorylation
multiple interactions

ISO

vandetanib results in decreased phosphorylation of RPS6 protein
INS protein inhibits the reaction [vandetanib results in decreased phosphorylation of RPS6 protein]

NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566

G

stearoyl-CoA desaturase

increases expression

ISO

vandetanib results in increased expression of SCD mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

solute carrier family 2 member 3

increases expression

ISO

vandetanib results in increased expression of SLC2A3 mRNA

NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186

G

SRY-box transcription factor 17

decreases localization

ISO

vandetanib results in decreased localization of SOX17 protein

NCBI chr 5:19,814,345...19,819,859
Ensembl chr 5:19,814,360...19,819,854

G

TSC22 domain family, member 3

increases expression

ISO

vandetanib results in increased expression of TSC22D3 mRNA

NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	20841
chemical entity	20839
atom	20839
nonmetal atom	20747
nitrogen atom	19577
nitrogen molecular entity	19577
organonitrogen compound	19407
organonitrogen heterocyclic compound	18549
quinazolines	571
(+)-penicamide A	0
(+)-penicilliumine	0
(-)-penicamide A	0
(14R)-oxoglyantrypine	0
(14S)-oxoglyantrypine	0
(2S)-2-[(\{4-[(1S)-2-(2-amino-4-hydroxyquinazolin-6-yl)-1-(\{[2-(\{5-O-phosphonoribofuranosyl\}amino)-2-oxoethyl]amino\}methyl)-1-hydroxyethyl]phenyl\}carbonyl)amino]pentanedioic acid	0
(4-\{3-[(6,7-diethoxyquinazolin-4-yl)amino]phenyl\}-1,3-thiazol-2-yl)methanol	0
(4-\{[(3,5-dimethylisoxazol-4-yl)methyl]amino\}quinazolin-2-yl)methanol	0
(5-amino-3-triazolo[1,5-a]quinazolinyl)-(4-morpholinyl)methanone	0
(5aR,9aR)-6-propyl-5a,7,8,9,9a,10-hexahydro-5H-pyrido[2,3-g]quinazolin-2-amine	0
(RR)-2-(1-hydroxyethyl)-2-methyl-2,3-dihydro-1H-quinazolin-4-one	0
(SR)-2-(1-Hydroxyethyl)-2-methyl-2,3-dihydro-1H-quinazolin-4-one	0
(S,S)-Anacine	0
1,2,3,9-Tetrahydropyrrolo[2,1-b]quinazolin-3-ol	0
1,3-dimethyl-6-(4-morpholinylsulfonyl)quinazoline-2,4-dione	0
1,5-Dihydro-7-(1-piperidinyl)-imidazo(2,1-b)quinazolin-2(3H)-one	0
1,5-dioxo-2,4-dihydropyrrolo[1,2-a]quinazoline-3-carboxylic acid ethyl ester	0
1,9,17-triazapentacyclo[14.8.0.02,7.010,15.018,23]tetracosa-2,4,6,10,12,14,16,18,20,22-decaene-8,24-dione	0
1-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)-3-(3-pyridinylmethyl)thiourea	0
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[2-(phenylmethyl)-4-quinazolinyl]thio]ethanone	0
1-(3,4-dihydro-1H-isoquinolin-2-yl)-2-[(2-propyl-4-quinazolinyl)thio]ethanone	0
1-(3,5-dimethyl-1-piperidinyl)-2-[[2-(thiophen-2-ylmethyl)-4-quinazolinyl]thio]ethanone	0
1-[(4-methylphenyl)methyl]-2,4-dioxo-N-(phenylmethyl)-3-prop-2-enyl-7-quinazolinecarboxamide	0
1-[(7-chloro-4-oxo-1H-quinazolin-2-yl)methyl]-4-piperidinecarboxamide	0
1-[amino-[(4,6-dimethyl-2-quinazolinyl)amino]methylidene]-3-(2-ethylphenyl)thiourea	0
1-[amino-[(4,6-dimethyl-2-quinazolinyl)amino]methylidene]-3-cyclohexylurea	0
1-[amino-[(4,7-dimethyl-2-quinazolinyl)amino]methylidene]-3-(3-methylphenyl)thiourea	0
1-[amino-[(4-methyl-2-quinazolinyl)amino]methylidene]-3-cyclohexylurea	0
1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea	0
1-butyl-1-methyl-3-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)thiourea	0
1-cyclohexyl-3-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)thiourea	0
1-cyclopentyl-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-3-(phenylmethyl)urea	0
1-fluoro-6,7,8,9,10,12-hexahydroazepino[2,1-b]quinazolin-12-ol	0
1-fluoro-7,8,9,11-tetrahydro-6H-pyrido[2,1-b]quinazolin-11-ol	0
12-oxo-N-(4-phenyl-2-thiazolyl)-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazoline-3-carboxamide	0
1H-Quinazoline-2,4-dione	0
1H-quinazolin-4-one	0
2',17-Dimethylspiro[13-oxa-2,10,17-triazatetracyclo[10.3.2.02,11.04,9]heptadeca-4,6,8,10-tetraene-14,4'-3,3a-dihydro-2H-imidazo[1,2-a]indole]-1',3,16-trione	0
2'-epi-fumiquinazoline C	0
2'-epi-fumiquinazoline D	0
2,4-Diamino-6,7-dimethoxyquinazoline	0
2,4-bis(1-pyrrolidinyl)quinazoline	0
2,4-dioxo-3-(2-oxolanylmethyl)-N-pentyl-1H-quinazoline-7-carboxamide	0
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide	0
2,6-dibromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol	0
2-(1,3-benzodioxol-5-yl)-3-hydroxy-1,2-dihydroquinazolin-4-one	0
2-(1,3-benzothiazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-(1,3-benzoxazol-2-ylamino)-7,7-dimethyl-4-(2-pyridinyl)-1,4,6,8-tetrahydroquinazolin-5-one	0
2-(1,3-benzoxazol-2-ylamino)-7-phenyl-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-(1-iminoethyl)-4-[[3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-3-oxobutanenitrile	0
2-(1-pyrrolidinyl)-1H-quinazolin-4-one	0
2-(1H-indol-3-yl)quinazolin-4-(3H)-one	0
2-(2,3-dihydro-1H-inden-5-ylamino)-8-fluoro-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one	0
2-(2,4-dichlorophenyl)-3-(phenylmethyl)-1,2-dihydroquinazolin-4-one	0
2-(2-amino-1-benzimidazolyl)-N-(phenylmethyl)-4-quinazolinamine	0
2-(2-amino-5,6-dichloro-1-benzimidazolyl)-8-methoxy-N-(phenylmethyl)-4-quinazolinamine	0
2-(2-bromophenyl)-3-[3-(4-morpholinyl)propyl]-1,2-dihydroquinazolin-4-one	0
2-(2-bromophenyl)-5-[(7-nitro-4-quinazolinyl)oxymethyl]-1,3,4-oxadiazole	0
2-(2-carboxyethyl)-6-hydroxyquinazolin-4(3H)-one	0
2-(2-carboxyethyl)-8-hydroxyquinazolin-4(3H)-one	0
2-(2-furanyl)-3-(2-furanylmethylideneamino)-7-nitro-1,2-dihydroquinazolin-4-one	0
2-(2-furanyl)-3-(6-methyl-2-pyridinyl)-4-quinazolinone	0
2-(2-hydroxyphenyl)-3,4-dihydroquinazolin-4-one	0
2-(2-hydroxyphenyl)-3-[1-(4-methoxyphenyl)ethylideneamino]-1,2-dihydroquinazolin-4-one	0
2-(2-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one	0
2-(3,4-dichloroanilino)-6-nitro-4-oxo-N-prop-2-enyl-1H-quinazoline-8-carboxamide	0
2-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-1H-quinazolin-4-one	0
2-(3-methoxyphenyl)-4-propan-2-yloxyquinazoline	0
2-(3-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one	0
2-(3-nitrophenyl)-N-(phenylmethyl)-4-quinazolinamine	0
2-(4,6,7-Trimethyl-2-quinazolinyl)guanidine	0
2-(4-chlorophenyl)-4-propan-2-yloxyquinazoline	0
2-(4-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]-4-quinazolinamine	0
2-(4-hydroxy-3-methoxyphenyl)-3-(2-methoxyphenyl)-1,2-dihydroquinazolin-4-one	0
2-(4-hydroxybenzyl)-4-(3-acetyl)quinazolinone	0
2-(4-hydroxybenzyl)quinazolin-4(3H)-one	0
2-(4-methoxyphenyl)-1H-quinazolin-4-one	0
2-(4-methoxyphenyl)-2-(4-quinazolinylhydrazinylidene)acetic acid	0
2-(4-methoxyphenyl)-3-(3-pyridinyl)-4-quinazolinone	0
2-(4-methylphenyl)sulfonyl-1-(4,6,7-trimethyl-2-quinazolinyl)guanidine	0
2-(4-morpholinyl)-10-pyridazino[6,1-b]quinazolinone	0
2-(4-nitrophenyl)-N-(2-oxolanylmethyl)-4-quinazolinamine	0
2-(4-oxo-3-quinazolinyl)-N-[3-(1-piperidinylsulfonyl)phenyl]acetamide	0
2-(5'-chloro-2'-phosphoryloxyphenyl)-6-chloro-4-(3H)-quinazolinone	0
2-(6,7-dimethoxy-4-quinazolinyl)-5-(2-pyridinyl)-1,2,4-triazol-3-amine	0
2-(6-amino-2-methyl-4-oxo-3-quinazolinyl)-N-(2-methylphenyl)acetamide	0
2-(6-benzimidazolo[1,2-c]quinazolinylthio)-N-(2-furanylmethyl)acetamide	0
2-(6-methylpyridin-2-yl)-N-(pyridin-4-yl)quinazolin-4-amine	0
2-(diethylaminomethyl)-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]one	0
2-(ethylthio)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one	0
2-(methylthio)-6-phenyl-6,7-dihydro-5H-[1,2,4]triazolo[5,1-b]quinazolin-8-one	0
2-(phenylmethylthio)-9-thiophen-2-yl-6,7,8a,9-tetrahydro-5H-[1,2,4]triazolo[5,1-b]quinazolin-8-one	0
2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline	0
2-Amino-5,6-dichloro-3,4,-dihydroquinazoline	0
2-[(1-amino-1-oxopropan-2-yl)thio]-3-butyl-4-oxo-7-quinazolinecarboxylic acid methyl ester	0
2-[(1-methyl-2-benzimidazolyl)amino]-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-[(2,4-dichlorophenyl)methylthio]-6,7-dimethoxy-3-(thiophen-2-ylmethyl)-4-quinazolinimine	0
2-[(2-cyclohexyl-4-quinazolinyl)thio]-N-(4-methyl-1,2,5-oxadiazol-3-yl)acetamide	0
2-[(2-methyl-2,3-dihydroindol-1-yl)methyl]-4-oxo-1H-quinazoline-7-carboxylic acid methyl ester	0
2-[(2-oxo-1-propan-2-yl-3-indolylidene)methyl]-1H-quinazolin-4-one	0
2-[(2-oxo-1-propan-2-yl-3-indolylidene)methyl]-3-phenyl-4-quinazolinone	0
2-[(2-propyl-4-quinazolinyl)thio]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	0
2-[(2-pyridinylthio)methyl]-1H-quinazolin-4-one	0
2-[(2-tert-butyl-4-quinazolinyl)thio]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	0
2-[(3-butan-2-yl-4-oxo-2-quinazolinyl)thio]propanenitrile	0
2-[(3-butyl-4-oxo-2-quinazolinyl)thio]-N-cyclopropylacetamide	0
2-[(3-ethyl-4-oxo-2-quinazolinyl)thio]acetic acid cyclohexyl ester	0
2-[(3-methyl-4-oxo-2-quinazolinyl)thio]-N-phenylacetamide	0
2-[(3-oxo-2-propan-2-yl-2H-imidazo[1,2-c]quinazolin-5-yl)thio]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide	0
2-[(4-chlorophenyl)methyl]-4-(prop-2-enylthio)quinazoline	0
2-[(5-bromo-1,3-benzoxazol-2-yl)amino]-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-[(5-methyl-1,3-benzoxazol-2-yl)amino]-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-[(5-phenyl-1,3-benzoxazol-2-yl)amino]-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-1H-quinazolin-4-one	0
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-6-(methoxymethyl)-1H-pyrimidin-4-one	0
2-[(6-methoxy-4-methyl-2-quinazolinyl)amino]-6-methyl-5-(3-methylbutyl)-1H-pyrimidin-4-one	0
2-[(6-methyl-1,3-benzoxazol-2-yl)amino]-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-[(7-chloro-4-quinazolinyl)oxy]-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone	0
2-[(7-methoxy-4-methyl-2-quinazolinyl)amino]-5,6-dimethyl-1H-pyrimidin-4-one	0
2-[(dimethylamino)methyl]-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]one	0
2-[1-(4-bromophenoxy)butyl]-8,9-dimethoxy-3H-[1,2,4]triazolo[1,5-c]quinazoline-5-thione	0
2-[1-chloro-2-(3-fluorophenyl)ethenyl]-7-(trifluoromethyl)-1H-quinazolin-4-one	0
2-[2,4-dioxo-3-(phenylmethyl)-1-quinazolinyl]-N-(5-methyl-3-isoxazolyl)acetamide	0
2-[2-(1,3-benzodioxol-5-yl)ethenyl]-3-(3-hydroxyphenyl)-4-quinazolinone	0
2-[2-(3-hydroxy-4-oxo-1-cyclohexa-2,5-dienylidene)ethylidene]-3-phenyl-1H-quinazolin-4-one	0
2-[2-(5-bromo-1H-indol-3-yl)ethyl]-3-(3-propan-2-yloxyphenyl)-4-quinazolinone	0
2-[2-[(2,5-dimethylphenyl)methylidene]hydrazinyl]-3-hydroxy-4-quinazolinone	0
2-[3-(1-benzotriazolylmethyl)-4-methoxyphenyl]-3-(4-methoxyphenyl)-1,2-dihydroquinazolin-4-one	0
2-[3-[(2,6-dimethylphenoxy)methyl]-4-methoxyphenyl]-3-(3-pyridinylmethyl)-1,2-dihydroquinazolin-4-one	0
2-[3-[(2,6-dimethylphenoxy)methyl]-4-methoxyphenyl]-3-(thiophen-2-ylmethyl)-1,2-dihydroquinazolin-4-one	0
2-[3-[(2,6-dimethylphenoxy)methyl]-4-methoxyphenyl]-3-[(5-methyl-2-furanyl)methyl]-1,2-dihydroquinazolin-4-one	0
2-[3-[(2,6-dimethylphenoxy)methyl]phenyl]-3-(2-furanylmethyl)-1,2-dihydroquinazolin-4-one	0
2-[3-[3-(4-morpholinyl)propyl]-4-oxo-1,2-dihydroquinazolin-2-yl]benzoic acid	0
2-[4'-(Methylamino)phenyl]quinazolin-4(3H)-one	0
2-[4-[1-[(2-fluorophenyl)methyl]-2,4-dioxo-3-quinazolinyl]phenyl]-N-(2-oxolanylmethyl)acetamide	0
2-[4-methoxy-3-(4-morpholinylmethyl)phenyl]-3-(phenylmethyl)-1,2-dihydroquinazolin-4-one	0
2-[5-(2-fluorophenyl)-2-furanyl]-3-hydroxy-1,2-dihydroquinazolin-4-one	0
2-[5-(3-chlorophenyl)-2-furanyl]-1H-quinazolin-4-one	0
2-[5-(3-fluorophenyl)-2-furanyl]-3-hydroxy-1,2-dihydroquinazolin-4-one	0
2-[5-[[2-(3-methoxypropylamino)-2-oxoethyl]thio]-3-oxo-2H-imidazo[1,2-c]quinazolin-2-yl]-N-(phenylmethyl)acetamide	0
2-[6,7-dimethoxy-3-(3-methoxyphenyl)-2,4-dioxo-1-quinazolinyl]-N-(5-methyl-1H-pyrazol-3-yl)acetamide	0
2-[[(6-ethyl-4-oxo-3-prop-2-enyl-2-thieno[2,3-d]pyrimidinyl)thio]methyl]-4-oxo-1H-quinazoline-7-carboxylic acid methyl ester	0
2-[[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone	0
2-[[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]thio]-3-ethyl-4-quinazolinone	0
2-[[2-(5-methyl-2-thiophenyl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone	0
2-[[2-(phenoxymethyl)-4-quinazolinyl]thio]acetic acid methyl ester	0
2-[[2-[(2-methoxy-2-oxoethyl)thio]-4-oxo-3-quinazolinyl]oxy]acetic acid methyl ester	0
2-[[2-[2-(1-piperidinyl)ethyl]-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]thio]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide	0
2-[[3-(2,4-difluorophenyl)-4-oxo-2-quinazolinyl]thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide	0
2-[[3-(3,4-dichlorophenyl)-4-oxo-2-quinazolinyl]thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide	0
2-[[3-(3-chloro-4-fluorophenyl)-4-oxo-2-quinazolinyl]thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide	0
2-[[3-[(4-fluorophenyl)methyl]-4-oxo-2-quinazolinyl]thio]-N-(thiophen-2-ylmethyl)acetamide	0
2-[[3-butyl-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]-N-(3-methoxyphenyl)acetamide	0
2-[[3-butyl-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]acetamide	0
2-[[6-(4-morpholinyl)-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]thio]-N-(2-oxolanylmethyl)acetamide	0
2-[[6-(4-morpholinyl)-4-oxo-3-(phenylmethyl)-2-quinazolinyl]thio]acetic acid ethyl ester	0
2-[[[5,7-bis(ethylamino)-[1,2,4]triazolo[4,3-a][1,3,5]triazin-3-yl]thio]methyl]-1H-quinazolin-4-one	0
2-acetylquinazolin-4 (3H)-one	0
2-bromo-6,7,8,9,10,12-hexahydroazepino[2,1-b]quinazolin-12-ol	0
2-butoxy-3-phenyl-4-quinazolinone	0
2-chloro-4-[(6-\{3-[(3-hydroxypropyl)amino]propoxy\}-7-methoxyquinazolin-4-yl)amino]phenol	0
2-chloro-4-[(6-\{3-[(hydroxymethyl)(3-hydroxypropyl)amino]propoxy\}-7-methoxyquinazolin-4-yl)amino]phenol	0
2-chloro-4-[(7-methoxy-6-\{3-[methyl(propyl)amino]propoxy\}quinazolin-4-yl)amino]phenol	0
2-chloro-N,N-dipropylquinazolin-4-amine	0
2-chloro-N-(phenylmethyl)-4-quinazolinamine	0
2-chloro-N-[(1R)-1-phenylethyl]-4-quinazolinamine	0
2-imino-1,2,3,4-tetrahydroquinazolin-4-one	0
2-methoxy-6-[4-(4-methyl-1-piperazinyl)-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
2-methoxy-6-[4-[2-(4-morpholinyl)ethylamino]-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
2-methoxy-N-(3-methyl-2-oxo-1,4-dihydroquinazolin-6-yl)benzenesulfonamide	0
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide +	0
2-methyl-3-[(5-methyl-3-nitro-6-oxo-1-cyclohexa-2,4-dienylidene)methylamino]-4-quinazolinone	0
2-methyl-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]thione	0
2-methyl-5-(3-thiophenyl)-3,5-dihydropyrazolo[1,5-c]quinazoline	0
2-methyl-5-phenyl-3,5-dihydropyrazolo[1,5-c]quinazoline	0
2-oxo-1,4-dihydroquinazoline-3-carboxylic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester	0
2-phenyl-1H-quinazoline-4-thione	0
2-pyridin-4-yl-2,3-dihydro-1H-quinazolin-4-one	0
2-thiophen-2-yl-2,3-dihydro-1H-quinazolin-4-one	0
2-thiophen-2-yl-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
3,3-dimethyl-1-[[9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl]thio]-2-butanone	0
3,4-dihydro-2H,6H-[1,3]thiazino[2,3-b]quinazolin-6-one	0
3,5,5-trimethyl-2-sulfanylidene-1,6-dihydrobenzo[h]quinazolin-4-one	0
3,5-diethyl-2-(2-hydroxyethylamino)-5-methyl-6H-benzo[h]quinazolin-4-one	0
3,5-diethyl-2-(3-hydroxypropylamino)-5-methyl-6H-benzo[h]quinazolin-4-one	0
3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-sulfanylidene-1H-quinazolin-4-one	0
3-(2-fluorophenyl)-4-oxo-2-sulfanylidene-1H-quinazoline-7-carboxylic acid methyl ester	0
3-(2-furanylmethyl)-2-[4-methoxy-3-[(2-methylphenoxy)methyl]phenyl]-1,2-dihydroquinazolin-4-one	0
3-(2-furanylmethyl)-2-phenyl-1,2-dihydroquinazolin-4-one	0
3-(2-furanylmethyl)-4-oxo-N,N-dipropyl-2-sulfanylidene-1H-quinazoline-7-carboxamide	0
3-(2-hydroxyphenyl)-2-[2-(4-oxo-1-cyclohexa-2,5-dienylidene)ethylidene]-1H-quinazolin-4-one	0
3-(2-methoxyethyl)-2,4-dioxo-N-pentyl-1H-quinazoline-7-carboxamide	0
3-(2-methoxyphenyl)-2-methyl-4-oxo-1H-quinazoline-2-carboxylic acid methyl ester	0
3-(3,4-Dihydroxy-2,2-dimethyl-1-oxo-3aH-imidazo[1,2-a]indol-4-yl)-2-(4-oxoquinazolin-3-yl)propanoic acid	0
3-(3-ethoxypropyl)-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-1-(phenylmethyl)thiourea	0
3-(3-morpholinopropyl)-2-(2-pyridinyl)-2,3-dihydro-4(1H)-quinazolinone	0
3-(4-Hydroxy-2,2-dimethyl-1-oxo-3,3a-dihydroimidazo[1,2-a]indol-4-yl)-2-(4-oxoquinazolin-3-yl)propanoic acid	0
3-(4-chlorophenyl)-2-(1-pyrrolidinyl)-4-quinazolinone	0
3-(4-methylphenyl)-5-oxo-8-thiazolo[2,3-b]quinazolinecarboxamide	0
3-(4-methylphenyl)-5-oxo-N-propyl-8-thiazolo[2,3-b]quinazolinecarboxamide	0
3-(4-nitrophenyl)[1,2,3]triazolo[1,5-a]quinazolin-5-amine	0
3-(4-oxo-1H-quinazolin-2-yl)propanoic acid (3,5-dimethyl-4-isoxazolyl)methyl ester	0
3-(4-oxo-3-quinazolinyl)-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)propanamide	0
3-(4-propan-2-ylphenyl)sulfonyl-1H-triazolo[1,5-a]quinazolin-5-one	0
3-(benzenesulfonyl)-N-(3-methylphenyl)-5-triazolo[1,5-a]quinazolinamine	0
3-(phenylmethyl)-2-[2-(3-pyridinyl)ethenyl]-4-quinazolinone	0
3-[(2-hydroxy-4-oxo-1-cyclohexa-2,5-dienylidene)methylamino]-2-methyl-4-quinazolinone	0
3-[(2-hydroxy-4-oxo-1-cyclohexa-2,5-dienylidene)methylamino]-2-propyl-4-quinazolinone	0
3-[(3-hydroxy-4-oxo-1-cyclohexa-2,5-dienylidene)methylamino]-2-(phenoxymethyl)-4-quinazolinone	0
3-[(4-methoxyphenyl)methyl]-N-(3-methoxypropyl)-2,4-dioxo-1H-quinazoline-7-carboxamide	0
3-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-diethoxy-2-sulfanylidene-1H-quinazolin-4-one	0
3-[2-[butyl(methyl)amino]ethyl]-6-(4-morpholinyl)-2-sulfanylidene-1H-quinazolin-4-one	0
3-[3-(N-ethylanilino)propyl]-6-(4-morpholinyl)-2-sulfanylidene-1H-quinazolin-4-one	0
3-[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-4-oxobutyl]-6,7-diethoxy-2-sulfanylidene-1H-quinazolin-4-one	0
3-[6-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-6-oxohexyl]-2-sulfanylidene-1H-quinazolin-4-one	0
3-[[1-(3-chlorophenyl)-3-methyl-5-oxo-4-pyrazolylidene]methylamino]-2-methyl-4-quinazolinone	0
3-[[4-(2-benzofuranyl)-2-thiazolyl]methyl]-2-[(dimethylamino)methyl]-4-quinazolinone	0
3-[[[[3-[(4-chlorophenyl)methyl]-2-methyl-4-oxo-6-quinazolinyl]amino]-oxomethyl]amino]propanoic acid ethyl ester	0
3-\{[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl](hydroxymethyl)amino\}propan-1-ol	0
3-\{[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]amino\}propan-1-ol	0
3-ethyl-2-(2-phenylethenyl)-4-quinazolinone	0
3-ethyl-2-[(4-oxo-1H-quinazolin-2-yl)methylthio]-4-quinazolinone	0
3-ethyl-2-[2-(2-methyl-1H-indol-3-yl)ethenyl]-4-quinazolinone	0
3-hydroxy-1,9,17-triazapentacyclo[14.8.0.02,7.010,15.018,23]tetracosa-2(7),3,5,10,12,14,16,18,20,22-decaene-8,24-dione	0
3-hydroxy-2-(2-hydroxy-3-methoxyphenyl)-1,2-dihydroquinazolin-4-one	0
3-hydroxy-2-(5-thiophen-2-yl-2-furanyl)-1,2-dihydroquinazolin-4-one	0
3-hydroxy-2-[5-[4-(trifluoromethyl)phenyl]-2-furanyl]-1,2-dihydroquinazolin-4-one	0
3-hydroxyglyantrypine	0
3-methoxy-2-(3-pyridinylmethylthio)-4-quinazolinone	0
3-methoxyglyantrypine	0
3-methyl-2-[2-(4-methyl-5-thiazolyl)ethylthio]-4-quinazolinone	0
3-phenyl-3-(4-quinazolinylhydrazinylidene)propanoic acid ethyl ester	0
4,5-dimethyl-2-[[1-oxo-2-(4-quinazolinyloxy)ethyl]amino]-3-thiophenecarboxylic acid ethyl ester	0
4-(2-methylpiperidin-1-yl)quinazoline	0
4-(3,4-dimethoxyphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazoline-2-thione	0
4-(3-methoxyphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazoline-2-thione	0
4-(4-anilinoanilino)-2-quinazolinecarboxylic acid ethyl ester	0
4-(4-ethoxycarbonylanilino)-2-quinazolinecarboxylic acid ethyl ester	0
4-(4-propan-2-ylphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazolin-2-one	0
4-(6-quinolinyl)-1,3,4,6,7,8-hexahydroquinazoline-2,5-dione	0
4-Methylquinazoline	0
4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxo-N-propan-2-ylbutanamide	0
4-[(3-chloro-4-fluorophenyl)amino]-6-\{3-[(3-hydroxypropyl)amino]propoxy\}quinazolin-7-ol	0
4-[(6,7-diethoxy-2,4-dioxo-1H-quinazolin-3-yl)methyl]-N-(3-methoxypropyl)-1-cyclohexanecarboxamide	0
4-[1,3-dioxo-3-[(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)amino]propyl]-1-piperazinecarboxylic acid ethyl ester	0
4-[2-[(6-chloro-4-quinazolinyl)amino]ethyl]phenol	0
4-[2-[[2-[(5-methyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]thio]-4-oxo-3-quinazolinyl]-N-(phenylmethyl)butanamide	0
4-[2-[[3-(4-methylphenyl)-5-triazolo[1,5-a]quinazolinyl]amino]ethyl]benzenesulfonamide	0
4-[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]-4-hydroxymorpholin-4-ium	0
4-[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]morpholin-3-ol	0
4-[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]morpholin-3-one	0
4-[4-(4-methylphenyl)sulfonyl-1-piperidinyl]-2-thiophen-2-ylquinazoline	0
4-[4-oxo-2-[[2-oxo-2-[(phenylmethyl)amino]ethyl]thio]-3-quinazolinyl]-1-piperidinecarboxylic acid ethyl ester	0
4-[5-(3-hydroxy-4-oxo-1,2-dihydroquinazolin-2-yl)-2-furanyl]benzonitrile	0
4-[[3-(3-chloro-4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-2-(1-iminoethyl)-3-oxobutanenitrile	0
4-[[3-[2-(1-cyclohexenyl)ethyl]-4-oxo-2-sulfanylidene-1H-quinazolin-7-yl]-oxomethyl]-1-piperazinecarboxylic acid ethyl ester	0
4-[[4-(1-pyrrolidinyl)-2-quinazolinyl]amino]phenol	0
4-[[4-hydroxy-2-(2-methylpropyl)-1-oxo-3,3a-dihydro-2h-imidazo[1,2-a]indol-4-yl]methyl]-1-methyl-2,4-dihydro-1h-pyrazino[2,1-b]quinazoline-3,6-dione	0
4-[[6,7-bis(hydroxymethyl)-4-quinazolinyl]amino]-2-bromophenol	0
4-[[6,7-bis(hydroxymethyl)-4-quinazolinyl]amino]phenol	0
4-[[[2-(2-fluorophenyl)-4-quinazolinyl]hydrazo]methylidene]-3-hydroxy-1-cyclohexa-2,5-dienone	0
4-chloro-2-[[4-(2-oxolanylmethylamino)-2-quinazolinyl]amino]phenol	0
4-chloro-N-(8-methyl-[1,3]dioxolo[4,5-g]quinazolin-6-yl)benzamide	0
4-defluoro-4-hydroxy Gefitinib	0
4-ethoxy-6,7-dimethoxyquinazoline	0
4-methoxy-2-(4-methoxyphenyl)quinazoline	0
4-methoxy-2-(4-propoxyphenyl)quinazoline	0
4-methoxy-N-(8-methyl-[1,3]dioxolo[4,5-g]quinazolin-6-yl)benzamide	0
4-methoxy-N-[2-[(4-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide	0
4-methyl-2-quinazolinamine	0
4-methyl-N'-(4-quinazolinyl)benzohydrazide	0
4-oxo-2-(trifluoromethyl)-1H-quinazoline-6-carboxylic acid ethyl ester	0
4-oxo-N-(7-quinolinylmethylideneamino)-1H-quinazoline-2-carboxamide	0
5,5-diethyl-2-(2-hydroxyethylamino)-1,6-dihydrobenzo[h]quinazolin-4-one	0
5,5-diethyl-2-hydrazinyl-1,6-dihydrobenzo[h]quinazolin-4-one	0
5,7-dichloro-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-9-ol	0
5-(1-piperidinyl)-3-pyrazolo[1,5-a]quinazolinecarbonitrile	0
5-(6,7-diethoxy-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl)-N-(2-furanylmethyl)pentanamide	0
5-[(4-morpholin-4-ylphenyl)thio]quinazoline-2,4-diamine	0
5-[4-[(2-methyl-4-thiazolyl)methylamino]-6-quinazolinyl]-2-furancarboxylic acid ethyl ester	0
5-[4-[methyl-[(3-methyl-2-thiophenyl)methyl]amino]-6-quinazolinyl]-2-furancarboxylic acid ethyl ester	0
5-hydroxydeoxyvasicinone	0
5-methyl-1H-quinazoline-2,4-dione	0
5-methyl-6-pyridin-4-yl-6H-benzimidazolo[1,2-c]quinazoline	0
5a,6,7,8,9,10-hexahydro-5H-azepino[2,1-b]quinazolin-12-one	0
6,6-dimethyl-9-thiophen-2-yl-5,7,8a,9-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-8-one	0
6,7,8-trimethoxy-3-phenyl-2-thioxo-1,2,3,4-tetrahydroquinazolin-4-one	0
6,7-Dichloro-3-hydroxy-1,5 dihydro-imidazo[2,1-b]quinazolin-2-one	0
6,7-bis(2-methoxyethoxy)quinazolin-4(3H)-one	0
6,7-diethoxy-3-(3-methoxypropyl)-2-sulfanylidene-1H-quinazolin-4-one	0
6,7-diethoxy-3-[3-(2-oxo-1-pyrrolidinyl)propyl]-2-sulfanylidene-1H-quinazolin-4-one	0
6,7-dimethoxy-2-[(1H-1,2,4-triazol-5-ylthio)methyl]-1H-quinazolin-4-one	0
6,7-dimethoxy-2-[[methyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-1H-quinazolin-4-one	0
6,7-dimethoxy-3-(2-oxolanylmethyl)-2-sulfanylidene-1H-quinazolin-4-one	0
6,7-dimethoxy-3-phenyl-1H-quinazoline-2,4-dione	0
6,7-dimethoxy-4-(2-oxolanylmethylamino)-1H-quinazoline-2-thione	0
6,7-dimethoxy-4-\{8-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydroisoquinolin-2-(1H)-yl\}quinazoline	0
6,7-dimethoxy-N,N-dipropyl-2-(1-pyrrolidinyl)-4-quinazolinamine	0
6,7-dimethoxy-N-[(4-methylphenyl)methyl]-4-quinazolinamine	0
6,8-dibromo-2-[[[4-(difluoromethoxy)phenyl]methyl-methylamino]methyl]-1H-quinazolin-4-one	0
6-(1,3-benzodioxol-5-yl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(2-oxanylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(2-oxolanylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(2-thiazolylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(3-oxanylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(3-oxolanylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(cyclopentylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(cyclopropylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[(2-methyl-3-furanyl)methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[(2-methyl-4-thiazolyl)methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[(3-fluorophenyl)methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[2-(2-furanyl)ethyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[[(2S)-2-oxolanyl]methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-ethyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-methyl-N-[(2-methyl-4-thiazolyl)methyl]-4-quinazolinamine	0
6-(1-methyl-5-indolyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	0
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(2-chlorophenyl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine	0
6-(2-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(2-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(2-chlorophenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	0
6-(2-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(2-methyl-3-furanyl)-N-[(5-methyl-2-furanyl)methyl]-4-quinazolinamine	0
6-(3,5-dimethyl-4-isoxazolyl)-1H-quinazolin-4-one	0
6-(3,5-dimethyl-4-isoxazolyl)-N-[(1-methyl-2-piperidinyl)methyl]-4-quinazolinamine	0
6-(3,5-dimethyl-4-isoxazolyl)-N-[(2-ethoxyphenyl)methyl]-4-quinazolinamine	0
6-(3,5-dimethyl-4-isoxazolyl)-N-[(3-methoxyphenyl)methyl]-4-quinazolinamine	0
6-(3,5-dimethyl-4-isoxazolyl)-N-[(3-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(3,5-dimethyl-4-isoxazolyl)-N-[1-(2-furanyl)ethyl]-4-quinazolinamine	0
6-(3-aminopropoxy)-4-[(3-chloro-4-fluorophenyl)amino]quinazolin-7-ol	0
6-(3-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(3-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(3-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(3-furanyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(3-furanyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(3-furanyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	0
6-(3-furanyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(3-furanyl)-N-methyl-N-[(3-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(3-methoxyphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(3-methoxyphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(3-methoxyphenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	0
6-(3-methoxyphenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(3-methylphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(3-methylphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(3-pyridinyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(3-pyridinyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(4-ethoxy-1H-quinazolin-2-ylidene)-1-cyclohexa-2,4-dienone	0
6-(4-fluoro-1,3-benzodioxol-5-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(4-morpholinyl)-3-(2-phenylethyl)-2-sulfanylidene-1H-quinazolin-4-one	0
6-(6-bromo-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl)-N-[2-(4-sulfamoylphenyl)ethyl]hexanamide	0
6-[4-(1-phenylethylamino)-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
6-[4-(2-methoxyanilino)-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
6-[4-[2-(4-morpholinyl)ethylamino]-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
6-[4-[4-(phenylmethyl)-1-piperazinyl]-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
6-amino-3-[(2-chlorophenyl)methyl]-2-propyl-4-quinazolinone	0
6-bromo-3-[4-nitro-3-(trifluoromethyl)phenyl]-2-propyl-4-quinazolinone	0
6-bromo-3-phenyl-2-sulfanylidene-1H-quinazolin-4-one	0
6-chloro-3-[2-(diethylamino)ethyl]-2-sulfanylidene-1H-quinazolin-4-one	0
6-methoxy-4-methyl-2-[(2-methylphenyl)methylthio]quinazoline	0
6-methoxy-N-(4-methoxyphenyl)-4-quinazolinamine	0
7-(4-quinazolinyloxymethyl)-5-thiazolo[3,2-a]pyrimidinone	0
7-Bromo-6-chloro-3-[3-(3-hydroxypiperidin-2-yl)-2-oxopropyl]-3,4-dihydroquinazolin-4-one	0
7-[(6,8-dichloro-4-quinazolinyl)oxymethyl]-5-thiazolo[3,2-a]pyrimidinone	0
7-[2-[2-(dimethylamino)ethoxy]ethoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1-methyl-4-piperidinyl)-4-quinazolinamine	0
7-[[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-5-thiazolo[3,2-a]pyrimidinone	0
7-[oxo-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)methyl]-3-prop-2-enyl-1H-quinazoline-2,4-dione	0
7-bromo-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline	0
7-chloro-2-methyl-3-(4-pyridylmethyl)-3,4-dihydroquinazolin-4-one	0
7-chloro-3-[2-(1-cyclohexenyl)ethyl]-2-sulfanylidene-1H-quinazolin-4-one	0
7-chloro-3-hydroxy-2-[3-(trifluoromethyl)phenyl]-4-quinazolinone	0
7-chloro-N-(2-furanylmethyl)-4-quinazolinamine	0
8-methylene-7-(phenylmethyl)-5H-[1,3]dioxolo[4,5-g]quinazoline-6-thione	0
9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine	0
9-methyl-5,6,7,8-tetrahydrotetrazolo[5,1-b]quinazoline	0
9-phenyl-1,5,6,7,8,9-hexahydro-[1,2,4]triazolo[5,1-b]quinazoline	0
ARS-1620	4
AZD-1152 +	0
AZT-1152	0
Altanserin	0
Amethysione	0
Aniflorine	0
Anisessine	0
Anisotine	0
Arborine	0
Aspamide F	0
Aspamide G	0
Aspergicin	0
Auranomide B	0
Aurantiomide A	0
Aurantiomide B	0
Aurantiomide C	0
Brevianamide M	0
Brevianamide N	0
Bunazosin hydrochloride	0
Chrysopiperazine C	0
Cladoquinazoline	0
Cottoquinazoline A	0
Cottoquinazoline B	0
Cottoquinazoline C	0
Cottoquinazoline D	0
Cottoquinazoline E	0
Cottoquinazoline F	0
Deoxypeganine	0
Deoxyvasicinone	0
Dictyoquinazol A	0
Dictyoquinazol B	0
Dictyoquinazol C	0
Dihydroquinazoline	0
EVP4593	0
Epi-cladoquinazoline	0
Epi-fiscalin A	0
Epi-fiscalin C	0
Epi-neofiscalin A	0
Farinamycin	0
Febrifugine	6
Fiscalin A	0
Fiscalin B	0
Fiscalin E	0
Fiscalin F	0
Fumigatoside F	0
Fumiquinazoline B	0
Fumiquinazoline D	0
Fumiquinazoline I	0
Fumiquinazoline K	0
Fumiquinazoline L	0
Fumiquinazoline M	0
Fumiquinazoline N	0
Fumiquinazoline O	0
Fumiquinazoline P	0
Fumiquinazoline Q	0
Fumiquinazoline S	0
Fumiquinazoline h	0
GSK3-XIII	0
Glyantrypine	0
Glycophymoline	0
Glycosminine	0
IC-87114	16
ITK7	0
Icotinib hydrochloride	0
Isofebrifugine	0
LSM-19241	0
LSM-19663	0
LSM-19894	0
LY-202769	0
Lapatinib ditosylate monohydrate	0
Luotonin A	0
ML240	0
Mdivi-1	0
N'-(4-quinazolinyl)acetohydrazide	0
N'-[2-[(2-cyclohexyl-4-quinazolinyl)thio]-1-oxoethyl]-2-methylpropanehydrazide	0
N,N-bis(2-methoxyethyl)-2-(4-methylphenyl)quinazolin-4-amine	0
N,N-dibutyl-2-(pyridin-4-yl)quinazolin-4-amine	0
N,N-diethyl-2-[[7-[(4-methoxyphenyl)methyl]-8-oxo-[1,3]dioxolo[4,5-g]quinazolin-6-yl]thio]acetamide	0
N,N-dipropyl-2-(pyrrolidin-1-yl)quinazolin-4-amine	0
N-(1,3-benzodioxol-5-ylmethyl)-3-cyclopentyl-2,4-dioxo-1H-quinazoline-7-carboxamide	0
N-(1,3-benzodioxol-5-ylmethyl)-3-methoxy-N-[(4-oxo-1H-quinazolin-2-yl)methyl]benzamide	0
N-(1,3-benzodioxol-5-ylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-(2-chlorophenyl)-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-furanyl)-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-pyridinyl)-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-[6-(4-morpholinyl)-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl]hexanamide	0
N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-methoxy-4-quinazolinamine	0
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine	0
N-(1-cyclohexyl-4-piperidinyl)-6-methoxy-7-[3-(1-piperidinyl)propoxy]-2-(4-propan-2-yl-1,4-diazepan-1-yl)-4-quinazolinamine	0
N-(1-phenylethyl)-2-(1-pyrrolidinyl)-4-quinazolinamine	0
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(4-oxo-3-quinazolinyl)acetamide	0
N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-oxo-3-phenyl-2-quinazolinyl)thio]acetamide	0
N-(2,3-dihydro-1H-inden-5-yl)-2-[(5-fluoro-4-oxo-3-phenyl-2-quinazolinyl)thio]acetamide	0
N-(2,3-dihydro-1H-inden-5-yl)-2-[(6-fluoro-4-oxo-3-phenyl-2-quinazolinyl)thio]acetamide	0
N-(2,3-dihydro-1H-inden-5-yl)-2-[[3-(2-fluorophenyl)-4-oxo-2-quinazolinyl]thio]acetamide	0
N-(2,4-dimethoxyphenyl)-2-(1-pyrrolidinyl)-4-quinazolinamine	0
N-(2-furanylmethyl)-6-(3-methoxyphenyl)-N-methyl-4-quinazolinamine	0
N-(2-furanylmethyl)-N-methyl-6-(1-methyl-5-indolyl)-4-quinazolinamine	0
N-(2-methoxyethyl)-2-[[3-[(4-methoxyphenyl)methyl]-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]acetamide	0
N-(2-methoxyethyl)-4-\{[6-(pyridin-4-yl)quinazolin-2-yl]amino\}benzamide	0
N-(2-methoxyethyl)-4-oxo-3-[3-(2-oxo-1-pyrrolidinyl)propyl]-2-sulfanylidene-1H-quinazoline-7-carboxamide	0
N-(2-pyridinylmethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-9-amine	0
N-(3-\{[2-(2-fluorophenyl)quinazolin-4-yl]amino\}phenyl)acetamide	0
N-(3-\{[7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]amino\}-4-methylphenyl)-2-morpholin-4-ylisonicotinamide	0
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-\{3-[methyl(propyl)amino]propoxy\}quinazolin-4-amine	0
N-(3-chlorophenyl)-2-[6,7-dimethoxy-2,4-dioxo-3-(2-oxolanylmethyl)-1-quinazolinyl]acetamide	0
N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine	0
N-(3-fluorophenyl)-2-(pyridin-4-yl)quinazolin-4-amine	0
N-(3-methoxyphenyl)-2-[(4-oxo-3-propyl-2-quinazolinyl)thio]-2-phenylacetamide	0
N-(3-methoxyphenyl)quinazolin-4-amine	0
N-(4-bromo-3-chlorophenyl)-2-[(4-oxo-1H-quinazolin-2-yl)thio]acetamide	0
N-(4-chloro-2-fluorophenyl)-6,7-dimethoxy-4-quinazolinamine	0
N-(4-ethylphenyl)-2-[[3-[3-(4-methyl-1-piperidinyl)propyl]-4-oxo-2-quinazolinyl]thio]acetamide	0
N-(4-methoxyphenyl)-2-(3-nitrophenyl)-4-quinazolinamine	0
N-(4-methylphenyl)-2-(pyridin-4-yl)quinazolin-4-amine	0
N-(4-oxo-2-phenyl-1,2-dihydroquinazolin-3-yl)benzenesulfonamide	0
N-(5-methyl-1H-pyrazol-3-yl)-2-[[3-oxo-2-(phenylmethyl)-2H-imidazo[1,2-c]quinazolin-5-yl]thio]acetamide	0
N-(5-methyl-3-isoxazolyl)-2-[(2-propan-2-yl-4-quinazolinyl)thio]acetamide	0
N-(6-ethoxy-1,3-benzothiazol-2-yl)-2-[[3-(2-furanylmethyl)-4-oxo-2-quinazolinyl]thio]acetamide	0
N-(7,8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-3-pyridinecarboxamide	0
N-(cyclohexylmethyl)-5,6,7,8-tetrahydrotetrazolo[5,1-b]quinazolin-9-amine	0
N-(phenylmethyl)-2-[[4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolin-2-yl]thio]acetamide	0
N-[(3-chlorophenyl)methylideneamino]-4-quinazolinamine	0
N-[(3-methylphenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine	0
N-[(3-nitrophenyl)methylideneamino]-4-oxo-1H-quinazoline-2-carboxamide	0
N-[(4-methyl-2-thiophenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine	0
N-[(4-oxo-1H-quinazolin-2-yl)methyl]-N-(2-phenylethyl)butanamide	0
N-[(cyclohexylamino)-oxomethyl]-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide	0
N-[2-(2-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-9-amine	0
N-[2-(4-methoxyphenyl)-4-oxo-1,2-dihydroquinazolin-3-yl]carbamic acid ethyl ester	0
N-[2-[(3-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide	0
N-[2-[4-(dimethylamino)phenyl]-4-oxo-1,2-dihydroquinazolin-3-yl]carbamic acid ethyl ester	0
N-[2-methyl-4-oxo-3-(phenylmethyl)-7-(1-piperidinyl)-6-quinazolinyl]-3-pyridinecarboxamide	0
N-[3,5-dimethyl-1-[(4-methylphenyl)methyl]-4-pyrazolyl]-2-[[4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolin-2-yl]thio]acetamide	0
N-[3-(1-azepanyl)propyl]-3-[(4-methoxyphenyl)methyl]-2,4-dioxo-1H-quinazoline-7-carboxamide	0
N-[3-(1-azepanylsulfonyl)-4-methylphenyl]-2-(4-quinazolinylthio)acetamide	0
N-[3-(4-morpholinyl)propyl]-2,4-dioxo-3-(2-phenylethyl)-1H-quinazoline-7-carboxamide	0
N-[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]-N-(3-hydroxypropyl)formamide	0
N-[3-(\{4-[(3-chloro-4-hydroxyphenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]-N-(3-hydroxypropyl)formamide	0
N-[3-(diethylamino)propyl]-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide	0
N-[3-(dimethylsulfamoyl)phenyl]-2-(4-quinazolinylthio)acetamide	0
N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine	0
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-4-thiazolyl]-4-quinazolinamine	0
N-[4-(3-chloro-4-fluoroanilino)-7-(3-oxolanyloxy)-6-quinazolinyl]-4-(dimethylamino)-2-butenamide	0
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide	0
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide	0
N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide	0
N-[4-[[2-methoxy-5-(4-oxo-2,3-dihydro-1H-quinazolin-2-yl)phenyl]methoxy]phenyl]acetamide	0
N-[4-[[2-methoxy-5-[4-oxo-3-(phenylmethyl)-1,2-dihydroquinazolin-2-yl]phenyl]methoxy]phenyl]acetamide	0
N-[4-[[2-methoxy-5-[4-oxo-3-(phenylmethyl)-2-quinazolinyl]phenyl]methoxy]phenyl]acetamide	0
N-[4-[[2-methoxy-5-[4-oxo-3-(pyridin-4-ylmethyl)-1,2-dihydroquinazolin-2-yl]phenyl]methoxy]phenyl]acetamide	0
N-[4-[[5-(3-butyl-4-oxo-1,2-dihydroquinazolin-2-yl)-2-methoxyphenyl]methoxy]phenyl]acetamide	0
N-[4-[[5-[3-(2-furanylmethyl)-4-oxo-1,2-dihydroquinazolin-2-yl]-2-methoxyphenyl]methoxy]-3,5-dimethylphenyl]acetamide	0
N-[4-[[5-[5-hydroxy-4-oxo-3-(phenylmethyl)-1,2-dihydroquinazolin-2-yl]-2-methoxyphenyl]methoxy]phenyl]acetamide	0
N-[4-[[[6-(3,5-dimethyl-4-isoxazolyl)-4-quinazolinyl]amino]methyl]phenyl]acetamide	0
N-[4-oxo-2-(2-pyridinyl)-1,2-dihydroquinazolin-3-yl]acetamide	0
N-[7-(2-furanyl)-5-oxo-7,8-dihydro-6H-quinazolin-2-yl]acetamide	0
N-[9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]-2-phenylacetamide	0
N-[amino-[(4,6,7-trimethyl-2-quinazolinyl)amino]methylidene]propanamide	0
N-\{(E)-amino[(4,7-dimethylquinazolin-2-yl)amino]methylidene\}-2-(4-chlorophenyl)acetamide	0
N-\{3-[(2-phenylquinazolin-4-yl)amino]phenyl\}acetamide	0
N-\{4-[(3-bromophenyl)amino]quinazolin-6-yl\}but-2-ynamide	0
N-\{5-[(7-\{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy\}-6-methoxyquinazolin-4-yl)amino]pyrimidin-2-yl\}benzamide	0
N-benzylquinazolin-4-amine	0
N-butyl-2-[[6-(4-morpholinyl)-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]thio]acetamide	0
N-butyl-3-[1-[(2,5-dimethylphenyl)methyl]-2,4-dioxo-3-quinazolinyl]propanamide	0
N-butyl-N-methyl-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide	0
N-cycloheptyl-3-(2-methoxyethyl)-2,4-dioxo-1H-quinazoline-7-carboxamide	0
N-cyclohexyl-2-(3-oxo-5-sulfanylidene-2,6-dihydroimidazo[1,2-c]quinazolin-2-yl)acetamide	0
N-cyclohexyl-6,7-dimethoxyquinazolin-4-amine	0
N-methyl-2-(4-methylphenyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine	0
N1-(6-bromo-4-quinazolinyl)-N4,N4-dimethylbenzene-1,4-diamine	0
N1-(6-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)-4-nitrobenzamide	0
N2,N2-dipropylquinazoline-2,4-diamine	0
N2-(2,5-dimethoxyphenyl)-N4-(2-furanylmethyl)quinazoline-2,4-diamine	0
N2-(5-chloro-2-methoxyphenyl)quinazoline-2,4-diamine	0
N4-(3,4-dimethylphenyl)quinazolin-4-amine hydrochloride	0
N4-(5-Fluoro-4-imino-3,4-dihydroquinazolin-3-yl)isonicotinamide	0
NU 1025	1
Neofiscalin A	0
Norquinadoline A	0
O-Desmorpholinopropyl Gefitinib	0
O-desmethyl Gefitinib	0
Oxysporizoline	0
PD 168393	19
PD-153035	0
PDGF receptor tyrosine kinase inhibitor III	0
Pegamine	0
Peganine	0
Polonimide A	0
Polonimide B	0
Polonimide C	0
Protuboxepin E	0
Protuboxepin H	0
Protuboxepin I	0
Protuboxepin J	0
Protuboxepin K	0
Puniceloid A	0
Puniceloid B	0
Puniceloid C	0
Puniceloid D	0
Quinadoline A	0
Quinadoline D	0
R(+)-2-(heptan-3-yl)quinazolin-4(3H)-one	0
R24	0
SMER 28	0
Scequinadoline A	0
Scequinadoline B	0
Scequinadoline C	0
Scequinadoline D	0
Scequinadoline E	0
Scequinadoline F	0
Scequinadoline G	0
Scequinadoline I	0
Scequinadoline J	0
Shewanelline C	0
Src Inhibitor-1	0
Src Inhibitor-5	0
Tryptoquivaline Q	0
UNC0638	0
UNC0642	4
Vasicinol	0
Vasicinolone	0
Vasicinone	0
Verrucine A	0
Verrucine B	0
Versicomide A	0
Versicomide B	0
Versicomide C	0
Versiquinazoline A	0
Versiquinazoline B	0
Versiquinazoline C	0
Versiquinazoline D	0
Versiquinazoline E	0
Versiquinazoline F	0
Versiquinazoline I	0
Versiquinazoline L	0
Versiquinazoline M	0
Versiquinazoline N	0
Versiquinazoline O	0
ZM 323881	0
ZM447439	0
[5-[4-[(5-methyl-2-furanyl)methylamino]-6-quinazolinyl]-2-furanyl]methanol	0
afatinib +	18
alfuzosin +	6
benquitrione	0
bunazosin	0
canertinib	12
chaetominine	0
chrysogine	0
ciliobrevin D	0
cyclazosin +	1
dacomitinib	2
doxazosin +	32
erastin	74
erlotinib +	135
etaqualone	0
fenazaquin	2
fenquizone	0
fluquinconazole	0
fruquintinib	0
gefitinib +	181
idelalisib	31
ketanserin	17
lapatinib	67
linagliptin	33
linkable gefitinib analogue	0
linkable vandetanib analogue	0
mecloqualone	0
methaqualone	0
metolazone	2
moquizone	0
poziotinib	0
prazosin +	59
proquinazid	0
pyraquinate	0
pyrifluquinazon	0
pyrrolidinoquinazoline +	0
quinaminoprole	0
quinazoline +	0
quinazoline alkaloid +	43
quinethazone	0
sapitinib	0
saracatinib	11
sotrastaurin	4
tandutinib	0
terazosin +	8
tesevatinib	0
trimetrexate	4
tyrphostin AG 1478	125
vandetanib +	36
Path 2
Term	Annotations
CHEBI ontology	20841
subatomic particle	20839
composite particle	20839
hadron	20839
baryon	20839
nucleon	20839
atomic nucleus	20839
atom	20839
main group element atom	20762
p-block element atom	20786
p-block molecular entity	20762
carbon group molecular entity	20718
organic molecular entity	20690
organic molecule	20634
organic cyclic compound	20385
organic heterocyclic compound	19373
organic heteropolycyclic compound	18633
organic heterobicyclic compound	17513
quinazolines	571
(+)-penicamide A	0
(+)-penicilliumine	0
(-)-penicamide A	0
(14R)-oxoglyantrypine	0
(14S)-oxoglyantrypine	0
(2S)-2-[(\{4-[(1S)-2-(2-amino-4-hydroxyquinazolin-6-yl)-1-(\{[2-(\{5-O-phosphonoribofuranosyl\}amino)-2-oxoethyl]amino\}methyl)-1-hydroxyethyl]phenyl\}carbonyl)amino]pentanedioic acid	0
(4-\{3-[(6,7-diethoxyquinazolin-4-yl)amino]phenyl\}-1,3-thiazol-2-yl)methanol	0
(4-\{[(3,5-dimethylisoxazol-4-yl)methyl]amino\}quinazolin-2-yl)methanol	0
(5-amino-3-triazolo[1,5-a]quinazolinyl)-(4-morpholinyl)methanone	0
(5aR,9aR)-6-propyl-5a,7,8,9,9a,10-hexahydro-5H-pyrido[2,3-g]quinazolin-2-amine	0
(RR)-2-(1-hydroxyethyl)-2-methyl-2,3-dihydro-1H-quinazolin-4-one	0
(SR)-2-(1-Hydroxyethyl)-2-methyl-2,3-dihydro-1H-quinazolin-4-one	0
(S,S)-Anacine	0
1,2,3,9-Tetrahydropyrrolo[2,1-b]quinazolin-3-ol	0
1,3-dimethyl-6-(4-morpholinylsulfonyl)quinazoline-2,4-dione	0
1,5-Dihydro-7-(1-piperidinyl)-imidazo(2,1-b)quinazolin-2(3H)-one	0
1,5-dioxo-2,4-dihydropyrrolo[1,2-a]quinazoline-3-carboxylic acid ethyl ester	0
1,9,17-triazapentacyclo[14.8.0.02,7.010,15.018,23]tetracosa-2,4,6,10,12,14,16,18,20,22-decaene-8,24-dione	0
1-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)-3-(3-pyridinylmethyl)thiourea	0
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[2-(phenylmethyl)-4-quinazolinyl]thio]ethanone	0
1-(3,4-dihydro-1H-isoquinolin-2-yl)-2-[(2-propyl-4-quinazolinyl)thio]ethanone	0
1-(3,5-dimethyl-1-piperidinyl)-2-[[2-(thiophen-2-ylmethyl)-4-quinazolinyl]thio]ethanone	0
1-[(4-methylphenyl)methyl]-2,4-dioxo-N-(phenylmethyl)-3-prop-2-enyl-7-quinazolinecarboxamide	0
1-[(7-chloro-4-oxo-1H-quinazolin-2-yl)methyl]-4-piperidinecarboxamide	0
1-[amino-[(4,6-dimethyl-2-quinazolinyl)amino]methylidene]-3-(2-ethylphenyl)thiourea	0
1-[amino-[(4,6-dimethyl-2-quinazolinyl)amino]methylidene]-3-cyclohexylurea	0
1-[amino-[(4,7-dimethyl-2-quinazolinyl)amino]methylidene]-3-(3-methylphenyl)thiourea	0
1-[amino-[(4-methyl-2-quinazolinyl)amino]methylidene]-3-cyclohexylurea	0
1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea	0
1-butyl-1-methyl-3-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)thiourea	0
1-cyclohexyl-3-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)thiourea	0
1-cyclopentyl-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-3-(phenylmethyl)urea	0
1-fluoro-6,7,8,9,10,12-hexahydroazepino[2,1-b]quinazolin-12-ol	0
1-fluoro-7,8,9,11-tetrahydro-6H-pyrido[2,1-b]quinazolin-11-ol	0
12-oxo-N-(4-phenyl-2-thiazolyl)-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazoline-3-carboxamide	0
1H-Quinazoline-2,4-dione	0
1H-quinazolin-4-one	0
2',17-Dimethylspiro[13-oxa-2,10,17-triazatetracyclo[10.3.2.02,11.04,9]heptadeca-4,6,8,10-tetraene-14,4'-3,3a-dihydro-2H-imidazo[1,2-a]indole]-1',3,16-trione	0
2'-epi-fumiquinazoline C	0
2'-epi-fumiquinazoline D	0
2,4-Diamino-6,7-dimethoxyquinazoline	0
2,4-bis(1-pyrrolidinyl)quinazoline	0
2,4-dioxo-3-(2-oxolanylmethyl)-N-pentyl-1H-quinazoline-7-carboxamide	0
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide	0
2,6-dibromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol	0
2-(1,3-benzodioxol-5-yl)-3-hydroxy-1,2-dihydroquinazolin-4-one	0
2-(1,3-benzothiazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-(1,3-benzoxazol-2-ylamino)-7,7-dimethyl-4-(2-pyridinyl)-1,4,6,8-tetrahydroquinazolin-5-one	0
2-(1,3-benzoxazol-2-ylamino)-7-phenyl-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-(1-iminoethyl)-4-[[3-(4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-3-oxobutanenitrile	0
2-(1-pyrrolidinyl)-1H-quinazolin-4-one	0
2-(1H-indol-3-yl)quinazolin-4-(3H)-one	0
2-(2,3-dihydro-1H-inden-5-ylamino)-8-fluoro-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one	0
2-(2,4-dichlorophenyl)-3-(phenylmethyl)-1,2-dihydroquinazolin-4-one	0
2-(2-amino-1-benzimidazolyl)-N-(phenylmethyl)-4-quinazolinamine	0
2-(2-amino-5,6-dichloro-1-benzimidazolyl)-8-methoxy-N-(phenylmethyl)-4-quinazolinamine	0
2-(2-bromophenyl)-3-[3-(4-morpholinyl)propyl]-1,2-dihydroquinazolin-4-one	0
2-(2-bromophenyl)-5-[(7-nitro-4-quinazolinyl)oxymethyl]-1,3,4-oxadiazole	0
2-(2-carboxyethyl)-6-hydroxyquinazolin-4(3H)-one	0
2-(2-carboxyethyl)-8-hydroxyquinazolin-4(3H)-one	0
2-(2-furanyl)-3-(2-furanylmethylideneamino)-7-nitro-1,2-dihydroquinazolin-4-one	0
2-(2-furanyl)-3-(6-methyl-2-pyridinyl)-4-quinazolinone	0
2-(2-hydroxyphenyl)-3,4-dihydroquinazolin-4-one	0
2-(2-hydroxyphenyl)-3-[1-(4-methoxyphenyl)ethylideneamino]-1,2-dihydroquinazolin-4-one	0
2-(2-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one	0
2-(3,4-dichloroanilino)-6-nitro-4-oxo-N-prop-2-enyl-1H-quinazoline-8-carboxamide	0
2-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-1H-quinazolin-4-one	0
2-(3-methoxyphenyl)-4-propan-2-yloxyquinazoline	0
2-(3-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one	0
2-(3-nitrophenyl)-N-(phenylmethyl)-4-quinazolinamine	0
2-(4,6,7-Trimethyl-2-quinazolinyl)guanidine	0
2-(4-chlorophenyl)-4-propan-2-yloxyquinazoline	0
2-(4-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]-4-quinazolinamine	0
2-(4-hydroxy-3-methoxyphenyl)-3-(2-methoxyphenyl)-1,2-dihydroquinazolin-4-one	0
2-(4-hydroxybenzyl)-4-(3-acetyl)quinazolinone	0
2-(4-hydroxybenzyl)quinazolin-4(3H)-one	0
2-(4-methoxyphenyl)-1H-quinazolin-4-one	0
2-(4-methoxyphenyl)-2-(4-quinazolinylhydrazinylidene)acetic acid	0
2-(4-methoxyphenyl)-3-(3-pyridinyl)-4-quinazolinone	0
2-(4-methylphenyl)sulfonyl-1-(4,6,7-trimethyl-2-quinazolinyl)guanidine	0
2-(4-morpholinyl)-10-pyridazino[6,1-b]quinazolinone	0
2-(4-nitrophenyl)-N-(2-oxolanylmethyl)-4-quinazolinamine	0
2-(4-oxo-3-quinazolinyl)-N-[3-(1-piperidinylsulfonyl)phenyl]acetamide	0
2-(5'-chloro-2'-phosphoryloxyphenyl)-6-chloro-4-(3H)-quinazolinone	0
2-(6,7-dimethoxy-4-quinazolinyl)-5-(2-pyridinyl)-1,2,4-triazol-3-amine	0
2-(6-amino-2-methyl-4-oxo-3-quinazolinyl)-N-(2-methylphenyl)acetamide	0
2-(6-benzimidazolo[1,2-c]quinazolinylthio)-N-(2-furanylmethyl)acetamide	0
2-(6-methylpyridin-2-yl)-N-(pyridin-4-yl)quinazolin-4-amine	0
2-(diethylaminomethyl)-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]one	0
2-(ethylthio)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one	0
2-(methylthio)-6-phenyl-6,7-dihydro-5H-[1,2,4]triazolo[5,1-b]quinazolin-8-one	0
2-(phenylmethylthio)-9-thiophen-2-yl-6,7,8a,9-tetrahydro-5H-[1,2,4]triazolo[5,1-b]quinazolin-8-one	0
2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline	0
2-Amino-5,6-dichloro-3,4,-dihydroquinazoline	0
2-[(1-amino-1-oxopropan-2-yl)thio]-3-butyl-4-oxo-7-quinazolinecarboxylic acid methyl ester	0
2-[(1-methyl-2-benzimidazolyl)amino]-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-[(2,4-dichlorophenyl)methylthio]-6,7-dimethoxy-3-(thiophen-2-ylmethyl)-4-quinazolinimine	0
2-[(2-cyclohexyl-4-quinazolinyl)thio]-N-(4-methyl-1,2,5-oxadiazol-3-yl)acetamide	0
2-[(2-methyl-2,3-dihydroindol-1-yl)methyl]-4-oxo-1H-quinazoline-7-carboxylic acid methyl ester	0
2-[(2-oxo-1-propan-2-yl-3-indolylidene)methyl]-1H-quinazolin-4-one	0
2-[(2-oxo-1-propan-2-yl-3-indolylidene)methyl]-3-phenyl-4-quinazolinone	0
2-[(2-propyl-4-quinazolinyl)thio]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	0
2-[(2-pyridinylthio)methyl]-1H-quinazolin-4-one	0
2-[(2-tert-butyl-4-quinazolinyl)thio]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	0
2-[(3-butan-2-yl-4-oxo-2-quinazolinyl)thio]propanenitrile	0
2-[(3-butyl-4-oxo-2-quinazolinyl)thio]-N-cyclopropylacetamide	0
2-[(3-ethyl-4-oxo-2-quinazolinyl)thio]acetic acid cyclohexyl ester	0
2-[(3-methyl-4-oxo-2-quinazolinyl)thio]-N-phenylacetamide	0
2-[(3-oxo-2-propan-2-yl-2H-imidazo[1,2-c]quinazolin-5-yl)thio]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide	0
2-[(4-chlorophenyl)methyl]-4-(prop-2-enylthio)quinazoline	0
2-[(5-bromo-1,3-benzoxazol-2-yl)amino]-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-[(5-methyl-1,3-benzoxazol-2-yl)amino]-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-[(5-phenyl-1,3-benzoxazol-2-yl)amino]-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-1H-quinazolin-4-one	0
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-6-(methoxymethyl)-1H-pyrimidin-4-one	0
2-[(6-methoxy-4-methyl-2-quinazolinyl)amino]-6-methyl-5-(3-methylbutyl)-1H-pyrimidin-4-one	0
2-[(6-methyl-1,3-benzoxazol-2-yl)amino]-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	0
2-[(7-chloro-4-quinazolinyl)oxy]-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone	0
2-[(7-methoxy-4-methyl-2-quinazolinyl)amino]-5,6-dimethyl-1H-pyrimidin-4-one	0
2-[(dimethylamino)methyl]-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]one	0
2-[1-(4-bromophenoxy)butyl]-8,9-dimethoxy-3H-[1,2,4]triazolo[1,5-c]quinazoline-5-thione	0
2-[1-chloro-2-(3-fluorophenyl)ethenyl]-7-(trifluoromethyl)-1H-quinazolin-4-one	0
2-[2,4-dioxo-3-(phenylmethyl)-1-quinazolinyl]-N-(5-methyl-3-isoxazolyl)acetamide	0
2-[2-(1,3-benzodioxol-5-yl)ethenyl]-3-(3-hydroxyphenyl)-4-quinazolinone	0
2-[2-(3-hydroxy-4-oxo-1-cyclohexa-2,5-dienylidene)ethylidene]-3-phenyl-1H-quinazolin-4-one	0
2-[2-(5-bromo-1H-indol-3-yl)ethyl]-3-(3-propan-2-yloxyphenyl)-4-quinazolinone	0
2-[2-[(2,5-dimethylphenyl)methylidene]hydrazinyl]-3-hydroxy-4-quinazolinone	0
2-[3-(1-benzotriazolylmethyl)-4-methoxyphenyl]-3-(4-methoxyphenyl)-1,2-dihydroquinazolin-4-one	0
2-[3-[(2,6-dimethylphenoxy)methyl]-4-methoxyphenyl]-3-(3-pyridinylmethyl)-1,2-dihydroquinazolin-4-one	0
2-[3-[(2,6-dimethylphenoxy)methyl]-4-methoxyphenyl]-3-(thiophen-2-ylmethyl)-1,2-dihydroquinazolin-4-one	0
2-[3-[(2,6-dimethylphenoxy)methyl]-4-methoxyphenyl]-3-[(5-methyl-2-furanyl)methyl]-1,2-dihydroquinazolin-4-one	0
2-[3-[(2,6-dimethylphenoxy)methyl]phenyl]-3-(2-furanylmethyl)-1,2-dihydroquinazolin-4-one	0
2-[3-[3-(4-morpholinyl)propyl]-4-oxo-1,2-dihydroquinazolin-2-yl]benzoic acid	0
2-[4'-(Methylamino)phenyl]quinazolin-4(3H)-one	0
2-[4-[1-[(2-fluorophenyl)methyl]-2,4-dioxo-3-quinazolinyl]phenyl]-N-(2-oxolanylmethyl)acetamide	0
2-[4-methoxy-3-(4-morpholinylmethyl)phenyl]-3-(phenylmethyl)-1,2-dihydroquinazolin-4-one	0
2-[5-(2-fluorophenyl)-2-furanyl]-3-hydroxy-1,2-dihydroquinazolin-4-one	0
2-[5-(3-chlorophenyl)-2-furanyl]-1H-quinazolin-4-one	0
2-[5-(3-fluorophenyl)-2-furanyl]-3-hydroxy-1,2-dihydroquinazolin-4-one	0
2-[5-[[2-(3-methoxypropylamino)-2-oxoethyl]thio]-3-oxo-2H-imidazo[1,2-c]quinazolin-2-yl]-N-(phenylmethyl)acetamide	0
2-[6,7-dimethoxy-3-(3-methoxyphenyl)-2,4-dioxo-1-quinazolinyl]-N-(5-methyl-1H-pyrazol-3-yl)acetamide	0
2-[[(6-ethyl-4-oxo-3-prop-2-enyl-2-thieno[2,3-d]pyrimidinyl)thio]methyl]-4-oxo-1H-quinazoline-7-carboxylic acid methyl ester	0
2-[[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone	0
2-[[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]thio]-3-ethyl-4-quinazolinone	0
2-[[2-(5-methyl-2-thiophenyl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone	0
2-[[2-(phenoxymethyl)-4-quinazolinyl]thio]acetic acid methyl ester	0
2-[[2-[(2-methoxy-2-oxoethyl)thio]-4-oxo-3-quinazolinyl]oxy]acetic acid methyl ester	0
2-[[2-[2-(1-piperidinyl)ethyl]-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]thio]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide	0
2-[[3-(2,4-difluorophenyl)-4-oxo-2-quinazolinyl]thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide	0
2-[[3-(3,4-dichlorophenyl)-4-oxo-2-quinazolinyl]thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide	0
2-[[3-(3-chloro-4-fluorophenyl)-4-oxo-2-quinazolinyl]thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide	0
2-[[3-[(4-fluorophenyl)methyl]-4-oxo-2-quinazolinyl]thio]-N-(thiophen-2-ylmethyl)acetamide	0
2-[[3-butyl-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]-N-(3-methoxyphenyl)acetamide	0
2-[[3-butyl-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]acetamide	0
2-[[6-(4-morpholinyl)-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]thio]-N-(2-oxolanylmethyl)acetamide	0
2-[[6-(4-morpholinyl)-4-oxo-3-(phenylmethyl)-2-quinazolinyl]thio]acetic acid ethyl ester	0
2-[[[5,7-bis(ethylamino)-[1,2,4]triazolo[4,3-a][1,3,5]triazin-3-yl]thio]methyl]-1H-quinazolin-4-one	0
2-acetylquinazolin-4 (3H)-one	0
2-bromo-6,7,8,9,10,12-hexahydroazepino[2,1-b]quinazolin-12-ol	0
2-butoxy-3-phenyl-4-quinazolinone	0
2-chloro-4-[(6-\{3-[(3-hydroxypropyl)amino]propoxy\}-7-methoxyquinazolin-4-yl)amino]phenol	0
2-chloro-4-[(6-\{3-[(hydroxymethyl)(3-hydroxypropyl)amino]propoxy\}-7-methoxyquinazolin-4-yl)amino]phenol	0
2-chloro-4-[(7-methoxy-6-\{3-[methyl(propyl)amino]propoxy\}quinazolin-4-yl)amino]phenol	0
2-chloro-N,N-dipropylquinazolin-4-amine	0
2-chloro-N-(phenylmethyl)-4-quinazolinamine	0
2-chloro-N-[(1R)-1-phenylethyl]-4-quinazolinamine	0
2-imino-1,2,3,4-tetrahydroquinazolin-4-one	0
2-methoxy-6-[4-(4-methyl-1-piperazinyl)-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
2-methoxy-6-[4-[2-(4-morpholinyl)ethylamino]-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
2-methoxy-N-(3-methyl-2-oxo-1,4-dihydroquinazolin-6-yl)benzenesulfonamide	0
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide +	0
2-methyl-3-[(5-methyl-3-nitro-6-oxo-1-cyclohexa-2,4-dienylidene)methylamino]-4-quinazolinone	0
2-methyl-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]thione	0
2-methyl-5-(3-thiophenyl)-3,5-dihydropyrazolo[1,5-c]quinazoline	0
2-methyl-5-phenyl-3,5-dihydropyrazolo[1,5-c]quinazoline	0
2-oxo-1,4-dihydroquinazoline-3-carboxylic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester	0
2-phenyl-1H-quinazoline-4-thione	0
2-pyridin-4-yl-2,3-dihydro-1H-quinazolin-4-one	0
2-thiophen-2-yl-2,3-dihydro-1H-quinazolin-4-one	0
2-thiophen-2-yl-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
3,3-dimethyl-1-[[9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl]thio]-2-butanone	0
3,4-dihydro-2H,6H-[1,3]thiazino[2,3-b]quinazolin-6-one	0
3,5,5-trimethyl-2-sulfanylidene-1,6-dihydrobenzo[h]quinazolin-4-one	0
3,5-diethyl-2-(2-hydroxyethylamino)-5-methyl-6H-benzo[h]quinazolin-4-one	0
3,5-diethyl-2-(3-hydroxypropylamino)-5-methyl-6H-benzo[h]quinazolin-4-one	0
3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-sulfanylidene-1H-quinazolin-4-one	0
3-(2-fluorophenyl)-4-oxo-2-sulfanylidene-1H-quinazoline-7-carboxylic acid methyl ester	0
3-(2-furanylmethyl)-2-[4-methoxy-3-[(2-methylphenoxy)methyl]phenyl]-1,2-dihydroquinazolin-4-one	0
3-(2-furanylmethyl)-2-phenyl-1,2-dihydroquinazolin-4-one	0
3-(2-furanylmethyl)-4-oxo-N,N-dipropyl-2-sulfanylidene-1H-quinazoline-7-carboxamide	0
3-(2-hydroxyphenyl)-2-[2-(4-oxo-1-cyclohexa-2,5-dienylidene)ethylidene]-1H-quinazolin-4-one	0
3-(2-methoxyethyl)-2,4-dioxo-N-pentyl-1H-quinazoline-7-carboxamide	0
3-(2-methoxyphenyl)-2-methyl-4-oxo-1H-quinazoline-2-carboxylic acid methyl ester	0
3-(3,4-Dihydroxy-2,2-dimethyl-1-oxo-3aH-imidazo[1,2-a]indol-4-yl)-2-(4-oxoquinazolin-3-yl)propanoic acid	0
3-(3-ethoxypropyl)-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-1-(phenylmethyl)thiourea	0
3-(3-morpholinopropyl)-2-(2-pyridinyl)-2,3-dihydro-4(1H)-quinazolinone	0
3-(4-Hydroxy-2,2-dimethyl-1-oxo-3,3a-dihydroimidazo[1,2-a]indol-4-yl)-2-(4-oxoquinazolin-3-yl)propanoic acid	0
3-(4-chlorophenyl)-2-(1-pyrrolidinyl)-4-quinazolinone	0
3-(4-methylphenyl)-5-oxo-8-thiazolo[2,3-b]quinazolinecarboxamide	0
3-(4-methylphenyl)-5-oxo-N-propyl-8-thiazolo[2,3-b]quinazolinecarboxamide	0
3-(4-nitrophenyl)[1,2,3]triazolo[1,5-a]quinazolin-5-amine	0
3-(4-oxo-1H-quinazolin-2-yl)propanoic acid (3,5-dimethyl-4-isoxazolyl)methyl ester	0
3-(4-oxo-3-quinazolinyl)-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)propanamide	0
3-(4-propan-2-ylphenyl)sulfonyl-1H-triazolo[1,5-a]quinazolin-5-one	0
3-(benzenesulfonyl)-N-(3-methylphenyl)-5-triazolo[1,5-a]quinazolinamine	0
3-(phenylmethyl)-2-[2-(3-pyridinyl)ethenyl]-4-quinazolinone	0
3-[(2-hydroxy-4-oxo-1-cyclohexa-2,5-dienylidene)methylamino]-2-methyl-4-quinazolinone	0
3-[(2-hydroxy-4-oxo-1-cyclohexa-2,5-dienylidene)methylamino]-2-propyl-4-quinazolinone	0
3-[(3-hydroxy-4-oxo-1-cyclohexa-2,5-dienylidene)methylamino]-2-(phenoxymethyl)-4-quinazolinone	0
3-[(4-methoxyphenyl)methyl]-N-(3-methoxypropyl)-2,4-dioxo-1H-quinazoline-7-carboxamide	0
3-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-diethoxy-2-sulfanylidene-1H-quinazolin-4-one	0
3-[2-[butyl(methyl)amino]ethyl]-6-(4-morpholinyl)-2-sulfanylidene-1H-quinazolin-4-one	0
3-[3-(N-ethylanilino)propyl]-6-(4-morpholinyl)-2-sulfanylidene-1H-quinazolin-4-one	0
3-[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-4-oxobutyl]-6,7-diethoxy-2-sulfanylidene-1H-quinazolin-4-one	0
3-[6-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-6-oxohexyl]-2-sulfanylidene-1H-quinazolin-4-one	0
3-[[1-(3-chlorophenyl)-3-methyl-5-oxo-4-pyrazolylidene]methylamino]-2-methyl-4-quinazolinone	0
3-[[4-(2-benzofuranyl)-2-thiazolyl]methyl]-2-[(dimethylamino)methyl]-4-quinazolinone	0
3-[[[[3-[(4-chlorophenyl)methyl]-2-methyl-4-oxo-6-quinazolinyl]amino]-oxomethyl]amino]propanoic acid ethyl ester	0
3-\{[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl](hydroxymethyl)amino\}propan-1-ol	0
3-\{[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]amino\}propan-1-ol	0
3-ethyl-2-(2-phenylethenyl)-4-quinazolinone	0
3-ethyl-2-[(4-oxo-1H-quinazolin-2-yl)methylthio]-4-quinazolinone	0
3-ethyl-2-[2-(2-methyl-1H-indol-3-yl)ethenyl]-4-quinazolinone	0
3-hydroxy-1,9,17-triazapentacyclo[14.8.0.02,7.010,15.018,23]tetracosa-2(7),3,5,10,12,14,16,18,20,22-decaene-8,24-dione	0
3-hydroxy-2-(2-hydroxy-3-methoxyphenyl)-1,2-dihydroquinazolin-4-one	0
3-hydroxy-2-(5-thiophen-2-yl-2-furanyl)-1,2-dihydroquinazolin-4-one	0
3-hydroxy-2-[5-[4-(trifluoromethyl)phenyl]-2-furanyl]-1,2-dihydroquinazolin-4-one	0
3-hydroxyglyantrypine	0
3-methoxy-2-(3-pyridinylmethylthio)-4-quinazolinone	0
3-methoxyglyantrypine	0
3-methyl-2-[2-(4-methyl-5-thiazolyl)ethylthio]-4-quinazolinone	0
3-phenyl-3-(4-quinazolinylhydrazinylidene)propanoic acid ethyl ester	0
4,5-dimethyl-2-[[1-oxo-2-(4-quinazolinyloxy)ethyl]amino]-3-thiophenecarboxylic acid ethyl ester	0
4-(2-methylpiperidin-1-yl)quinazoline	0
4-(3,4-dimethoxyphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazoline-2-thione	0
4-(3-methoxyphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazoline-2-thione	0
4-(4-anilinoanilino)-2-quinazolinecarboxylic acid ethyl ester	0
4-(4-ethoxycarbonylanilino)-2-quinazolinecarboxylic acid ethyl ester	0
4-(4-propan-2-ylphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazolin-2-one	0
4-(6-quinolinyl)-1,3,4,6,7,8-hexahydroquinazoline-2,5-dione	0
4-Methylquinazoline	0
4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxo-N-propan-2-ylbutanamide	0
4-[(3-chloro-4-fluorophenyl)amino]-6-\{3-[(3-hydroxypropyl)amino]propoxy\}quinazolin-7-ol	0
4-[(6,7-diethoxy-2,4-dioxo-1H-quinazolin-3-yl)methyl]-N-(3-methoxypropyl)-1-cyclohexanecarboxamide	0
4-[1,3-dioxo-3-[(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)amino]propyl]-1-piperazinecarboxylic acid ethyl ester	0
4-[2-[(6-chloro-4-quinazolinyl)amino]ethyl]phenol	0
4-[2-[[2-[(5-methyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]thio]-4-oxo-3-quinazolinyl]-N-(phenylmethyl)butanamide	0
4-[2-[[3-(4-methylphenyl)-5-triazolo[1,5-a]quinazolinyl]amino]ethyl]benzenesulfonamide	0
4-[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]-4-hydroxymorpholin-4-ium	0
4-[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]morpholin-3-ol	0
4-[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]morpholin-3-one	0
4-[4-(4-methylphenyl)sulfonyl-1-piperidinyl]-2-thiophen-2-ylquinazoline	0
4-[4-oxo-2-[[2-oxo-2-[(phenylmethyl)amino]ethyl]thio]-3-quinazolinyl]-1-piperidinecarboxylic acid ethyl ester	0
4-[5-(3-hydroxy-4-oxo-1,2-dihydroquinazolin-2-yl)-2-furanyl]benzonitrile	0
4-[[3-(3-chloro-4-methylphenyl)-4-oxo-2-quinazolinyl]thio]-2-(1-iminoethyl)-3-oxobutanenitrile	0
4-[[3-[2-(1-cyclohexenyl)ethyl]-4-oxo-2-sulfanylidene-1H-quinazolin-7-yl]-oxomethyl]-1-piperazinecarboxylic acid ethyl ester	0
4-[[4-(1-pyrrolidinyl)-2-quinazolinyl]amino]phenol	0
4-[[4-hydroxy-2-(2-methylpropyl)-1-oxo-3,3a-dihydro-2h-imidazo[1,2-a]indol-4-yl]methyl]-1-methyl-2,4-dihydro-1h-pyrazino[2,1-b]quinazoline-3,6-dione	0
4-[[6,7-bis(hydroxymethyl)-4-quinazolinyl]amino]-2-bromophenol	0
4-[[6,7-bis(hydroxymethyl)-4-quinazolinyl]amino]phenol	0
4-[[[2-(2-fluorophenyl)-4-quinazolinyl]hydrazo]methylidene]-3-hydroxy-1-cyclohexa-2,5-dienone	0
4-chloro-2-[[4-(2-oxolanylmethylamino)-2-quinazolinyl]amino]phenol	0
4-chloro-N-(8-methyl-[1,3]dioxolo[4,5-g]quinazolin-6-yl)benzamide	0
4-defluoro-4-hydroxy Gefitinib	0
4-ethoxy-6,7-dimethoxyquinazoline	0
4-methoxy-2-(4-methoxyphenyl)quinazoline	0
4-methoxy-2-(4-propoxyphenyl)quinazoline	0
4-methoxy-N-(8-methyl-[1,3]dioxolo[4,5-g]quinazolin-6-yl)benzamide	0
4-methoxy-N-[2-[(4-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide	0
4-methyl-2-quinazolinamine	0
4-methyl-N'-(4-quinazolinyl)benzohydrazide	0
4-oxo-2-(trifluoromethyl)-1H-quinazoline-6-carboxylic acid ethyl ester	0
4-oxo-N-(7-quinolinylmethylideneamino)-1H-quinazoline-2-carboxamide	0
5,5-diethyl-2-(2-hydroxyethylamino)-1,6-dihydrobenzo[h]quinazolin-4-one	0
5,5-diethyl-2-hydrazinyl-1,6-dihydrobenzo[h]quinazolin-4-one	0
5,7-dichloro-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-9-ol	0
5-(1-piperidinyl)-3-pyrazolo[1,5-a]quinazolinecarbonitrile	0
5-(6,7-diethoxy-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl)-N-(2-furanylmethyl)pentanamide	0
5-[(4-morpholin-4-ylphenyl)thio]quinazoline-2,4-diamine	0
5-[4-[(2-methyl-4-thiazolyl)methylamino]-6-quinazolinyl]-2-furancarboxylic acid ethyl ester	0
5-[4-[methyl-[(3-methyl-2-thiophenyl)methyl]amino]-6-quinazolinyl]-2-furancarboxylic acid ethyl ester	0
5-hydroxydeoxyvasicinone	0
5-methyl-1H-quinazoline-2,4-dione	0
5-methyl-6-pyridin-4-yl-6H-benzimidazolo[1,2-c]quinazoline	0
5a,6,7,8,9,10-hexahydro-5H-azepino[2,1-b]quinazolin-12-one	0
6,6-dimethyl-9-thiophen-2-yl-5,7,8a,9-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-8-one	0
6,7,8-trimethoxy-3-phenyl-2-thioxo-1,2,3,4-tetrahydroquinazolin-4-one	0
6,7-Dichloro-3-hydroxy-1,5 dihydro-imidazo[2,1-b]quinazolin-2-one	0
6,7-bis(2-methoxyethoxy)quinazolin-4(3H)-one	0
6,7-diethoxy-3-(3-methoxypropyl)-2-sulfanylidene-1H-quinazolin-4-one	0
6,7-diethoxy-3-[3-(2-oxo-1-pyrrolidinyl)propyl]-2-sulfanylidene-1H-quinazolin-4-one	0
6,7-dimethoxy-2-[(1H-1,2,4-triazol-5-ylthio)methyl]-1H-quinazolin-4-one	0
6,7-dimethoxy-2-[[methyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-1H-quinazolin-4-one	0
6,7-dimethoxy-3-(2-oxolanylmethyl)-2-sulfanylidene-1H-quinazolin-4-one	0
6,7-dimethoxy-3-phenyl-1H-quinazoline-2,4-dione	0
6,7-dimethoxy-4-(2-oxolanylmethylamino)-1H-quinazoline-2-thione	0
6,7-dimethoxy-4-\{8-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydroisoquinolin-2-(1H)-yl\}quinazoline	0
6,7-dimethoxy-N,N-dipropyl-2-(1-pyrrolidinyl)-4-quinazolinamine	0
6,7-dimethoxy-N-[(4-methylphenyl)methyl]-4-quinazolinamine	0
6,8-dibromo-2-[[[4-(difluoromethoxy)phenyl]methyl-methylamino]methyl]-1H-quinazolin-4-one	0
6-(1,3-benzodioxol-5-yl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(2-oxanylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(2-oxolanylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(2-thiazolylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(3-oxanylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(3-oxolanylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(cyclopentylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(cyclopropylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[(2-methyl-3-furanyl)methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[(2-methyl-4-thiazolyl)methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[(3-fluorophenyl)methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[2-(2-furanyl)ethyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-[[(2S)-2-oxolanyl]methyl]-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-ethyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(1,3-benzodioxol-5-yl)-N-methyl-N-[(2-methyl-4-thiazolyl)methyl]-4-quinazolinamine	0
6-(1-methyl-5-indolyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	0
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(2-chlorophenyl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine	0
6-(2-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(2-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(2-chlorophenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	0
6-(2-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(2-methyl-3-furanyl)-N-[(5-methyl-2-furanyl)methyl]-4-quinazolinamine	0
6-(3,5-dimethyl-4-isoxazolyl)-1H-quinazolin-4-one	0
6-(3,5-dimethyl-4-isoxazolyl)-N-[(1-methyl-2-piperidinyl)methyl]-4-quinazolinamine	0
6-(3,5-dimethyl-4-isoxazolyl)-N-[(2-ethoxyphenyl)methyl]-4-quinazolinamine	0
6-(3,5-dimethyl-4-isoxazolyl)-N-[(3-methoxyphenyl)methyl]-4-quinazolinamine	0
6-(3,5-dimethyl-4-isoxazolyl)-N-[(3-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(3,5-dimethyl-4-isoxazolyl)-N-[1-(2-furanyl)ethyl]-4-quinazolinamine	0
6-(3-aminopropoxy)-4-[(3-chloro-4-fluorophenyl)amino]quinazolin-7-ol	0
6-(3-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(3-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(3-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(3-furanyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(3-furanyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(3-furanyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	0
6-(3-furanyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(3-furanyl)-N-methyl-N-[(3-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(3-methoxyphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(3-methoxyphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(3-methoxyphenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	0
6-(3-methoxyphenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	0
6-(3-methylphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(3-methylphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(3-pyridinyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	0
6-(3-pyridinyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(4-ethoxy-1H-quinazolin-2-ylidene)-1-cyclohexa-2,4-dienone	0
6-(4-fluoro-1,3-benzodioxol-5-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	0
6-(4-morpholinyl)-3-(2-phenylethyl)-2-sulfanylidene-1H-quinazolin-4-one	0
6-(6-bromo-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl)-N-[2-(4-sulfamoylphenyl)ethyl]hexanamide	0
6-[4-(1-phenylethylamino)-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
6-[4-(2-methoxyanilino)-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
6-[4-[2-(4-morpholinyl)ethylamino]-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
6-[4-[4-(phenylmethyl)-1-piperazinyl]-1H-quinazolin-2-ylidene]-1-cyclohexa-2,4-dienone	0
6-amino-3-[(2-chlorophenyl)methyl]-2-propyl-4-quinazolinone	0
6-bromo-3-[4-nitro-3-(trifluoromethyl)phenyl]-2-propyl-4-quinazolinone	0
6-bromo-3-phenyl-2-sulfanylidene-1H-quinazolin-4-one	0
6-chloro-3-[2-(diethylamino)ethyl]-2-sulfanylidene-1H-quinazolin-4-one	0
6-methoxy-4-methyl-2-[(2-methylphenyl)methylthio]quinazoline	0
6-methoxy-N-(4-methoxyphenyl)-4-quinazolinamine	0
7-(4-quinazolinyloxymethyl)-5-thiazolo[3,2-a]pyrimidinone	0
7-Bromo-6-chloro-3-[3-(3-hydroxypiperidin-2-yl)-2-oxopropyl]-3,4-dihydroquinazolin-4-one	0
7-[(6,8-dichloro-4-quinazolinyl)oxymethyl]-5-thiazolo[3,2-a]pyrimidinone	0
7-[2-[2-(dimethylamino)ethoxy]ethoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1-methyl-4-piperidinyl)-4-quinazolinamine	0
7-[[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-5-thiazolo[3,2-a]pyrimidinone	0
7-[oxo-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)methyl]-3-prop-2-enyl-1H-quinazoline-2,4-dione	0
7-bromo-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline	0
7-chloro-2-methyl-3-(4-pyridylmethyl)-3,4-dihydroquinazolin-4-one	0
7-chloro-3-[2-(1-cyclohexenyl)ethyl]-2-sulfanylidene-1H-quinazolin-4-one	0
7-chloro-3-hydroxy-2-[3-(trifluoromethyl)phenyl]-4-quinazolinone	0
7-chloro-N-(2-furanylmethyl)-4-quinazolinamine	0
8-methylene-7-(phenylmethyl)-5H-[1,3]dioxolo[4,5-g]quinazoline-6-thione	0
9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine	0
9-methyl-5,6,7,8-tetrahydrotetrazolo[5,1-b]quinazoline	0
9-phenyl-1,5,6,7,8,9-hexahydro-[1,2,4]triazolo[5,1-b]quinazoline	0
ARS-1620	4
AZD-1152 +	0
AZT-1152	0
Altanserin	0
Amethysione	0
Aniflorine	0
Anisessine	0
Anisotine	0
Arborine	0
Aspamide F	0
Aspamide G	0
Aspergicin	0
Auranomide B	0
Aurantiomide A	0
Aurantiomide B	0
Aurantiomide C	0
Brevianamide M	0
Brevianamide N	0
Bunazosin hydrochloride	0
Chrysopiperazine C	0
Cladoquinazoline	0
Cottoquinazoline A	0
Cottoquinazoline B	0
Cottoquinazoline C	0
Cottoquinazoline D	0
Cottoquinazoline E	0
Cottoquinazoline F	0
Deoxypeganine	0
Deoxyvasicinone	0
Dictyoquinazol A	0
Dictyoquinazol B	0
Dictyoquinazol C	0
Dihydroquinazoline	0
EVP4593	0
Epi-cladoquinazoline	0
Epi-fiscalin A	0
Epi-fiscalin C	0
Epi-neofiscalin A	0
Farinamycin	0
Febrifugine	6
Fiscalin A	0
Fiscalin B	0
Fiscalin E	0
Fiscalin F	0
Fumigatoside F	0
Fumiquinazoline B	0
Fumiquinazoline D	0
Fumiquinazoline I	0
Fumiquinazoline K	0
Fumiquinazoline L	0
Fumiquinazoline M	0
Fumiquinazoline N	0
Fumiquinazoline O	0
Fumiquinazoline P	0
Fumiquinazoline Q	0
Fumiquinazoline S	0
Fumiquinazoline h	0
GSK3-XIII	0
Glyantrypine	0
Glycophymoline	0
Glycosminine	0
IC-87114	16
ITK7	0
Icotinib hydrochloride	0
Isofebrifugine	0
LSM-19241	0
LSM-19663	0
LSM-19894	0
LY-202769	0
Lapatinib ditosylate monohydrate	0
Luotonin A	0
ML240	0
Mdivi-1	0
N'-(4-quinazolinyl)acetohydrazide	0
N'-[2-[(2-cyclohexyl-4-quinazolinyl)thio]-1-oxoethyl]-2-methylpropanehydrazide	0
N,N-bis(2-methoxyethyl)-2-(4-methylphenyl)quinazolin-4-amine	0
N,N-dibutyl-2-(pyridin-4-yl)quinazolin-4-amine	0
N,N-diethyl-2-[[7-[(4-methoxyphenyl)methyl]-8-oxo-[1,3]dioxolo[4,5-g]quinazolin-6-yl]thio]acetamide	0
N,N-dipropyl-2-(pyrrolidin-1-yl)quinazolin-4-amine	0
N-(1,3-benzodioxol-5-ylmethyl)-3-cyclopentyl-2,4-dioxo-1H-quinazoline-7-carboxamide	0
N-(1,3-benzodioxol-5-ylmethyl)-3-methoxy-N-[(4-oxo-1H-quinazolin-2-yl)methyl]benzamide	0
N-(1,3-benzodioxol-5-ylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-(2-chlorophenyl)-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-furanyl)-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-pyridinyl)-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-[6-(4-morpholinyl)-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl]hexanamide	0
N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine	0
N-(1,3-benzodioxol-5-ylmethyl)-6-methoxy-4-quinazolinamine	0
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine	0
N-(1-cyclohexyl-4-piperidinyl)-6-methoxy-7-[3-(1-piperidinyl)propoxy]-2-(4-propan-2-yl-1,4-diazepan-1-yl)-4-quinazolinamine	0
N-(1-phenylethyl)-2-(1-pyrrolidinyl)-4-quinazolinamine	0
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(4-oxo-3-quinazolinyl)acetamide	0
N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-oxo-3-phenyl-2-quinazolinyl)thio]acetamide	0
N-(2,3-dihydro-1H-inden-5-yl)-2-[(5-fluoro-4-oxo-3-phenyl-2-quinazolinyl)thio]acetamide	0
N-(2,3-dihydro-1H-inden-5-yl)-2-[(6-fluoro-4-oxo-3-phenyl-2-quinazolinyl)thio]acetamide	0
N-(2,3-dihydro-1H-inden-5-yl)-2-[[3-(2-fluorophenyl)-4-oxo-2-quinazolinyl]thio]acetamide	0
N-(2,4-dimethoxyphenyl)-2-(1-pyrrolidinyl)-4-quinazolinamine	0
N-(2-furanylmethyl)-6-(3-methoxyphenyl)-N-methyl-4-quinazolinamine	0
N-(2-furanylmethyl)-N-methyl-6-(1-methyl-5-indolyl)-4-quinazolinamine	0
N-(2-methoxyethyl)-2-[[3-[(4-methoxyphenyl)methyl]-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]acetamide	0
N-(2-methoxyethyl)-4-\{[6-(pyridin-4-yl)quinazolin-2-yl]amino\}benzamide	0
N-(2-methoxyethyl)-4-oxo-3-[3-(2-oxo-1-pyrrolidinyl)propyl]-2-sulfanylidene-1H-quinazoline-7-carboxamide	0
N-(2-pyridinylmethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-9-amine	0
N-(3-\{[2-(2-fluorophenyl)quinazolin-4-yl]amino\}phenyl)acetamide	0
N-(3-\{[7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]amino\}-4-methylphenyl)-2-morpholin-4-ylisonicotinamide	0
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-\{3-[methyl(propyl)amino]propoxy\}quinazolin-4-amine	0
N-(3-chlorophenyl)-2-[6,7-dimethoxy-2,4-dioxo-3-(2-oxolanylmethyl)-1-quinazolinyl]acetamide	0
N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine	0
N-(3-fluorophenyl)-2-(pyridin-4-yl)quinazolin-4-amine	0
N-(3-methoxyphenyl)-2-[(4-oxo-3-propyl-2-quinazolinyl)thio]-2-phenylacetamide	0
N-(3-methoxyphenyl)quinazolin-4-amine	0
N-(4-bromo-3-chlorophenyl)-2-[(4-oxo-1H-quinazolin-2-yl)thio]acetamide	0
N-(4-chloro-2-fluorophenyl)-6,7-dimethoxy-4-quinazolinamine	0
N-(4-ethylphenyl)-2-[[3-[3-(4-methyl-1-piperidinyl)propyl]-4-oxo-2-quinazolinyl]thio]acetamide	0
N-(4-methoxyphenyl)-2-(3-nitrophenyl)-4-quinazolinamine	0
N-(4-methylphenyl)-2-(pyridin-4-yl)quinazolin-4-amine	0
N-(4-oxo-2-phenyl-1,2-dihydroquinazolin-3-yl)benzenesulfonamide	0
N-(5-methyl-1H-pyrazol-3-yl)-2-[[3-oxo-2-(phenylmethyl)-2H-imidazo[1,2-c]quinazolin-5-yl]thio]acetamide	0
N-(5-methyl-3-isoxazolyl)-2-[(2-propan-2-yl-4-quinazolinyl)thio]acetamide	0
N-(6-ethoxy-1,3-benzothiazol-2-yl)-2-[[3-(2-furanylmethyl)-4-oxo-2-quinazolinyl]thio]acetamide	0
N-(7,8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-3-pyridinecarboxamide	0
N-(cyclohexylmethyl)-5,6,7,8-tetrahydrotetrazolo[5,1-b]quinazolin-9-amine	0
N-(phenylmethyl)-2-[[4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolin-2-yl]thio]acetamide	0
N-[(3-chlorophenyl)methylideneamino]-4-quinazolinamine	0
N-[(3-methylphenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine	0
N-[(3-nitrophenyl)methylideneamino]-4-oxo-1H-quinazoline-2-carboxamide	0
N-[(4-methyl-2-thiophenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine	0
N-[(4-oxo-1H-quinazolin-2-yl)methyl]-N-(2-phenylethyl)butanamide	0
N-[(cyclohexylamino)-oxomethyl]-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide	0
N-[2-(2-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-9-amine	0
N-[2-(4-methoxyphenyl)-4-oxo-1,2-dihydroquinazolin-3-yl]carbamic acid ethyl ester	0
N-[2-[(3-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide	0
N-[2-[4-(dimethylamino)phenyl]-4-oxo-1,2-dihydroquinazolin-3-yl]carbamic acid ethyl ester	0
N-[2-methyl-4-oxo-3-(phenylmethyl)-7-(1-piperidinyl)-6-quinazolinyl]-3-pyridinecarboxamide	0
N-[3,5-dimethyl-1-[(4-methylphenyl)methyl]-4-pyrazolyl]-2-[[4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolin-2-yl]thio]acetamide	0
N-[3-(1-azepanyl)propyl]-3-[(4-methoxyphenyl)methyl]-2,4-dioxo-1H-quinazoline-7-carboxamide	0
N-[3-(1-azepanylsulfonyl)-4-methylphenyl]-2-(4-quinazolinylthio)acetamide	0
N-[3-(4-morpholinyl)propyl]-2,4-dioxo-3-(2-phenylethyl)-1H-quinazoline-7-carboxamide	0
N-[3-(\{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]-N-(3-hydroxypropyl)formamide	0
N-[3-(\{4-[(3-chloro-4-hydroxyphenyl)amino]-7-methoxyquinazolin-6-yl\}oxy)propyl]-N-(3-hydroxypropyl)formamide	0
N-[3-(diethylamino)propyl]-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide	0
N-[3-(dimethylsulfamoyl)phenyl]-2-(4-quinazolinylthio)acetamide	0
N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine	0
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-4-thiazolyl]-4-quinazolinamine	0
N-[4-(3-chloro-4-fluoroanilino)-7-(3-oxolanyloxy)-6-quinazolinyl]-4-(dimethylamino)-2-butenamide	0
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide	0
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide	0
N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide	0
N-[4-[[2-methoxy-5-(4-oxo-2,3-dihydro-1H-quinazolin-2-yl)phenyl]methoxy]phenyl]acetamide	0
N-[4-[[2-methoxy-5-[4-oxo-3-(phenylmethyl)-1,2-dihydroquinazolin-2-yl]phenyl]methoxy]phenyl]acetamide	0
N-[4-[[2-methoxy-5-[4-oxo-3-(phenylmethyl)-2-quinazolinyl]phenyl]methoxy]phenyl]acetamide	0
N-[4-[[2-methoxy-5-[4-oxo-3-(pyridin-4-ylmethyl)-1,2-dihydroquinazolin-2-yl]phenyl]methoxy]phenyl]acetamide	0
N-[4-[[5-(3-butyl-4-oxo-1,2-dihydroquinazolin-2-yl)-2-methoxyphenyl]methoxy]phenyl]acetamide	0
N-[4-[[5-[3-(2-furanylmethyl)-4-oxo-1,2-dihydroquinazolin-2-yl]-2-methoxyphenyl]methoxy]-3,5-dimethylphenyl]acetamide	0
N-[4-[[5-[5-hydroxy-4-oxo-3-(phenylmethyl)-1,2-dihydroquinazolin-2-yl]-2-methoxyphenyl]methoxy]phenyl]acetamide	0
N-[4-[[[6-(3,5-dimethyl-4-isoxazolyl)-4-quinazolinyl]amino]methyl]phenyl]acetamide	0
N-[4-oxo-2-(2-pyridinyl)-1,2-dihydroquinazolin-3-yl]acetamide	0
N-[7-(2-furanyl)-5-oxo-7,8-dihydro-6H-quinazolin-2-yl]acetamide	0
N-[9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]-2-phenylacetamide	0
N-[amino-[(4,6,7-trimethyl-2-quinazolinyl)amino]methylidene]propanamide	0
N-\{(E)-amino[(4,7-dimethylquinazolin-2-yl)amino]methylidene\}-2-(4-chlorophenyl)acetamide	0
N-\{3-[(2-phenylquinazolin-4-yl)amino]phenyl\}acetamide	0
N-\{4-[(3-bromophenyl)amino]quinazolin-6-yl\}but-2-ynamide	0
N-\{5-[(7-\{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy\}-6-methoxyquinazolin-4-yl)amino]pyrimidin-2-yl\}benzamide	0
N-benzylquinazolin-4-amine	0
N-butyl-2-[[6-(4-morpholinyl)-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]thio]acetamide	0
N-butyl-3-[1-[(2,5-dimethylphenyl)methyl]-2,4-dioxo-3-quinazolinyl]propanamide	0
N-butyl-N-methyl-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide	0
N-cycloheptyl-3-(2-methoxyethyl)-2,4-dioxo-1H-quinazoline-7-carboxamide	0
N-cyclohexyl-2-(3-oxo-5-sulfanylidene-2,6-dihydroimidazo[1,2-c]quinazolin-2-yl)acetamide	0
N-cyclohexyl-6,7-dimethoxyquinazolin-4-amine	0
N-methyl-2-(4-methylphenyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine	0
N1-(6-bromo-4-quinazolinyl)-N4,N4-dimethylbenzene-1,4-diamine	0
N1-(6-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)-4-nitrobenzamide	0
N2,N2-dipropylquinazoline-2,4-diamine	0
N2-(2,5-dimethoxyphenyl)-N4-(2-furanylmethyl)quinazoline-2,4-diamine	0
N2-(5-chloro-2-methoxyphenyl)quinazoline-2,4-diamine	0
N4-(3,4-dimethylphenyl)quinazolin-4-amine hydrochloride	0
N4-(5-Fluoro-4-imino-3,4-dihydroquinazolin-3-yl)isonicotinamide	0
NU 1025	1
Neofiscalin A	0
Norquinadoline A	0
O-Desmorpholinopropyl Gefitinib	0
O-desmethyl Gefitinib	0
Oxysporizoline	0
PD 168393	19
PD-153035	0
PDGF receptor tyrosine kinase inhibitor III	0
Pegamine	0
Peganine	0
Polonimide A	0
Polonimide B	0
Polonimide C	0
Protuboxepin E	0
Protuboxepin H	0
Protuboxepin I	0
Protuboxepin J	0
Protuboxepin K	0
Puniceloid A	0
Puniceloid B	0
Puniceloid C	0
Puniceloid D	0
Quinadoline A	0
Quinadoline D	0
R(+)-2-(heptan-3-yl)quinazolin-4(3H)-one	0
R24	0
SMER 28	0
Scequinadoline A	0
Scequinadoline B	0
Scequinadoline C	0
Scequinadoline D	0
Scequinadoline E	0
Scequinadoline F	0
Scequinadoline G	0
Scequinadoline I	0
Scequinadoline J	0
Shewanelline C	0
Src Inhibitor-1	0
Src Inhibitor-5	0
Tryptoquivaline Q	0
UNC0638	0
UNC0642	4
Vasicinol	0
Vasicinolone	0
Vasicinone	0
Verrucine A	0
Verrucine B	0
Versicomide A	0
Versicomide B	0
Versicomide C	0
Versiquinazoline A	0
Versiquinazoline B	0
Versiquinazoline C	0
Versiquinazoline D	0
Versiquinazoline E	0
Versiquinazoline F	0
Versiquinazoline I	0
Versiquinazoline L	0
Versiquinazoline M	0
Versiquinazoline N	0
Versiquinazoline O	0
ZM 323881	0
ZM447439	0
[5-[4-[(5-methyl-2-furanyl)methylamino]-6-quinazolinyl]-2-furanyl]methanol	0
afatinib +	18
alfuzosin +	6
benquitrione	0
bunazosin	0
canertinib	12
chaetominine	0
chrysogine	0
ciliobrevin D	0
cyclazosin +	1
dacomitinib	2
doxazosin +	32
erastin	74
erlotinib +	135
etaqualone	0
fenazaquin	2
fenquizone	0
fluquinconazole	0
fruquintinib	0
gefitinib +	181
idelalisib	31
ketanserin	17
lapatinib	67
linagliptin	33
linkable gefitinib analogue	0
linkable vandetanib analogue	0
mecloqualone	0
methaqualone	0
metolazone	2
moquizone	0
poziotinib	0
prazosin +	59
proquinazid	0
pyraquinate	0
pyrifluquinazon	0
pyrrolidinoquinazoline +	0
quinaminoprole	0
quinazoline +	0
quinazoline alkaloid +	43
quinethazone	0
sapitinib	0
saracatinib	11
sotrastaurin	4
tandutinib	0
terazosin +	8
tesevatinib	0
trimetrexate	4
tyrphostin AG 1478	125
vandetanib +	36

paths to the root